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ABSTRACT
I. Total Synthesis of the (-)-Agelastatin Alkaloids
The pyrrole-imidazole family of marine alkaloids, derived from linear clathrodin-like
precursors, constitutes a diverse array of structurally complex natural products. The bioactive
agelastatins are members of this family that possess a tetracyclic molecular framework
incorporating C4-C8 and C7-N12 bond connectivities. We provide a hypothesis for the
formation of the unique agelastatin architecture that maximally exploits the intrinsic chemistry of
plausible biosynthetic precursors. We report the concise enantioselective total syntheses of all
known agelastatin alkaloids including the first total syntheses of agelastatins C, D, E, and F. Our
gram-scale chemical synthesis of agelastatin A was inspired by our hypothesis for the biogenesis
of the cyclopentane C-ring and required the development of new transformations including an
imidazolone-forming annulation reaction and a carbohydroxylative trapping of imidazolones.
II. Total Synthesis of the (-)-Trigonoliimine Alkaloids
The concise and enantioselective total syntheses of (-)-trigonoliimines A, B, and C are
described. Our unified strategy to all three natural products is based on asymmetric oxidation
and reorganization of a single bistryptamine, a sequence of transformations with possible
biogenetic relevance. We revise the absolute stereochemistry of (-)-trigonoliimines A, B, and C.
Thesis Supervisor: Professor Mohammad Movassaghi
Title: Associate Professor of Chemistry
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Introduction and Background
The agelastatins are a family of highly cytotoxic pyrrole-imidazole alkaloids, comprising
a tetracyclic backbone structure with four contiguous stereogenic centers around the central C-
ring. In 1993, Pietra and coworkers isolated (-)-agelastatins A (1) and B (2) from the Coral Sea
sponge Agelas dendromorpha and chemically studied their unique tetracyclic structures.1,2 (_ _
Agelastatins C (3) and D (4) were isolated from Cymbastela sp. native to the Indian Ocean by
Molinski and coworkers in 1998.3 In 2010, Al-Mourabit and coworkers isolated (-)-agelastatins
E (5) and F (6) from the New Caledonian sponge A. dendromorpha.4 (-)-Agelastatin A (1)
exhibits anti-neoplastic activities against multiple cancers such as breast, lung, colon, head, neck,
and bladder cancers.' It inhibits osteopontin mediated neoplastic transformation and metastasis in
addition to slowing cancer cell proliferation by causing cells to accumulate in the G 2 phase of the
cell cycle.'' A recent in vivo central nervous system (CNS) pharmacokinetic study showed that
(-)-agelastatin A (1) can penetrate the CNS with permeation into CNS compartments including
the brain, parenchyma, cerebrospinal fluid, and eyes. 7 (-)-Agelastatin A (1) also exhibits toxicity
towards anrthropods,3 and selectively inhibits the glycogen synthase kinase-3p.8 '9 In addition,
agelastatin A (1) has been reported to possess potent insecticidal activity against brine shrimp,
larvae of beet armyworm, and corn rootworm. 3
Me 0 Me 0 Me 0
HO, N- HO, N-f HO, N
Br Hh H Br H BrH H
B N-H N-H N N-H
o Br 14 O O
(-)-agelastatin A (1) (-)-agelastatin B (2) (-)-agelastatin C (3)
H 1 0 Me, 0 H 1 0
HO N' MeO N-' HO,H .
H H HH H
Br H H Br H H Br H HN IN-H \N N-H
O 0 Br 14 0
(-)-agelastatin D (4) (-)-agelastatin E (5) (-)-agelastatin F (6)
Figure 1. Structure of agelastatin alkaloids (1-6).
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The agelastatins are the only isolated pyrrole-imidazole alkaloids with C4-C8 and
C7-N12 connectivity, likely derived from a linear biogenetic precursor such as clathrodin (7),10
hymenidin (8)," and oroidin (9)1213 (Scheme 1). Kerr and coworkers showed that histidine and
ornithine (or proline) are the amino acid precursors for related pyrrole-imidazole alkaloids.14
Prior to our synthetic report of all (-)-agelastatin alkaloids, 5 there were two reported
biosynthetic hypotheses for agelastatin A (1) from its linear precursor (Scheme 2).1a,16 Both
biosynthetic hypotheses proposed that the formation of central the C-ring results from C8-
nucleophilic trapping of a C4-electrophile in a clathrodin (7) derivative. Furthermore, these
initial biosynthetic hypotheses suggest the formation of C-ring prior to B-ring, and attribute the
stereochemical information present in (-)-agelastatin A (1) to the action of putative enzymes. In
2006, Lindel showed a conversion of oroidin (9) to cyclooroidin (10) under acidic condition.17
However, biosynthetic or chemical explanation that links cyclooroidin (10) or its derivative to
(-)-agelastatin A (1) was not present at the time that we set out this synthetic program (Scheme
1).
R 1 N H NH2H7 NH
R212j HN
R OBr 12
R = R2=H clathrodin (7) Br
R = Br, R2 = H hymenidin (8) (-)-CYCl
R = R2 = Br oroidin (9)
Scheme 1. Structurally related pyrrole-imidazole alkaloids.
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Davis' total synthesis of (-)-agelastatin A
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Trost's total synthesis of (-)-agelastatin A
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Yoshimitsu and Tanaka's 2nd generation total synthesis of (-)-agelastatin A




















Du Bois' total synthesis of (-)-agelastatin A
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a. Number of steps from commercially available material.
The potent biological activities, in conjunction with its intriguing molecular structure
have prompted considerable efforts toward the total synthesis of agelastatin A (1), and 1 has
served as an active arena for the development of new chemistry.' 8 To date, 13 different research
groups, including our own research group, reported inventive solutions toward the total synthesis
of agelastatin alkaloids. In 1999, Weinreb completed the first total synthesis of (±)-agelastatin A
(1) using a key N-sulfinyl dienophile hetero-Diels-Alder reaction (Scheme 3).19 Notably, they
formed the B-ring of 1 employing N12 addition to C7, a disconnection with potential
biosynthetic relevance. Feldman reported the first enantioselective syntheses of (-)-agelastatins
A (1) and B (2) applying an alkylidenecarbene C-H insertion reaction. 20 Hale applied an
aziridine opening strategy to access synthetic sample of (-)-agelastatin A (1).21 Davis's synthesis
utilized a N-sulfinyl imine based methodology and ring-closing metathesis to efficiently secure
(-)-agelastatin A (1) in 15.7% overall yield (Scheme 3).22 Trost's elegant total synthesis of (+)-1
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ring of the target natural product with excellent enantioselectivity (Scheme 3).23 Ichikawa' S24
sigmatropic rearrangement of an allyl cyanate followed by Wardrop25 and Chida's 26 respective
use of the Overman rearrangement constituted additional successful total synthesis of 1.
Agelastatin A (1) has continued to serve as source of inspiration and furnished inventive
applications of an aziridination strategy for its enantioselective total syntheses by Yoshimitsu
and Tanaka,27 Du Bois,28 and Hamada.29 In a subsequent report, Yoshimitsu could further
optimize the synthetic sequence to (-)-1, utilizing a radical aminobromination strategy (Scheme
3)30 Importantly, the robustness of Du Bois' synthetic approach was evidenced by their 270 mg
preparation of (-)-1 in a single pass (Scheme 3). Most recently, Maruoka completed the formal
total synthesis of (-)-1 using asymmetric Mannich reaction as a key step.3 1 Interestingly, all of
these syntheses focused on an early introduction of the central C-ring followed by further
derivatization to the natural product 1. Additionally, these reported syntheses of agelastatin A (1)
do not focus on examining existing biosynthetic hypotheses for biogenesis of the intriguing
tetracyclic framework using a C4-C8 bond forming strategy.32 Distinct from these synthetic
approaches, our biosynthetically inspired unified synthetic approach involving C4-C8 bond
formation enabled the total synthesis of all (-)-agelastatins (1-6)."1
Results and Discussion
Biosynthetic Hypothesis and Design Plan for Total Synthesis
The fascinating molecular architecture of the agelastatins and interest in evaluating our
new hypothesis for the biogenetic origins of the C-ring involving cyclization with concomitant
introduction of three stereocenters motivated the studies described here. We envisioned an
advanced-stage biosynthetic sequence (Scheme 4) distinct from existing hypotheses (Scheme 2)
that relies on: 1) reverse polarity in C-ring formation involving C4-nucleophilic trapping of a C8-
electrophile for the C-ring formation, 2) introduction of the C-ring after the B-ring formation,
and 3) substrate directed stereochemical control and use of intrinsic chemistry that is perhaps
enhanced by the action of biosynthetic enzymes. Our retrosynthetic factoring of (-)-agelastatin A
(1) inspired by our retrobiosynthetic analysis' 5 of 1 is illustrated in Scheme 4. Ionization of the
C5-hydroxyl of 1 followed by the strategic disconnection of C4-C8 reveals N-acyliminium ion
45 and clears the carbocyclic C-ring along with three stereocenters. The mechanistic
development of a transform33 linking 1 to 45 prompted consideration of a versatile precursor,
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pre-agelastatin A (44, Scheme 4). In the forward direction, our hypothesis asserts that pre-
agelastatin A (44) may be ionized to the C8-acyliminium ion 45, allowing a 5-exo-trig
cyclization via the kinetic trapping of the top face of the D-ring, followed by C5-hydroxylation
to secure the C4-, C5-, and C8-stereocenters in the final stage of the biosynthesis (44--1,
Scheme 4). We envisioned that pre-agelastatin A (44) would result from C2-hydrolysis and C8-
oxidation of the cyclooroidin analogue 42. Tricycle 42 would be formed by C4-protonation of
linear precursor 39 followed by C7-trapping by the pyrrolyl-nitrogen (N12) via a 6-exo-trig
cyclization.34 Notably, this pathway suggests a link between the agelastatins and the natural
product cyclooroidin (10, Figure 1),35 and is consistent with Lindel's reported acid promoted
conversion of oroidin (9) to tricycle 10.17 Motivated by the potential direct conversion of pre-
agelastatin A (44) to (-)-agelastatin A (1), we targeted the related structure, 0-methyl-pre-
agelastatin A (47) and envisioned its concise synthesis from readily available D-aspartic acid
derivative 50 (50->47, Scheme 1).
H 1 NH2
N N H, NH2 R, NH2 Me, 2
protonation N cyclization N hydrolysis N-H
H NBr Br Br
7 12 :7N
NH f B-ring / N1 N
N formation N methylation: N
NH 'H H 41, R =H 'H
39 O 40 0 42, R =Me 43 O
Br Retrobiosynthetic Analysis: Ca
Me 0 Me, Me
HO,. N C5 H20 C4-C8 N C8 N -N'H hydroxylation 5 -H cyclization N-H ionization N-H
H4~{U~-CBr 4 Br -
Br H H Br H H Br - B OHN N-H N N-H C-ring N / N
formation NH NH
00 + HH
(-)-agelastatin A (1) 46 45 0 pre-agelastatin A (44) 0
from Me 0
D-aspartic 0 013 O C4-C5 - O - N1-C5 MeN4
acid bromination formation H H1 cyclization D N-H
-
5 OMe ( Br :5 OMe & Br 7 4 N'M
N 5OMe B-ring NQ OMe OMe 0 D-ring OMeN- formation NH / tNT formation /N
0- NH
50 49 00 480
0-Me-pre-agelastatin A (47)
Scheme 4. Our retro(bio)synthetic analysis of (-)-agelastatin A (1) inspired by our biosynthetic hypothesis that
involves intermediacy of pre-agelastatin A (44) in the final stage formation of the C-ring.
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Total Synthesis of the Agelastatin Alkaloids
Our convergent synthesis for the desired 0-methyl-pre-agelastatin A (47) commenced
with pyrrole (+)-50 (Scheme 5), accessible in one step from commercially available D-aspartic
acid dimethyl ester. 36 Exposure of pyrrole (+)-50 to N-bromosuccinimide (NBS) in the presence
of 2,6-di-tert-butyl-4-methylpyridine (DTBMP) afforded the bromopyrrole (+)-51 in 85% yield
and 99% ee. Treatment of bromopyrrole (+)-51 with chlorosulfonyl isocyanate afforded amide
(+)-52 in 85% yield on greater than 9-gram scale. Subsequently, addition of sodium borohydride
followed by p-toluenesulfonic acid (TsOH) to a methanolic solution of (+)-52 generated bicycle
(+)-49 as a single diastereomer in 80% yield and 99% ee. The X-ray crystal structure analysis of
bicycle (+)-49 confirmed its absolute and relative stereochemistry (Scheme 5).37 The conversion
of (+)-52 to bicycle (+)-49 occurs via formation and immediate C8-reduction of the imide 53,
preventing an undesired C7-epimerization.38 Identical B-ring formation with the
desbromopyrrole derivative of 52 resulted in significant erosion of enantiopurity. This
observation was consistent with our postulate that the C7-H bond would be forced to adopt a
pseudo-equatorial conformation to minimize allylic strain between the C13-bromine and C6-
methylene, which suppressed undesired C7-deprotonation. Interestingly, the use of pyrrole (+)-
52, possessing the C13-bromine present in all known agelastatins, provided chemical reactivity
beneficial to our synthetic strategy (vide infra).
0 000
- OMe Br -AOMe Br -OMe F
-a 3 0b C Br
N~~~_ N800e8*o 
~
(+)-50, 99% ee (+)-51 HgscaleH2N (+)-52~
thermal ellipsoid
representation of (+)-49 ~
Br OMeMe
ON e +--- OH
OH
(+)-49, 99% ee ~54 -
Scheme 5. Synthesis of bicycle (+)-49. Conditions: a) NBS, DTBMP, THF, 85%. b) CISO 2 NCO, MeCN, 0 'C;
Na(Hg), NaH 2PO 4, 85%. c) NaBH4, MeOH, 0 0C; TsOH-H 20, 23 'C, 80%.
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We next aimed to develop a general strategy for the introduction of the imidazolone 39
substructure present in the targeted pre-agelastatin 44. Initially, we focused on the direct addition
of transmetallated derivatives of triazone 5540'41 (Metal = Li, Mg, Cu, Ce, Zn, Scheme 6) to the
bicyclic C5-ester (+)-49. When the lithiated triazone was allowed to react with methyl ester (+)-
49, the reaction was plagued by undesired reactivity between the C13-bromide and the
organolithium species, and ketone (+)-56 could not be obtained in a synthetically useful yield
(Scheme 6). In an attempt to solve this problem, we synthesized the corresponding Grignard
reagent, organocerium, organocuprate, and organozinc derivatives, but these chemical species
failed to add to methyl ester (+)-49. Furthermore, these metallated 42 triazone derivatives were
generally unstable at temperatures above 0 'C. Thus, the development of a new strategy for the




















Scheme 7. Synthesis of thioester (+)-57.
Inspired by studies of Liebeskind group, which reported the cross-coupling reaction
between the thioester and organostannane, 43 '44 we set our goal to develop an efficient metal
mediated cross-coupling reaction between thioester derivative of methyl ester (+)-49 and stannyl
triazone derivative 55. Thioester (+)-57 was readily prepared in 92% yield through treatment of
19
ester (+)-49 with trimethylaluminum and 4-methylbenzenethiol in dichloromethane (Scheme 7).
The structure of (+)-57 was secured via X-ray crystallographic analysis,3 7 revealing the pseudo-
equatorial C7-H bond.
C6H4-p-Me0
Br C6H4-p-Me CH 4-p-Me OBr -
--
N N N, Mi.. N a Br 4 I
N + 4r N'Me a / N OMe 0
NH CHxSn O 88% - N (+)-56
(+)-57 0 58 0
b 89%
M NHBrMe




representation of (+)-47 agelastatin A (47)
Scheme 8. Synthesis of the key intermediate (+)-O-methyl-pre-agelastatin A (47). Conditions: a) CuTC, THF, 50
0C, 88%. b) HC1 (0.5 N), MeOH, 23 0C, 89%.48
After extensive experimentation, we found that the union of thioester (+)-57 with the
readily available triazone 5845 could be achieved efficiently in the presence of stoichiometric
copper(I)-thiophene-2-carboxylate (CuTC) to give the ketone (+)-56 in 88% yield (Scheme 8).46
Exposure of triazone (+)-56 to methanolic hydrogen chloride unraveled the keto-urea 48, which
upon spontaneous condensative cyclization4 7 provided the desired (+)-O-methyl-pre-agelastatin
A (47) in 89%48 yield with 99% ee (Scheme 8). The structure of (+)-47 was secured via X-ray
crystallographic analysis, and its thermal ellipsoid representation illustrates that the C7-
methylimidazolone and C8-methoxy group reside in a pseudo-diaxial conformation (C6-C7-C8-
08' dihedral angle of 173 o).37
With (+)-O-methyl-pre-agelastatin A (47) in hand, we proceeded to evaluate our
hypothesis for C-ring biogenesis and rapid introduction of the C4-, C5-, and C8-stereocenters.
Gratifyingly, heating an aqueous solution of (+)-47 with methanesulfonic acid provided (-)-
agelastatin A (1, Scheme 9) as the major product along with (-)-4,5-di-epi-agelastatin A
(structure not illustrated) as the minor stereoisomer (2:1). Monitoring of this reaction by 1H
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NMR revealed that (-)-4,5-di-epi-agelastatin A is the kinetic product, which equilibrates to the
thermodynamically favored desired product (-)-agelastatin A (1). Careful analysis of the rate of
solvolysis of each isomer illustrated that the C5-hydroxyl of (-)-4,5-di-epi-agelastatin A ionizes
significantly faster than the corresponding C5-hydroxyl of (-)-agelastatin A (1). In the event,
upon complete consumption of pre-agelastatin A (44), simple exposure of the reaction mixture to
methanol efficiently converted (-)-4,5-di-epi-agelastatin A to (-)-O-methyl-di-epi-agelastatin A
(61), enabling facile separation of (-)-1 and (-)-61 (Scheme 9).
Me0 O
N" Me, Me,+ O Me % O
N-H N4 N{N
Br OMe a Br N H H 4 H H H
N/ N Br Br NIOY >lgscale N N-H N N-H
(+)-O-Me-pre- 0 45 59 60 _
agelastatin A (47)




Br H H + Br H HN N-H
2 1 /0 0
0 (-)-Q-Me-di-epi-
(-)-agelastatin A (1) agelastatin A (61)
49% 22%
66%
Scheme 9. Gram-scale synthesis of (-)-agelastatin A (1). Conditions: a) MeSO 3H, H2 0, 100 'C; MeOH, 49% (-)-1,
22% (-)-61.48 b) MeSO 3H, H20, 100 'C; MeOH, 66% (30% recovered (-)-61).48
Under preparative conditions, our putative biomimetic cyclization of (+)-47 afforded (-)-
agelastatin A (1) in 49% yield (1.4 g, 99% ee) along with (-)-O-methyl-di-epi-agelastatin A (61)
in 22% yield. 48 This constitutes a total chemical synthesis of (-)-agelastatin A (1) in eight steps
for the longest linear sequence from commercially available starting material with 22% overall
yield. Furthermore, resubmission of (-)-61 to the above protocol afforded (-)-agelastatin A (1)
in 66% yield along with recovered (-)-61 (30%) post equilibration. 48 The structure of (-)-1 was
secured through X-ray crystallographic analysis (Scheme 9).37 It should be noted that this 5-
(enolendo)-exo-trig49 type of cyclization with an acyliminium ion is a rare and challenging
reaction as evidenced by the paucity of relevant examples in the literature. 50 Importantly, the
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versatility of our new imidazolone annulation allows for the union of thioester (+)-57 and the
simple stannylurea derivative 63 (Hx 3SnCH2NH(CO)NHMe) to afford (+)-O-methyl-pre-
agelastatin A (47) without isolation of any intermediates, providing the shortest total synthesis of
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Scheme 10. 7-Steps total synthesis of (-)-agelastatin A (1).51
Under optimal conditions, treatment of (-)-agelastatin A (1) with NBS and DTBMP in a
water-tetrahydrofuran solvent mixture afforded (-)-agelastatin B (2) in 84% yield (Scheme 11).
Interestingly, X-ray crystallographic analysis of (-)-agelastatin B (2) revealed that its C-ring
conformation is distinct from that of (-)-agelastatin A (1) as highlighted by the 250 and 310







THF, H200 *C, 3 h
84% b_-
(-)-agelastatin A (1) (-)-agelastatin B (2)
Scheme 11. Total synthesis of (-)-agelastatin B (2).
Our new imidazolone annulation methodology proved most effective for accessing the
desired pre-agelastatin D intermediate for the first synthesis of (-)-agelastatin D (4, Scheme 12).
Under our optimized conditions, treatment of thioester (+)-57 with stannylurea 64 and CuTC
followed by exposure to methanolic hydrogen chloride afforded (+)-O-methyl-pre-agelastatin D
(65) in 62% yield. With a successful synthetic access to (+)-O-methyl-pre-agelastatins D (65),
we next investigated its conversion to (-)-agelastatin D (4). Application of our key cyclization
22
0
protocol described above (Scheme 9) indeed provided the first synthetic sample of (-)-agelastatin
D (4) in 26% yield along with (-)-di-epi-agelastatin D (67, 9%, Scheme 12). The X-ray crystal
structure analysis of (-)-agelastatin D (4) showed a C-ring conformation similar to (-)-1.37
Resubmission of (-)-O-methyl-di-epi-agelastatin D (67) to MeSO 3H in H20 at reflux afforded
(-)-agelastatin D (4) in 68% yield. While we were pleased to access (-)-4 via our putative
biomimetic cyclization, this key cyclization was plagued by competing reaction pathways
involving the C6-C7 bond-cleavage, resulting in byproduct 68 (20%) and C4-C13 cyclization,
giving byproduct 70 (20%). Formation of tetracycle 70 is consistent with a competing loss of
methanol to afford pyrrolopyrazinone 69, an observed intermediate, which prevents the desired
C-ring formation and permits Cl 3 to engage the imidazolone.
O H1 O
Br -%S-C6H4-P-Me N H
OMe + N a, b Br
_L 62% / )x~
0 64H
(+)-57 0(+)-O-Me-pre-agelastatin D (65)
c
HOHN MeO H 1
+ 6" C N-H
Br Br H H Br NN N-H N N-H 13
26%0 +%O- H
(-)-agelastatin D (4) (--ledkp "66 O
d agelastatin 0 (67)
68% Br N N-H
thermal ellipsoid
representation00
of (-)-4 68, 20% H, O
H ~ N-
N H Br 4
HNH N N-H NH
(±)-70, 20% O69
Scheme 12. Total synthesis of (-)-agelastatin D (4). Conditions: (a) CuTC, THF, 50 'C; (b) HCl (0.5N), MeOH, 23
*C (62% (2-steps)); (c) MeSO 3H, H20, 100 *C; HCl, MeOH (26% (-)-4, 9% (-)-67, 20% 68, 20% (+)-70). (d)
MeSO 3H, H20, 100 0C; HCl, MeOH, 68%.
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The formation of byproducts 68 and 70 indicates the attenuated C4-nucleophilicity of (+)-
0-methyl-pre-agelastatin D (65) compared to (+)-O-methyl-pre-agelastatin A (47) in polar-protic
solvent. Monitoring of the rates of deuterium incorporation at C4 position of (+)-O-methyl-pre-
agelastatins A (47) and D (65) revealed that deuterium incorporation at C4 of (+)-47 was ten
time faster than (+)-65, consistent with its more efficient C4-C8 bond formation. Furthermore,
C6-C7 bond fragmentation, requiring C5-C6 n-bond formation, is likely facilitated by
diminished allylic strain imposed by the Ni-H intermediate 66 compared to Ni-Me derivative
45. Interestingly, the observed lower efficiency of the desired cyclization with 65 compared to 47
echoes the scarcity of natural (-)-agelastatin D (4) compared to other N-methyl agelastatin
alkaloids.3'4 '53
Furthermore, we have accessed the structures of the two newly isolated (-)-agelastatins E
(5) and F (6) by their direct synthesis from (-)-agelastatin A (1) and D (4), respectively (Scheme
13). Heating a methanolic solution of (-)-agelastatin A (1) with Bronsted acid at 65 'C for 2 h
afforded (-)-agelastatin E (5) in 100% yield (Scheme 13)." A synthetic sample of (-)-agelastatin
F (6) was generated in 86% yield by bromination of (-)-agelastatin D (4) under the optimal
conditions described above for the synthesis of (-)-agelastatin B (2), thereby confirming its
molecular structure.
Me 0 Me 0O
HO, N-( MeOeN
a H "H
Br H H Br H H
N N-H 100% N-H
O 0
(-)-agelastatin A (1) (-)-agelastatin E (5)
H 0 H 0
HO, NO HO,H N
54 N'H 5 4 N'H
Br H 4 H Br H 4H
N N-H 86% N-H
O Br 0
(-)-agelastatin D (4) (-)-agelastatin F (6)
Scheme 13. Total synthesis of (-)-agelastatin E (5) and (-)-agelastatin F (6). Conditions: (a) Amberlyst 15, MeOH,
65 -C, 100%. (b) NBS, DTBMP, THF, H2 0, 0 -C, 86%.
Our biosynthetically inspired strategy for the advanced stage C-ring formation drew on
the intrinsic chemistry of our proposed pre-agelastatin intermediates for rapid generation of
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molecular complexity, enabling a unified approach to all known agelastatin alkaloids.
Collectively, our observations hint at a plausible sequence of events for the biogenesis of the
alkaloids 1-6 (Scheme 4). For example, the C13-bromopyrrole and the imidazolinone
substructures (present in all agelastatins) were critical in the successful C-ring cyclization.
Treatment of the des-bromo derivative 71 under the optimized cyclization conditions did not
afford the desired C-ring due to a more facile conversion to pyrrolopyrazinone 72 (57% 48
Scheme 14), 5 suggesting a beneficial role for the allylic strain between the C13-bromine and
C6-methylene to restrict the C7-methine in a pseudo-equatorial conformation during the key
cyclization event. Additionally, the aminoimidazole 73 failed to undergo the desired cyclization
reaction due to a more competitive pyrrolopyrazinone 74 formation (92%, Scheme 14), an
observation we attribute to the greater propensity of the aminoimidazolone substructure to
remain protonated and thus less nucleophilic under the reaction conditions.
A. Me 0  Me O B. H NH2  H NH2
N-H a N-H N b N
Br Br
13 O M e 57% N 'O M e 92%
N- N -' NH N 'H NH N
71 0 720 7 3 o 74O
Scheme 14. Key observations concerning our bioinspired C-ring synthesis strategy. Attempted cyclization of A)
desbromo-pre-agelastatin A (71) and B) imidazole derivative 73. Reagents and conditions: (a) MeSO 3H, H2 0, 100
0C, 20 min, 57% .48 (b) Dowex, H20, 100 'C, 92%.
Consequently, we suggest a higher probability for biosynthetic introduction of the C 13-
bromopyrrole and imidazolone substructures prior to C-ring formation. Moreover, our
observations regarding the higher predisposition for the pre-agelastatin A derivative (+)-47, to
undergo C-ring formation as compared to the desmethyl derivative (+)-65 may suggest
predominant Ni -methylation prior to C-ring cyclization in the biogenesis of the agelastatins. The
stereochemical outcome for the key C-ring cyclization is controlled by the C7-methine to secure
the desired thermodynamically favored C4-, C5-, and C8-stereocenters. Specifically, the C5-
center is controlled by the C4-stereochemistry to give a cis-fused CD-ring system upon
hydroxylation. It is conceivable that putative agelastatin biosynthetic enzymes have evolved to
enhance the innate stereoselectivity of compounds related to those utilized in our synthesis.55
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While our total syntheses of alkaloids 1-6 do not confirm our hypothesis for their biogenesis, it
is gratifying to have chemical validation for our proposed mode and timing of bond and ring
formations in the biosynthesis of these alkaloids.
Conclusion
We have completed the total syntheses of the agelastatin alkaloids through a unified
strategy inspired by our hypothesis for their biogenesis (Scheme 15). Key features of our
syntheses include: 1) the concise multi-gram scale enantioselective synthesis of our proposed
"pre-agelastatin" derivatives, 2) the use of the bromopyrrole substructure to suppress C7-
deprotonation, 3) a versatile synthesis of imidazolone derivatives via a new [4+1] annulation
strategy, 4) the validation of our bioinspired 5-exo-trig advanced stage C-ring formation, and 5)
utilization of the intrinsic chemistry of plausible biosynthetic intermediates for rapid generation
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Scheme 15. Summary of the enantioselective synthesis of the agelastatin alkaloids. Conditions: (a) NBS, DTBMP,
THF, 85%. (b) ClSO 2NCO, MeCN, 0 'C; Na(Hg), NaH2PO4 , 85%. (c) NaBH4 MeOH, 0 'C; TsOH-H 20, 23 *C,
80%. (d) HSC6H4-p-Me, AlMe 3, CH 2Cl2, 0 'C, 92%. (e) CuTC, THF, 50 0C, 88%.46 (f) HCl (0.5N), MeOH, 65 *C,
89%.48 (g) c-Hx 3SnCH 2NH(CO)NHMe (63), CuTC, THF, 50 'C, HCl (0.5 N), MeOH, 65 0 C, 58%.51 (h) MeSO 3H,
H20, 100 'C; MeOH, 49% (-)-1.41 (i) NBS, DTBMP, THF, H20, 0 'C, 84%. (j) Amberlyst 15, MeOH, 65 'C, 100%;
(k) cHx 3SnCH2NH(CO)NH 2 (64), CuTC, THF, 50 *C; (1) HCl (0.5N), MeOH, 23 'C, 62% (2 steps). (m) MeSO 3H,






batch enantioselective synthesis of (-)-agelastatin A (1). With this most concise total chemical
synthetic access to all natural agelastatin alkaloids and related derivatives, studies aimed at
probing their chemical and biological mode of action are ongoing.
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Experimental Section
General Procedures. All reactions were performed in oven-dried or flame-dried round bottomed
flasks or modified Schlenk (Kjeldahl shape) flasks. The flasks were fitted with rubber septa and
reactions were conducted under a positive pressure of argon. Stainless steel syringes or cannulae
were used to transfer air- and moisture-sensitive liquids. Where necessary (so noted), solutions were
deoxygenated by argon purging for a minimum of 10 min. Flash column chromatography was
performed as described by Still et al. using silica gel (60-A pore size, 40-63 tm, 4-6% H20 content,
Zeochem).1 Analytical thin-layer chromatography was performed using glass plates pre-coated with
0.25 mm 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer
chromatography plates were visualized by exposure to ultraviolet light and/or by exposure to an
ethanolic phosphomolybdic acid (PMA), an acidic solution of p-anisaldehyde (Anis), an aqueous
solution of ceric ammonium molybdate (CAM), an aqueous solution of potassium permanganate
(KMnO4) or an ethanolic solution of ninhydrin followed by heating (<1 min) on a hot plate (-250
C). Organic solutions were concentrated on Bfichi R-200 rotary evaporators at -10 torr (house
vacuum) at 25-35 'C, then at -0.5 torr (vacuum pump) unless otherwise indicated.
Materials. Commercial reagents and solvents were used as received with the following exceptions:
dichloromethane, diethyl ether, tetrahydrofuran, acetonitrile, toluene, methanol, triethylamine, and
pyridine were purchased from J.T. Baker (CycletainerTM ) and were purified by the method of Grubbs
et al. under positive argon pressure.2 Copper thiophene 2-carboxylate (CuTC), a tan colored solid,
was purchased from Matrix Inc. and was used as received. Chlorosulfonyl isocyanate was purchased
from TCI and was used as received. Sodium Amalgam was freshly prepared before use.3 The
molarity of sec-butyllithium solutions were determined by titration using diphenylacetic acid as an
indicator (average of three determinations).4
Instrumentation. Proton (lH) and carbon (13C) nuclear magnetic resonance spectra were recorded
with Varian inverse Probe 500 INOVA and Varian 500 INOVA spectrometers. Proton nuclear
magnetic resonance ( H NMR) spectra are reported in parts per million on the 6 scale and are
referenced from the residual protium in the NMR solvent (CDCl 3: 8 7.24 (CHC13), Toluene-d: 6 2.09
(Toluene-d 7); CD 30D: 6 3.31 (CHD 2OD), Pyridine-d: 6 8.74 (Pyridine-d 4), DMSO-d6 : 6 2.50
(DMSO-d)). Data is reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, t =
triplet, q = quartet, st = sextet, sp = septet, m = multiplet, app = apparent, br = broad), coupling
constant(s) in Hertz, integration, assignment. Carbon-13 nuclear magnetic resonance (13 C NMR)
spectra are reported in parts per million on the 6 scale and are referenced from the carbon resonances
of the solvent (CDCl 3: 6 77.23, Toluene-d: 6 20.40, CD 30D: 6 49.15, Pyridine-d: 6 150.35, DMSO-
d6 : 6 39.51). Data is reported as follows: chemical shift. Infrared data (IR) were obtained with a
Perkin-Elmer 2000 FTIR and are reported as follows: [frequency of absorption (cm-1), intensity of
Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2925.
2 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518-1520.
Sodium amalgam (5% wt) was prepared according to: Brasen, W. R.; Hauser, C. R. Org. Synth. 1954, 34, 56-57.
4 Kofron, W. G.; Baclawski, L. M. J. Org. Chem. 1976, 41, 1879-1880.
31
absorption (s = strong, m = medium, w = weak, br = broad)]. Optical Rotation was recorded on a
Jasco P-1010 Polarimeter (chloroform, Aldrich, Chromosolv Plus 99.9%; methanol, Aldrich,
Chromosolv Plus 99.9%; pyridine, purified by the method of Grubbs et al.2 ). Chiral HPLC analysis
was performed on an Agilent Technologies 1100 Series system. Semi-preparative HPLC was
performed on a Waters system with the 1525 Binary HPLC Pump, 2489 UV/Vis Detector, SFO
System Fluidics Organizer, and 2767 Sample Manager components. The structures of (-)-1, (-)-2,
(-)-4, (+)-47, (+)-49, and (+)-57 were obtained at the X-ray crystallography laboratory of the
Department of Chemistry, Massachusetts Institute of Technology, with the assistance of Mr. Justin
Kim. We are grateful to Dr. Li Li for obtaining the mass spectrometric data at the Department of
Chemistry's Instrumentation Facility, Massachusetts Institute of Technology. High-resolution mass
spectrometric data (HRMS) were recorded on a Bruker APEXIV 4.7 t FT-ICR-MS spectrometer
using electrospray ionization (ESI) source or direct analysis in real time (DART) ionization source.
Positional Numbering System. In assigning the 'H and 13 C NMR data of all intermediates en route
to our total synthesis of (-)-1 through (-)-6 we have employed a uniform numbering system consistent
with that of the final targets.
R2 1 0
R4 0 N R' = H, R2 = Me, R3 = H, R4 = H (-)-agelastatin A (1)
6 Z4 N'H R1 = H, R
2 
= Me, R3 = Br, R4 = H (-)-agelastatin B (2)
H 8 R' =OH, R2 = Me, R3 = H, R4 = H (-)-agelastatin C (3)
Br N 4H R1 = H, R2 = H, R3 = H, R4 = H (-)-agelastatin D (4)
13 N R = H, R2 = Me, R3 = H, R4 = Me (-)-agelastatin E (5)














To a solution of (-)-dimethyl D-aspartate hydrogenchloride6 (Si, 3.95 g, 20.0 mmol, 1 equiv)
in water (30 ml) at 23 'C was added 1,2-dichloroethane (30 mL) via syringe followed by 2,5-
dimethoxytetrahydrofuran (2.65 mL, 20 mmol, 1.00 equiv), and the resulting mixture was heated to
80 'C. After 45 min, the brown reaction mixture was cooled to 23 'C, and the aqueous layer was
separated and was extracted with dichloromethane (3 x 30 mL). The combined organic layers were
dried over anhydrous sodium sulfate and were concentrated under reduced pressure. The brown
residue was purified by flash column chromatography (silica gel: diam. 4 cm, ht. 11 cm; eluent: 40%
diethyl ether in hexanes) to afford pyrrole (+)-50 (3.22 g, 76%) as colorless oil.
Pyrrole (+)-50 was found to be 99% ee by chiral HPLC analysis [Welk-O (S,S); 3 mL/min;
2% isopropanol in hexanes; tR(major) = 4.5 min, tR(minor) = 5.2 min]. (+)-50 could be stored for
greater than a month as a solution frozen in benzene at -8 *C without any erosion of enantiomeric
excess.
IH NMR (500 MHz, CDCl 3, 21 'C):
13 C NMR (125.8 MHz, CDCl 3, 21 'C):
FTIR (neat) cm- 1:
HRMS (DART) (m/z):
[a]D 22:
TLC (25% ethyl acetate in hexanes), Rf
8 6.69 (t, J= 2.2 Hz, 2H, CIIH, C13H), 6.15 (t, J= 2.1
Hz, 2H, C14H, C15H), 5.11 (dd, J= 7.9, 6.8 Hz, 1H,
C7H), 3.71 (s, 3H, OCH 3), 3.66 (s, 3H, OCH 3 ), 3.26 (dd,
J= 16.8, 8.0 Hz, 1H, C6Ha), 2.92 (dd, J= 16.7, 6.8 Hz,
1H, C6Hb).
8 170.4, 170.0, 120.1, 109.2, 57.8, 53.0, 52.2, 37.5.
3643 (m), 3466 (m), 3103 (m), 2956 (s),
1557 (w), 1490 (s), 729 (s).
1739 (br-s),
calc'd for CioH14NNaO4 , [M+Na]*: 212.0917
found: 212.0911.
±71.3 (c 0.37, CHCl3).
0.50 (CAM, UV).
' For a previous report of the synthesis of (-)-50 in 99% ee, see: Jefford, C. W.; de Villedone de Naide, F.; Sienkiewicz, K.
Tetrahedron: Asymmetry 1996, 7, 1069-1076.
6 (-)-Dimethyl D-aspartate hydrochloride (Si) can be purchased from commercial sources. Additionally, we prepared S1 from (-)-D-
aspartic acid in 99% yield on greater than 35 gram scale according to the following procedure: Gmeiner, P.; Feldman, P. L.; Chu-

















N-Bromosuccinimide (NBS, 1.88 g, 10.6 mmol, 1.00 equiv) was added as solid in one portion
to a solution of pyrrole (+)-50 (2.25 g, 10.6 mmol, 1 equiv) and 2,6-di-tert-butyl-4-methylpyridine
(DTBMP, 2.66 g, 12.7 mmol, 1.20 equiv) in tetrahydrofuran (53 mL) at 0 'C. After 1.5 h, the clear
colorless reaction mixture was allowed to warm to 23 0C. After 30 min, the reaction mixture was
quenched with a mixture of saturated aqueous sodium thiosulfate solution and saturated aqueous
sodium bicarbonate solution (1:1, 100 mL). The solution was diluted with ethyl acetate (100 mL)
and water (100 mL), and the layers were separated. The aqueous layer was extracted with ethyl
acetate (2 x 100 mL), and the combined organic layers were dried over anhydrous sodium sulfate and
were concentrated under reduced pressure. The sample of the crude colorless residue was purified by
flash column chromatography (silica gel: diam. 5 cm, ht. 15 cm; eluent: 10% ethyl acetate in
hexanes) to afford bromopyrrole (+)-51 (2.60 g, 85%) as a colorless oil.
Bromopyrrole (+)-51 was found to be 99% ee by chiral HPLC analysis [Welk-O (R,R); 3
mL/min; 2% isopropanol in hexanes; tR(major) = 3.5 min, tR(minor) = 4.1 min]. While neat (+)-51 is
sensitive toward long term storage, it could be stored for greater than a month as a solution frozen in
benzene at -8 'C without any C13->C14 bromine migration.
IH NMR (500 MHz, CDCl3, 21 'C):
13 C NMR (125.8 MHz, CDCl 3, 21 0C):
FTIR (neat) cii:
HRMS (ESI) (m/z):
5 6.74 (ddd, J= 3.1, 1.9, 0.2 Hz, 1H, C IH), 6.18-6.16
(m, 2H, C14H, C15H), 5.38 (t, J= 7.2 Hz, 1H, C7H), 3.73
(s, 3H, OCH 3), 3.67 (s, 3H, OCH 3 ), 3.27 (dd, J= 16.8,
7.5 Hz, 1H, C6Ha), 2.92 (dd, J= 16.8, 7.0 Hz, 1H,
C6Hb).
8 170.3, 169.8, 120.6, 111.7, 110.6, 102.1, 56.2, 53.3,
52.4, 37.2.
3654 (w), 3468 (w), 3130 (m), 2954 (s), 1739 (br-s),
1437 (s), 1010 (s), 709 (s).
calc'd for CioHl 2BrNNaO 4, [M+Na]*: 311.9842
found: 313.9847.
+65.9 (c 1.06, CHCl3).







CISO 2NCOCH 3CN, O 'C, 1 h;
Na(Hg), NaH2PO4
0 -C, 1 h
85%
0






Chlorosulfonyl isocyanate (2.99 mL, 33.7 mmol, 1.05 equiv) was added slowly via syringe to
a solution of bromopyrrole (+)-51 (9.30 g, 32.1 mmol, 1 equiv) in acetonitrile (160 mL) at 0 'C.
After 1 h, anhydrous powdered sodium phosphate monobasic (19.2 g, 160 mmol, 5.00 equiv)
followed by freshly prepared sodium amalgam (5%-Na, 73.7 g, 160 mmol, 5.00 equiv) were added as
solids to the reaction mixture. After lh, the reaction mixture was diluted with ethyl acetate (530 mL),
and silica gel (290 mL) was added to the reaction mixture. The resulting slurry was filtered through a
plug of silica gel (diam. 9 cm, ht. 10 cm; eluent: ethyl acetate). The filtrate was concentrated under
reduced pressure, and the residue was purified by flash column chromatography (silica gel: diam. 11
cm, ht. 10 cm; eluent: from 50% ethyl acetate in hexanes to ethyl acetate) to afford (+)-52 (9.10 g,
85%) as white solid. Pyrrole (+)-52 could be stored for greater than a month as a solution frozen in
benzene at -8 'C. Exposure of (+)-52 to alcoholic solvents, namely methanol, or base results in rapid
lactamization and erosion of enantiomeric excess.
'H NMR (500 MHz, CDCl 3, 21 oC)7 :




TLC (33% in hexanes in ethyl acetate) Rf
6 6.69 (br-d, J= 3.9 Hz, I, C15H), 6.23 (d, J= 4.1 Hz,
1H, C14H), 5.78 (br-s, 2H, N9H2), 5.78 (br-s, 1H, C7H),
3.69 (s, 3H, OCH 3), 3.65 (s, 3H, OCH3), 3.59 (br-d, J=
14.4 Hz, 1H, C6Ha), 2.89 (br-dd, J= 16.4, 6.3 Hz, 1H,
C6Hb).
6 171.2, 169.5, 162.5, 125.2, 115.1, 111.7, 111.78, 56.8,
53.0, 52.3, 37.3.
3359 (m), 3191 (m), 2953 (m), 1740 (s), 1660 (m), 1602
(m), 1534 (w), 1438 (s), 1413 (m), 1272 (m), 1011 (m)
751 (m).
calc'd for CInH 14BrN2 0 5, [M+H] : 333.0081
found: 333.0074.
+74.0 (c 1.25, CHC13).
45-49 "C.
0.44 (CAM, UV).
'Resonances at 21 *C are broadened due to atropisomerism.
'Resonance is obscured due to line broadening. At higher temperature in toluene-d8 the signals are resolved; however,
atropisomerism persist for "C NMR. 'H NMR (500 MHz, Toluene-d8 , 80 *C 8 6.30 (br-s, 1H, C7H), 6.27 (dd, J = 4.1, 1.1 Hz, 1H,
C15H), 6.01 (dd, J = 4.1 0.6 Hz, 1H, C14H), 5.40 (br-s, 2H, N9H2), 3.66 (dd, J = 16.5, 6.7 Hz, 1H, C6Ha), 3.37 (s, 3H, OCH 3), 3.36 (s,
3H, OCH3), 2.86 (dd, J = 16.6, 6.5 Hz, 1H, C6Hb). 3C NMR (125.8 MHz, Toluene-d,, 80 *C; Minor rotamer resonances denoted by *)
6 170.7, 169.2, 162.9, 126.8, 115.1*, 114.9*, 114.8, 114.6*, 112.2*, 112.0*, 111.6, 111.4*, 110.9 (br), 57.1 (br), 52.3, 52.1*, 51.7*,







-20 *C, 13 min;











Anhydrous methanol (17 mL, cooled to -20 *C) was added to (+)-52 (573 mg, 1.72 mmol, 1
equiv) at -20 'C followed immediately by sodium borohydride (257 mg, 6.88 mmol, 4.00 equiv) as a
solid in one portion (Note: Significant gas evolution was observed. The internal temperature
remained below -10 C). After 13 minutes, acetone (2.53 mL, 34.4 mmol, 20.0 equiv) was added
slowly via syringe to the reaction mixture. After 6 min, the reaction mixture was diluted with
methanol (34 mL, -20 C), and p-toluenesulfonic acid hydrate (TsOH-H 20, 2.17 g, 11.2 mmol, 6.50
equiv) in methanol (100 mL) was added slowly over a 10 min period, while maintaining an internal
temperature of -20 'C. The resulting mixture (pH = 3) was allowed to slowly warm to 23 'C. After
11 h, the reaction mixture was basified with saturated aqueous sodium bicarbonate solution (pH = 7)
and was concentrated under reduced pressure to a volume of approximately 15 mL. The resulting
mixture was partitioned between dichloromethane (150 mL) and saturated aqueous sodium
bicarbonate solution (150 mL). The layers were separated, and the aqueous layer was extracted with
dichloromethane (3 x 150 mL). The combined organic layers were dried over anhydrous sodium
sulfate, and were concentrated under reduced pressure to provide a white solid residue. This solid
was purified by flash column chromatography (silica gel: diam. 3 cm, ht. 5.5 cm; eluent: 25%
hexanes in ethyl acetate) to afford the bicycle (+)-49 (435 mg, 90%) as white crystalline solid.
Bicycle (+)-49 was found to be 99% ee by chiral HPLC analysis [Chiralpak AD-H; 0.54
mL/min; 21% isopropanol in hexanes; tR(major) = 16.2 min, tR(minor) = 11.6 min]. Crystals of the
bicycle (+)-49 suitable for X-ray diffraction were obtained from methanol.
IH NMR (500 MHz, CDCl 3, 21 'C):




TLC (25% hexanes in ethyl acetate), Rf-
6 7.73 (br-d, J= 4.4 Hz, 1H, N 9H), 6.94 (d, J= 4.1 Hz,
1H, CisH), 6.29 (d, J= 4.1 Hz, 1H, C14H), 4.84 (dd, J=
9.8, 3.5 Hz, 1H, C7H), 4.80 (dd, J= 4.8, 1.5 Hz, 1H,
CsH), 3.73 (s, 3H, OCH3 ), 3.37 (s, 3H, OCH 3), 2.75 (dd,
J= 17.0, 10.8 Hz, 1H, C6Ha), 2.65 (dd, J= 17.0, 3.6 Hz,
1H, C6Hb).
8 170.2, 159.7, 123.5, 115.3, 113.2, 106.3, 84.7, 55.2,
53.6, 52.5, 36.6.
3226 (br-m), 2952 (m), 1736 (s), 1669 (s), 1553 (m),
1423 (s), 1384 (w), 1319 (m), 1088 (m).
calc'd for CliH 13BrN2NaO4, [M+Na]*: 317.0131,
found: 317.0135.











0 'C, 16 h
92%
0







Trimethyl aluminum (2 M in toluene, 30.7 mL, 61.5 mmol, 5.00 equiv) was added slowly via
syringe to a solution of 4-methylbenzenethiol (7.80 g, 61.5 mmol, 5.00 equiv) in dichloromethane
(123 mL) at 0 'C. After 40 min, a pre-cooled solution (0 'C) of bicycle (+)-49 (3.90 g, 12.3 mmol, 1
equiv) in dichloromethane (90 mL) was added via cannula. After 16 h, the light yellow reaction
mixture was diluted with saturated aqueous potassium sodium tartrate solution (360 mL) and
saturated aqueous sodium bicarbonate solution (250 mL). After 1 h, the layers were separated and the
aqueous layer was extracted with dichloromethane (3 x 250 mL). The combined organic layers were
dried over anhydrous sodium sulfate and were concentrated under reduced pressure to afford an
opaque white oil. The residue was purified by flash column chromatography (silica gel: diam. 5 cm,
ht. 14 cm; eluent: 50% ethyl acetate in hexanes) to afford thioester (+)-57 (4.8 g, 92%) as white
crystalline solid. Crystals of the thioester (+)-57 suitable for X-ray diffraction were obtained from
isopropanol.
IH NMR (500 MHz, CDCl 3, 21 *C):





TLC (25% hexanes in ethyl acetate), Rf:
8 8.01 (br-d, J= 4.6 Hz, 1H, N9H), 7.30 (app-d, J= 8.1
Hz, 2H, SAr-o-H), 7.24 (d, J = 7.9 Hz, 2H, SAr-m-H),
6.95 (d, J= 4.1 Hz, 1H, C15H), 6.30 (d, J= 4.1 Hz, 1H,
C14H), 4.89 (app-dd, J= 10.4, 3.5 Hz, 1H, C7H), 4.79
(dd, J= 4.8, 1.5 Hz, 1H, C8H), 3.33 (s, 3H, OCH 3), 3.09
(dd, J= 16.6, 10.5 Hz, 1H, C6Ha), 2.98 (dd, J= 16.6, 3.5
Hz, 1H, C6Hb), 2.37 (s, 3H, SArCH 3).
8 194.9, 159.9, 140.6, 134.6, 130.5, 123.5, 123.0, 115.4,
113.2, 106.4, 83.6, 55.3, 53.7, 45.1, 21.6.
3216 (s), 3094 (m), 2931 (s), 2248 (w), 1670 (br-s),
1553 (s), 1423 (s), 1318 (s), 1087 (s), 733 (s).
calc'd for C17HI 8BrN2O3S, [M+H]*: 409.0216,
found: 409.0212.



















p-Toluidine (S2, 12.2 g, 113 mmol, 1.00 equiv) was added as a solid to a solution of NN-
dimethylurea (S3, 10.0 g, 113 mmol, 1 equiv) in formalin (37% wt in water, 18.4 ml, 227 mmol, 2.00
equiv) at 23 'C, and the resulting suspension was heated to 100 'C. After 2 d, the reaction mixture
was allowed to cool to 23 'C, and was partitioned between dichloromethane (500 mL) and water (500
mL). The layers were separated, and the aqueous layer was extracted with dichloromethane (3 x 100
mL). The combined organic layers were dried over anhydrous sodium sulfate, and were concentrated
under reduced pressure. The solid residue was purified by crystallization from hot hexanes to afford
triazone S4 (17.4 g, 70%) as a tan crystalline solid.9
'H NMR (500 MHz, CDCl 3, 21 'C):
"C NMR (125.8 MHz, CDCl3, 21 'C):
FTIR (neat) cni':
HRMS (ESI) (m/z):
TLC (10% ethyl acetate in hexanes), Rf
8 7.06 (d, J= 8.5 Hz, 2H, NAr-o-H), 6.89 (d, J= 8.5 Hz,
2H, NAr-m-H), 4.60 (s, 4H, NCH 2N, NCH 2N), 2.85 (s,
6H, NCH 3, NCH 3), 2.27 (s, 3H, NArCH 3).
155.9, 145.6, 132.0, 129.7, 119.2, 67.1, 32.1, 20.4.
3029 (s), 2872 (s), 1638 (s), 1513 (s), 1451 (m), 1403
(m), 1294 (m), 1197 (m), 1093 (w).




9 The reaction procedure was developed and optimized in collaboration with Dr. Dustin Siegel. Final experimental procedure and
yield were adopted from Dr. Dustin Siegel's experimental result.
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CHx 3SnCI CHx 3Sn 0 16
SBuLi, THF 4kN NMe




To a solution of triazone S4 (10.0 g, 46.0 mmol, 1 equiv) in tetrahydrofuran (400 mL) at -78
*C was added sec-butyllithium (1.4 M in cyclohexane, 34.5 mL, 48.0 mmol, 1.05 equiv) rapidly via
cannula. After 10 min, the resulting bright orange mixture was added via cannula over a 15 min
period to a solution of tricyclohexyltin chloride (20.3 g, 50.0 mmol, 1.10 equiv) in tetrahydrofuran
(400 mL) at -78 'C. After 1.5 h, saturated aqueous ammonium chloride solution (100 mL) was added
via syringe, and the resulting mixture was concentrated under reduced pressure. The residue was
partitioned between dichloromethane (800 mL) and water (800 mL). The layers were separated, and
the organic layer was washed with brine (800 mL), was dried over anhydrous sodium sulfate, and
was concentrated under reduced pressure. The crude residue absorbed onto silica gel was purified by
flash column chromatography (silica gel: diam. 6 cm, ht. 15 cm; eluent: hexanes then 10% ethyl
acetate in hexanes) to afford stannyltriazone 58 (12.1 g, 45%) as a white solid.9
'H NMR (500 MHz, CDCl 3, 21 'C):
13 C NMR (125.8 MHz, CDCl3, 21 'C):
FTIR (neat) cm:
HRMS (DART) (m/z):
TLC (15% ethyl acetate in hexanes), Rf:
6 7.07 (dd, J= 8.7, 0.7 Hz, 2H, NAr-o-H), 6.89 (d, J=
8.5 Hz, 2H, NAr-m-H), 4.60 (s, 2H, NCH 2N), 4.58 (s,
2H, NCH2N), 2.85 (s, 3H, NCH3), 2.78 (t, J= 12.2 Hz,
2H, NCH 2Sn), 2.27 (s, 3H, NArCH 3), 1.82-1.74 (m, 6H,
cHx), 1.65-1.56 (m, 9H, cHx), 1.52-1.13 (m, 18H, CHx).
6 156.3, 146.1, 132.2, 130.0, 119.5, 69.2, 67.3, 32.7,
32.3, 29.5, 28.7, 27.9, 27.4, 20.8.
2915 (s), 2844 (s), 1636 (s), 1515 (s), 1444 (s), 1407
(m), 1299 (s), 1201 (m), 991 (m).





















Br 6 N 'Me





A flask was charged with thioester (+)-57 (173 mg, 0.423 mmol, 1 equiv), stannyltriazone 58
(298 mg, 0.508 mmol, 1.20 equiv), and copper(I)-thiophene-2-carboxylate (CuTC, 202 mg, 1.06
mmol 2.50 equiv) at 23 'C and placed under an argon atmosphere. Anhydrous tetrahydrofuran (8.4
mL) was added via syringe, and the entire reaction mixture was degassed thoroughly by passage of a
stream of argon. After the reaction mixture was heated to 60 'C for 1 h, the resulting brown reaction
mixture was allowed to cool to 23 'C, was diluted with ethyl acetate (10 mL) and saturated aqueous
ammonium chloride solution (15 mL), and was stirred at 23 *C. After 15 min, the reaction mixture
was diluted with water (10 mL) and ethyl acetate (10 mL). The layers were separated and the aqueous
layer was extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried over
anhydrous sodium sulfate and was concentrated under reduced pressure. The residue was purified by
flash column chromatography (silica gel: diam. 3 cm, ht. 11 cm; eluent: 3% methanol in ethyl acetate
then 7% methanol in ethyl acetate) and was lyophilized from benzene to afford ketone (+)-56 (188
mg, 88%) as a light tan solid.
'H NMR (500 MHz, CDCl3, 21 'C):




8 7.04 (dd, J= 8.6, 0.6 Hz, 2H, NAr-o-H), 6.93 (d, J=
4.0 Hz, 1H, Ci5H), 6.89 (d, J = 8.5 Hz, 2H, NAr-m-H),
6.55 (d, J= 4.6 Hz, 1H, N9H), 6.26 (d, J= 4.1 Hz, 1H,
C14H), 4.85 (ddd, J = 11.2, 2.8, 1.4 Hz, 1H, C7H), 4.81
(d, J= 11.6 Hz, 1H, NCH 2N), 4.71 (d, J= 12.0, Hz, 1H,
NCH 2N), 4.66 (dd, J= 11.7, 1.3 Hz, 1H, NCH 2N), 4.63-
4.60 (m, 2H, C8H, NCH 2N), 3.92 (d, J= 17.7 Hz, 1H,
C4 Ha), 3.85 (d, J= 17.7 Hz, 1H, C4Hb) 3.33 (s, 3H,
OCH3), 2.92 (s, 3H, Ci6H3), 2.79 (dd, J= 17.9, 11.2,
Hz, 1H, C6Ha), 2.39 (dd, J= 17.9, 2.9 Hz, 1H, C6Hb),
2.23 (s, 3H, NArCH 3).
8 204.4, 159.5, 155.8, 145.4, 132.7, 130.1, 123.6, 119.4,
114.7, 112.7, 105.7, 83.4, 67.8, 66.8, 55.6, 55.0, 52.7,
41.1, 32.2, 20.7.
3248 (in), 2921 (m), 1724, (m), 1667 (s), 1640 (s), 1514
(s), 1422 (s), 1316 (s), 1087 (m).
calc'd for C22H26BrN5NaO4, [M+Na]*: 526.1060,
found: 526.1063.
+81.1 (c 0.62, CHCl3).
101-105 *C.


















Aqueous hydrochloric acid solution (0.5 N, 23.8 mL, 11.9 mmol, 2.00 equiv) was added via
syringe to a solution of ketone (+)-56 (3.00 g, 5.90 mmol, 1 equiv) in methanol (1.18 L) at 23 'C, and
the entire reaction mixture was degassed thoroughly by passage of a stream of argon. After the
reaction mixture was heated to 65 *C for 4 h, the light pink reaction mixture was allowed to cool to
23 'C, and was concentrated to approximately 250 mL volume under reduced pressure. The resulting
solution was basified to pH = 8 by the addition of a 5% aqueous ammonium hydroxide in methanol
solution and the reaction mixture became a clear light orange color. A silica gel (50 mL) slurry in a
1% aqueous ammonium hydroxide in methanol solution (75 mL) was added and the resulting mixture
was concentrated to dryness under reduced pressure. The crude residue adsorbed onto silica gel was
purified by flash column chromatography (silica gel: diam. 5 cm, ht. 15 cm; eluent: 9% methanol, 1%
ammonium hydroxide in chloroform to 13.5% methanol, 1.5% ammonium hydroxide in chloroform)
to afford (+)-O-methyl-pre-agelastatin A (47, 1.87 g, 89%) as a light tan solid.9
(+)-O-Methyl-pre-agelastatin A (47) was found to be 99% ee by chiral HPLC analysis
[Chiralcel OD-H; 0.8 mL/min; 35% isopropanol in hexanes; tR(major) = 14.9 min, tR(minor) = 12.1
min]. Crystals of (+)-O-methyl-pre-agelastatin A (47) suitable for X-ray diffraction were obtained
from methanol. (+)-O-Methyl-pre-agelastatin A (47) is best used immediately in the following step;
however, it could be stored as a dry solid at -8 'C under an argon atmosphere, or as a suspension
frozen in benzene at -8 0C under an argon atmosphere for greater than a month. (+)-O-Methyl-pre-
agelastatin A (47) is sparingly soluble in organic solvents, methanol, and water.
'H NMR (500 MHz, CD 30D, 21 *C):




8 6.90 (dd, J= 4.1, 0.4 Hz, 1H, Ci5H), 6.27 (d, J= 4.1
Hz, 1H, C14H), 5.97 (t, J= 0.7 Hz, 1H, C4H), 4.76 (d, J
= 1.6 Hz, 1H, C8H), 4.54 (ddd, J= 8.4, 6.1, 1.5 Hz, 1H,
C7H), 3.35 (s, 3H, OCH 3), 3.14 (s, 3H, C16H3), 2.95
(ddd, J= 15.4, 6.0, 0.8 Hz, 1H, C6Ha), 2.78 (ddd, J
15.4, 8.5, 0.8 Hz, 1H, C6Hb).
8 161.2, 156.1, 124.5, 120.2, 116.1, 113.5, 108.8, 108.5,
84.9, 58.0, 55.2, 29.5, 27.7.
3227 (br-m), 2936 (w), 1666 (s), 1552 (m), 1460 (w),
1421 (m), 1386 (w), 1319 (m), 1085 (m).
calc'd for C13Hi 5BrN4NaO3, [M+Na]*: 377.0220,
found: 377.0221.
+248.7 (c 0.032, methanol).
M.P.: 157-161 'C (dec.).








MeSO3H, H20100 *C, 15 h;
MeSO 3H,MeOH










(-)-Agelastatin A (1) and (-)-O-methyl-di-epi-agelastatin A (61):
A solution of methanesulfonic acid (10.9 mL, 168 mmol, 20.0 equiv) in water (100 mL) was
added slowly via syringe to a solution of (+)-O-methyl-pre-agelastatin A (47, 2.97 g, 8.39 mmol, 1
equiv) in water (1.68 L) at 23 *C. The entire reaction mixture was degassed thoroughly by passage of
a stream of argon, and the mixture was heated to 100 *C. After 15 h, the reaction mixture was
allowed to cool to 23 'C and was basified to pH = 8 by addition of 5% aqueous ammonium
hydroxide solution. The resulting mixture was concentrated under reduced pressure. The crude
residue was dissolved in methanol (839 mL) and the resulting mixture was acidified to pH = 2 by the
addition of a solution of 5% methanesulfonic acid in methanol (20 mL). After 5 min, the reaction
mixture was basified to pH = 8 by addition of by addition of 5% aqueous ammonium hydroxide
solution. The resulting mixture was concentrated under reduced pressure, and the crude residue
adsorbed onto silica gel was purified by flash column chromatography (silica gel: diam. 7 cm, ht. 14
cm; eluent: 9% methanol, 1.0% ammonium hydroxide in chloroform to 13.5% methanol, 1.5%
ammonium hydroxide in chloroform) to afford (-)-agelastatin A (1, 1.40 g, 49%) as a tan solid.9
(-)-Agelastatin A (1) was found to be 99% ee by chiral HPLC analysis [Chiralpak AD-H; 0.53
mL/min; 10% isopropanol in hexanes; tR(major) = 40.0 min, tR(minor) = 24.5 min]. (-)-O-Methyl-di-
epi-agelastatin A (61, 668 mg, 22%) was also isolated as light tan solid. (-)-Agelastatin A (1) is
sparingly soluble in organic solvents, methanol, and water. Crystals of (-)-agelastatin A (1) suitable
for X-ray diffraction were obtained from methanol.
(-)-agelastatin A (1):
IH NMR (500 MHz, CD 30D, 21 'C):
1C NMR (125.8 MHz, CD 30D, 21 "C):
FTIR (neat) cm-1:
HRMS (ESI) (m/z):
6 6.92 (d, J= 4.0 Hz, 1H, C15H), 6.33 (d, J= 4.1 Hz,
1H, C14H), 4.60 (app-dt, J= 11.9, 6.0 Hz, 1H, C7H),
4.09 (d, J= 5.4 Hz, 1H, C8H), 3.88 (s, 1H, C4H), 2.81
(s, 3H, C16H3 ), 2.65 (dd, J= 13.1, 6.3 Hz, 1H, C6H),
2.10 (app-t, J= 12.7 Hz, 1H, C6H).
8 161.6, 161.2, 124.3, 116.2, 113.9, 107.4, 95.8, 67.5,
62.3, 54.5, 40.1, 24.4.
3269 (m), 2921 (w), 1651 (s), 1552 (w), 1423 (m), 1378
(w), 1090 (w), 746 (w).
calc'd for C12H13BrN4NaO 3, [M+Na]*: 363.0063,
found: 363.0073.
42
[a]D 22 -87.6 (c 0.10, methanol).10
M.p.: 213-215 'C (dec.).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.34 (CAM, UV).
(-)-O-methyl-di-epi-agelastatin A (61):
'H NMR (500 MHz, CD 30D, 21 C):




8 6.90 (d, J= 4.1 Hz, 1H, C1sH), 6.33 (d, J= 4.1 Hz,
1H, C14H), 4.95 (ddd, J= 10.4, 7.2, 5.1 Hz, 1H, C7H),
4.42 (app-t, J= 5.4 Hz, 1H, CsH), 4.22 (d, J= 5.9 Hz,
1H, C4H), 3.13 (s, 3H, OCH 3), 2.69 (s, 3H, NCH 3 ), 2.53
(dd, J= 13.4, 7.1 Hz, 1H, C6H), 2.32 (dd, J= 13.5 10.5
Hz, 1H, C6H).
8 162.4, 161.6, 124.9, 116.3, 114.3, 107.2, 100.1, 59.3,
58.6, 55.1, 49.9, 42.2, 24.9.
3374 (m), 2951 (w), 1703 (s), 1659 (s), 1552 (m), 1424
(m), 1346 (w).
calc'd for C13HisBrN4NaO3, [M+Na]+: 377.0220,
found: 377.0220.
-70.0 (c 0.042, methanol).
205-208 *C.
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.60 (CAM, UV).
10 Optical rotations from natural samples of (-)-agelastatin A (1):
[a]D =-59.3 (c 0.13, methanol), Hong, T. W.; Jimenez, D. R.; Molinski, T. F. J. Nat. Prod., 1998,61, 158-161.
[a]D2 6 = -88.9 (c 0.09, chloroform), Pettit, G. R.; Ducki, S.; Herald, D. L.; Doubek, D. L.; Schmidt, J. M.; Chapuis, J. Oncol. Res.
2005,15, 11-20.
[a]D2 = -58.5 (c 0.21, methanol), Tilvi, S.; Moriou, C.; Martin, M.; Gallard, J.; Sorres, J.; Patel, K.; Petek, S.; Debitus, C.;
Ermolenko, L.; Al-Mourabit, A. J. Nat. Prod. 2010, 73, 720-723.
Optical rotations from synthetic samples of (-)-agelastatin A (1):
[a]D 20 = -65.5 (c 0.5, methanol), Feldman, K. S.; Saunders, J. C. J. Am. Chem. Soc. 2002,124, 9060-9061.
[a]D = -84.2 (c 1, methanol), Domostoj, M. M.; Irving, E.; Scheinmann, F.; Hale, K. J. Org. Lett. 2004, 6, 2615-2618.
[a]D 20 = -62.2 (c 0.18, methanol), Davis, F. A.; Deng, J. Org. Lett. 2005, 7, 621-623.
(+)-Agelastatin A, [a]D = +53.2 (c 0.13, methanol), Trost, B. M.; Dong, G. J. Am. Chem. Soc. 2006, 128, 6054-6055.
[a]D14 = -83.8 (c 0.21, methanol), Ichikawa, Y.; Yamaoka, T.; Nakano, K.; Kotsuki, H. Org. Lett. 2007, 9, 2989-2992.
[a]D26 = -64.4 (c 0.15, methanol), Yoshimitsu, T.; Ino, T.; Tanaka, T. Org. Lett. 2008, 10, 5457-5460.
[a]D23 = -83.4 (c 0.93, methanol), Hama, N.; Matsuda, T.; Sato, T.; Chida, N. Org. Lett. 2009, 11, 2687-2690.
[a]D23 = -87.0 (c 1.1, methanol), When, P. M.; Du Bois, J. Angew. Chem., Int. Ed. Engl. 2009, 48, 3802-3805.
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aggelastatin A (1) ageiastatin A (61)
66% 30%
Equilibration of (-)-O-methyl-di-epi-agelastatin A (29) to (-)-agelastatin A (1):
A solution of methanesulfonic acid (613 ptL, 9.44 mmol, 5.00 equiv) in water (10 mL) was
added slowly via syringe to a solution of (-)-O-methyl-di-epi-agelastatin A (61, 668 mg, 1.89 mmol,
1 equiv) in water (378 mL) at 23 *C. The entire reaction mixture was degassed thoroughly by passage
of a stream of argon and was heated to 100 *C. After 21 h, the reaction mixture was allowed to cool
to 23 'C and was basified to pH = 8 by addition of 5% aqueous ammonium hydroxide solution. The
resulting mixture was concentrated under reduced pressure. The crude residue was dissolved in
methanol (378 mL) and the resulting mixture was acidified to pH = 2 by the addition of a solution of
5% methanesulfonic acid in methanol (20 mL). After 5 min, the reaction mixture was basified to pH
= 8 by addition of by addition of 5% aqueous ammonium hydroxide solution. The resulting mixture
was concentrated under reduced pressure, and the crude residue adsorbed onto silica gel was purified
by flash column chromatography (silica gel: diam. 4 cm, ht. 14 cm; eluent: 9% methanol, 1.0%
ammonium hydroxide in chloroform to 13.5% methanol, 1.5% ammonium hydroxide in chloroform)
to afford (-)-agelastatin A (1, 421 mg, 66%) as a tan solid. (-)-O-Methyl-di-epi-agelastatin A (61,
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1-Methyl-3-((tricyclohexylstannvl)methvl)urea (63):
Aqueous hydrochloric acid solution (0.5 N, 2.30 mL, 1.15 mmol, 2.00 equiv) was added via
syringe to a solution of stannyltriazone 58 (338 mg, 0.576 mmol, 1 equiv) in methanol (11.5 mL) at
23 'C, and the resulting mixture was heated to 60 'C. After 5 h, the reaction mixture was allowed to
cool to 23 'C, and was neutralized with saturated aqueous sodium bicarbonate solution (4 mL). The
resulting mixture was concentrated under reduced pressure, and the residue was partitioned between
dichloromethane (50 mL) and water (50 mL). The layers were separated, and the aqueous layer was
extracted with dichloromethane (2 x 50 mL). The combined organic layers were dried over
anhydrous sodium sulfate and were concentrated under reduced pressure. The crude residue was
purified by flash column chromatography (silica gel: diam. 2.5 cm, ht. 15 cm; eluent: 15% ethyl
acetate in dichloromethane) to afford stannylurea 63 (104 mg, 40%) as a white crystalline solid.9
'H NMR (500 MHz, CDCl 3, 21 'C):
"C NMR (125.8 MHz, CDCl 3, 21 *C):
FTIR (neat) cm-1:
HRMS (ESI) (m/z):
6 4.63 (br-s, 1H, NH), 4.33 (br-s, 1H, NH), 2.77 (br-d, J
= 4.6 Hz, C16H3 ), 2.75-2.65 (m, 2H, C4 H2 ), 1.85-1.74
(m, 6H, cHx), 1.70-1.44 (m, 18H, cHx), 1.36-1.16 (m,
9H, cHx).
8 160.7, 32.5, 29.3, 27.5, 27.2, 26.9. 22.3.
3357 (br-m), 2912 (s), 2842 (s), 1628 (s), 1580 (s), 1442
(m), 1279 (m), 1167 (w).
calc'd for C21H4oN2NaOSn, [M+Na]*: 479.2068,
found: 479.2056.
M.P.: 144-148 0C.
TLC (15% ethyl acetate in dichloromethane), Rf 0.25 (CAM, UV).
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Direct synthesis of (+)-O-methyl-pre-agelastatin A (47):
Anhydrous tetrahydrofuran (1 mL) was added via syringe to a flask charged with (+)-57 (20.0
mg, 49.0 imol, 1 equiv), urea 63 (67.0 mg, 147 pimol, 3.00 equiv), and copper(I)-thiophene-2-
carboxylate (CuTC, 23.3 mg, 123 pmol, 2.50 equiv) at 23 *C and under an argon atmosphere. The
entire reaction mixture was degassed thoroughly by passage of a stream of argon, and the mixture
was heated to 40 'C. After 4 h, the reaction mixture was allowed to cool to 23 'C, was diluted with
methanol (7 mL), and was filtered through a plug of celite with methanol washings (3 x 1 mL).
Aqueous hydrochloric acid solution (0.5 N, 196 gL, 98.0 pmol, 2.00 equiv) was added to the filtrate,
and the resulting mixture was heated to 65 'C. After 4 h, the reaction mixture was allowed to cool to
23 *C and was basified to pH = 8 by the addition of a 5% aqueous ammonium hydroxide in methanol
solution. The resulting mixture was concentrated under reduced pressure, and the crude residue
adsorbed onto silica gel was purified by flash column chromatography (silica gel: diam. 1.5 cm, ht.
10 cm; eluent: 10% methanol in dichloromethane to 15% methanol in dichloromethane) to afford (+)-
O-methyl-pre-agelastatin A (47, 10.0 mg, 58%) as a tan solid."
(+)-O-Methyl-pre-agelastatin A (47) was found to be 99% ee by chiral HPLC analysis
[Chiralcel OD-H; 0.8 mL/min; 35% isopropanol in hexanes; tR(major) = 14.9 min, tR(minor) = 12.1
min.
" The reaction procedure was developed and optimized by Dr. Dustin Siegel. Final experimental procedure and yield were adopted












Br 15 0(-)-agelastatin B (2)
(-)-Agelastatin B (2):
N-Bromosuccinimide (NBS, 5.0 mg, 28 .tmol, 1.1 equiv) was added as a solid in one portion
to a solution of (-)-agelastatin A (1, 9.1 mg, 27 Imol, 1 equiv) and 2,6-di-tert-butyl-4-methylpyridine
(DTBMP, 8.3 mg, 41 jtmol, 1.5 equiv) in water (500 [tL) and tetrahydrofuran (1.00 mL) at 0 *C.
After 2 h, a mixture of saturated aqueous sodium thiosulfate solution and saturated aqueous sodium
bicarbonate solution (1:1, 100 [tL,) was added, and the resulting mixture was purified directly by
flash column chromatography (silica gel: diam. 1.5 cm, ht. 9 cm; eluent: 9% methanol, 1.0%
ammonium hydroxide in chloroform to 13.5% methanol, 1.3% ammonium hydroxide in chloroform)
to afford (-)-agelastatin B (2, 9.4 mg, 84%) as a white crystalline solid.
(-)-Agelastatin B (2) was found to be 99% ee by chiral HPLC analysis [Chiralpak AD-H;
0.53 mL/min; 10% isopropanol in hexanes; tR(major) = 27.7 min, tR(minor) = 21.1 min). (-)-
Agelastatin B (2) is sparingly soluble in organic solvents, methanol, and water. Crystals of (-)-
agelastatin B (2) suitable for X-ray diffraction were obtained from methanol. For a thermal ellipsoid
representation of (-)-agelastatin B (2), see page S58.
'H NMR (500 MHz, CD 30D, 21 'C):




8 6.97 (s, 1H, Ci5H), 4.60 (app-dt, J= 12.0, 6.0 Hz, 1H,
C7H), 4.11 (d, J= 5.4 Hz, 1H, C8H), 3.88 (s, IH, C4H),
2.81 (s, 3H, C16H3), 2.68 (dd, J= 13.1, 6.5 Hz, 1H,
C6Ha), 2.12 (app-t, J= 12.6 Hz, 1H, C6Hb).
8 161.5, 160.2, 124.9, 117.1, 108.9, 101.8, 95.7, 67.5,
62.2, 55.5, 40.0, 24.4.
3219 (m), 2919 (m), 1639 (s), 1548 (m), 1497 (m), 1403
(m), 1360 (m).
calc'd forC 12H1 3Br 2N40 3, [M+H]: 418.9349,
found: 418.9343.
-60.6 (c 0.018, methanol).1 2
211-214 'C (dec.).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.25 (CAM, UV).
12 Literature value: []D 2 = -60.3 (c 0.50, methanol), Feldman, K. S.; Saunders, J. C. J. Am. Chem. Soc. 2002,124,9060-9061.
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Diiodomethane (3.3 mL, 40 mmol, 5.0 equiv) was added dropwise via syringe to a solution of
diethylzinc (1 M in hexanes, 20 mL, 20 mmol, 2.5 equiv) in tetrahydrofuran (27 mL) at -78 'C, and
the reaction mixture was warmed to -40 *C. After 1 h, a solution of tricyclohexyltin chloride (S5, 3.3
g, 8.0 mmol, 1 equiv) in tetrahydrofuran (6 mL) was added via cannula, and the reaction mixture was
warmed to 0 'C. After 3 h, the reaction mixture was allowed to warm to 23 'C. After an additional
12 h, the reaction mixture was partitioned between heptanes (80 mL) and water (26 mL). Aqueous
hydrochloric acid solution (1 N, 30 mL) was added, and the layers were separated. The organic
phase was washed with water (2 x 25 mL) and brine (25 mL), was dried over anhydrous sodium
sulfate, and was concentrated under reduced pressure to afford crude S6 as a white solid.
Crude S6 was dissolved in dimethylformamide (40 mL), and potassium phthalimide (2.4 g, 13 mmol,
1.6 equiv) was added as a solid at 23 'C. After 3 h, the reaction mixture was partitioned between
water (400 mL) and ethyl acetate (400 mL). The layers were separated, and the organic layer was
washed with water (200 mL), was dried over anhydrous sodium sulfate, and was concentrated under
reduced pressure. The residue was purified by flash column chromatography (silica gel: diam. 4 cm,
ht. 11 cm; eluent: 2.5% ethyl acetate in hexane) to afford stannylphthalimide S7 (2.6 g, 62% over 2
steps) as a light green solid.
'H NMR (500 MHz, CDCl 3, 21 'C):
1C NMR (125.8 MHz, CDCl 3, 21 'C):
FTIR (neat) cni t:
HRMS (ESI) (m/z):
6 7.75 (dd, J = 5.3, 3.1 Hz, 2H, Arl), 7.62 (dd, J = 5.5,
3.1 Hz, 2H, ArH), 3.19 (s, 2H, C4H2) 1.86-1.74 (M, 6H,
'Hx), 1.64-1.46 (in, 18H, cHx), 1.30-1.10 (in, 9H, cHx).
6 168.9, 133.7, 132.5, 122.8, 32.2, 29.3, 28.0, 27.2, 19.4.
3451 (w), 2920 (s), 2843 (s), 1773 (s), 1705 (s),
(s), 1056 (s), 879 (s), 717 (s).




TLC (9% ethyl acetate in hexane), Rf. 0.5 (CAM, UV).
"For a previous report of the synthesis of compounds related to S7, see: Jensen, M. S.; Yang, C.; Hsiao, Y.; Rivera, N.; Wells, K. M.;
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Hydrazine monohydrate (10.6 mL) was added dropwise via syringe to a solution of
stannylphthalimide S7 (2.61 g, 4.95 mmol, 1 equiv) in ethanol (80 mL) at 80 'C. After 1 h, the
reaction mixture was allowed to cool to 23 *C, and was partitioned between water (480 mL) and
diethyl ether (480 mL). The layers were separated, and the organic layer was washed with water (3 x
400 mL) and brine (200 mL), was dried over anhydrous sodium sulfate, and was concentrated under
reduced pressure to afford stannylamine S9. Stannylamine S9 was observed to be highly sensitive,
and was used immediately in the following step. 14
Stannylamine S9 was dissolved in tetrahydrofuran (96 mL), and trimethylsilyl isocyanate (2.07 mL
14.4 mmol, 2.97 equiv) and isopropanol (590 L, 7.66 mmol, 1.55 equiv) were added sequentially at
23 'C. After 2 h, water (10 mL) was added and the resulting mixture was concentrated under reduced
pressure. The residue was purified by flash column chromatography (silica gel: diam. 4.0 cm, ht. 9
cm; eluent: 50% ethyl acetate in hexane)
white crystalline solid.
H NMR (500 MHz, CDCl3, 21 'C):
"C NMR (125.8 MHz, CDCl3, 21 *C):
FTIR (neat) cnfi:
HRMS (ESI) (m/z):
TLC (50% ethyl acetate in hexane), Rf
to afford stannylurea 64 (1.58 g, 72% over two steps) as a
6 4.46 (br-s, 2H, NIH 2), 4.39 (br-s, lH, N3H), 2.75 (br-s,
2H, C4H 2), 1.88-1.78 (m, 6H, cHx), 1.68-1.46 (m, 18H,
cHx), 1.36-1.16 (m, 9H, cHx).
6 160.4, 32.5, 29.4, 27.3, 27.1, 23.0.
3353 (m), 3207 (w), 2917 (s), 2845 (s), 1646 (s), 1589
(s), 1554 (s), 1444 (s), 1350 (m), 1169 (m).




1 For a previous report of the synthesis of derivatives related to S9, see: Pearson, W. H.; Stoy, P.; Mi, Y J. Org. Chem. 2004, 69,19 19-1939.
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Anhydrous tetrahydrofuran (77 mL, degassed thoroughly by passage of a stream of argon)
was added via cannula to a flask charged with thioester (+)-57 (314 mg, 769 pmol, 1 equiv), urea 64
(1.02 g, 2.31 mmol, 3.00 equiv), and copper(I)-thiophene-2-carboxylate (CuTC, 306 mg, 1.54 mmol,
2.00 equiv) at 23 'C under an argon atmosphere, and the reaction mixture was heated to 50 'C. After
2 h, the reaction mixture was allowed to cool to 23 'C and was filtered through a plug of celite with
methanol washings (3 x 10 mL). The resulting mixture was concentrated under reduced pressure,
and the crude residue adsorbed onto silica gel was purified by flash column chromatography (silica
gel: diam. 4.0 cm, ht. 10 cm; eluent: 14.0% methanol, 1.5% ammonium hydroxide in chloroform) to
afford a mixture of the C4-C5 coupled open urea and Ni-C5 hemiaminal cyclized diastereomers
(194.1 mg) as a clear colorless oil. Aqueous hydrochloric acid solution (0.5 N, 2.20 mL, 1.08 mmol,
1.40 equiv) was added via syringe to a solution of this colorless oil in methanol (54 mL) at 23 'C, and
the resulting mixture was heated to 45 'C under an argon atmosphere. After 18 h, the reaction
mixture was allowed to cool to 23 'C and was neutralized with an 18.0% methanol, 2.0% ammonium
hydroxide in chloroform solution. The resulting mixture was concentrated under reduced pressure,
and the crude residue adsorbed onto silica gel was purified by flash column chromatography (silica
gel: diam. 2.5 cm, ht. 10 cm; eluent: 14.0% methanol, 1.5% ammonium hydroxide in chloroform) to
afford (+)-O-methyl-pre-agelastatin D (65, 162.2 mg, 62% over two steps) as a tan solid.
IH NMR (500 MHz, CD 30D, 21 'C):




8 6.89 (dd, J= 4.0, 0.4 Hz, 1H, Ci5H), 6.26 (d, J= 4.1
Hz, 1H, C14H), 5.94 (t, J= 0.7 Hz, 1H, C4H), 4.68 (d, J
= 1.6 Hz, 1H, C8H), 4.62 (ddd, J= 7.9, 6.9, 1.4 Hz, 1H,
C7 H), 3.34 (s, 3H, OCH 3 ), 2.76 (ddd, J= 15.0, 6.8, 0.9
Hz, 1H, C6Ha), 2.70 (ddd, J= 15.0, 7.7, 0.9 Hz, 1H,
C6Hb).
8 161.2, 157.2, 124.4, 118.7, 116.1, 113.4, 109.1, 108.7,
84.9, 57.8, 55.2, 30.7.
3219 (br-s), 2936 (w), 2408 (w), 1680 (s), 1553 (m),
1459 (w), 1422 (m), 1387 (w), 1323 (m), 1088 (m).
calc'd for C12H12BrN4NaO3, [M+Na]*: 363.0063,
found: 363.0053.
+234.5 (c 0.362, methanol).










100 0, 22 h;
HCI, MeOH
23 *C, 10 min
(-)-agelastatin 0 (4) (-)-O-Me-di-epi-
agelastatin 0 (67)
26% 9%
(-)-Agelastatin D (4), (-)-O-methyl-di-epi-agelastatin D (67), 68, and 70:
To a solution of (+)-O-methyl-pre-agelastatin D (65, 32.9 mg, 96.4 [tmol, 1 equiv) in water
(32 mL, degassed thoroughly by passage of a stream of argon) at 23 'C was added methanesulfonic
acid (313 [tL, 4.82 mmol, 50.0 equiv), and the reaction mixture was heated to 100 'C. After 22 h, the
reaction mixture was allowed to cool to 23 'C, was basified to pH = 8 by addition of ammonium
hydroxide, and was concentrated under reduced pressure. The residue was dissolved in methanol (32
mL) and the resulting mixture was acidified to pH = 3 by the addition of aqueous hydrochloric acid
solution (1 N, 386 [tL, 0.386 mmol, 4.00 equiv). After 10 min, the reaction mixture was basified to
pH = 8 by the addition of ammonium hydroxide. The resulting mixture was concentrated under
reduced pressure, and the crude residue adsorbed onto silica gel was purified by flash column
chromatography (silica gel: diam. 2 cm, ht. 3 cm; eluent: 14.0% methanol, 1.5% ammonium
hydroxide in chloroform) to afford (-)-agelastatin D (4, 8.2 mg, 26%) as a tan solid.
(-)-Agelastatin D (4) was found to be 99% ee by chiral HPLC analysis [Chiralpak AD-H;
0.53 mL/min; 10% isopropanol in hexanes; tR(major) = 47.7 min, tR(minor) = 29.3 min]. Crystals
suitable for X-ray diffraction were obtained from methanol. For a thermal ellipsoid representation of
(-)-agelastatin D (4), see page S62. (-)-Agelastatin D (4) was sparingly soluble in organic solvents,
methanol, and water. (-)-Di-epi-methoxy-agelastatin D (67, 2.9 mg, 9%) was also isolated from the
reaction mixture as a light yellow solid. An equal amount of pyrrolopyrazinone 68 and tetracycle 70
constituted approximately 40% of the mass balance.
(-)-agelastatin D (4):
'H NMR (500 MHz, CD 30D, 21 'C):
'H NMR (500 MHz, Pyridine-d, 21 *C):
"C NMR (125.8 MHz, Pyridine-d, 21 'C):
FTIR (neat) cm':
6 6.91 (d, J= 4.1 Hz, 1H, Ci 5H), 6.33 (d, J= 4.1 Hz,
1H, C14H), 4.74 (app-dt, J= 11.9, 6.0 Hz, 1H, C7H),
4.10 (d, J= 5.7 Hz, 1H, C8H), 3.91 (s, 1H, C4H), 2.54
(dd, J = 12.6, 6.6 Hz, 1H, C6Ha), 2.21 (app-t, J= 12.4
Hz, 1H, C6Hb).
8 9.20 (s, 1H, NH), 8.92 (s, 1H, NH), 8.82 (s, 1H, NH),
8.30 (s, 1H, NH), 7.28 (d, J= 3.9 Hz, 1H, C15H), 6.42
(d, J= 3.9 Hz, 1H, C14H), 5.13 (app-dt, J= 11.9, 6.0 Hz,
1H, C7H), 4.66 (d, J= 2.2 Hz, 1H, C4H), 4.44 (d, J= 5.5
Hz, 1H, CsH) 2.95 (dd, J= 12.4, 6.5 Hz, 1H, C6 Ha),
2.84 (app-t, J= 12.2 Hz, 1H, C6Hb).
6 162.1, 159.7, 125.5, 114.7, 113.0, 105.5, 93.1, 69.9,
62.7, 54.8, 44.5.
3461 (br-s), 2360 (w), 1674 (s), 1640 (s), 1424 (w),
1218 (w), 1114 (w), 1073 (w), 734 (m).
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HRMS (ESI) (m/z): calc'd for CIIH11BrN 4NaO3 , [M+Na]*: 348.9907,
found: 348.9910.
-43.2 (c 0.04, methanol)," -79.4 (c 0.02, pyridine).[a]D 22:
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.18 (CAM, UV).
(-)-O-methyl-di-epi-agelastatin D (67):
H NMR (500 MHz, CD30D, 21 'C):




6 6.91 (d, J= 4.1 Hz, 1H, Ci5H), 6.33 (d, J= 4.1 Hz,
lH, C14H), 4.94-4.8616 (M, 1H, C7H), 4.41 (app-t, J=
5.3 Hz, 1H, C8H), 4.22 (d, J= 5.6 Hz, 1H, C4H), 3.25 (s,
3H, OCH 3), 2.64 (dd, J= 13.3, 7.2 Hz, 1H, C6Ha), 2.20
(dd, J= 13.4, 10.8 Hz, 1H, C6Hb).
8 162.8, 159.8, 125.8, 114.9, 113.2, 105.3, 97.0, 62.6,
58.3, 55.0, 49.5, 44.0.
3428 (m), 1688 (s), 1647 (s), 1550 (s), 1422 (m), 1344
(w), 1068 (m).
calc'd for C12H13BrN4NaO3, [M+Na]+: 363.0063,
found: 363.0062.
-78.1 (c 0.06, pyridine).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.5 (CAM, UV).
Br jH HMac




H NMR (500 MHz, CD 30D, 21 'C):
'H NMR (500 MHz, CDCl 3, 21 'C):
3C NMR (125.8 MHz, CDCl 3, 21 'C):
7.29 (dd, J=
1H), 6.72 (d,
5.9, 0.8 Hz, 1H), 7.12 (dd, J= 4.3, 0.8 Hz,
J= 5.9 Hz, 1H), 6.69 (d, J= 4.2 Hz, 1H).
6 8.96 (s, 1H, NH), 7.16 (dd, J= 4.2, 0.8 Hz, 1H, C15H),
7.09 (d, J= 5.96, 1H, C7H), 6.61 (d, J= 4.2 Hz, 1H,
C14H), 6.55 (app-t, J= 5.8 Hz, 1H, C8H).
6 156.8"1, 125.017, 115.2, 114.3, 111.6, 106.6, 101.1.
" Literature value: [a]aD = -12 (c 0.07, methanol), Tilvi, S.; Moriou, C.; Martin, M.; Gallard, J.; Sorres, J.; Patel, K.; Petek, S.;
Debitus, C.; Ermolenko, L.; Al-Mourabit, A. J. Nat. Prod. 2010, 73, 720-723.
16 Resonance is partially obscured by the H20 resonance in CD 30D.
17 Resonance is partially obscured due to low solubility/concentration, however, this signal is clearly observed via gHMBC analysis.
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FTIR (neat) cm 1:
HRMS (ESI) (m/z):
3030 (w), 1656 (s), 1412 (m), 1360 (m), 1207 (w), 941
(m).
calc'd for C7H6BrN20, [M+H]+: 212.9658,
found: 212.9664.
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.69 (CAM, UV).
HMBC correlations (500 MHz, CDC13, 21 'C): C1O-H8, C11-H14, C11-H7, C11-H15, C14-H15,
C8-H7, C15-H14, C7-H8, C13-H14, C13-H7, C13-




'H NMR (500 MHz, DMSO-d, 21 'C):
13C NMR (125.8 MHz, DMSO-d, 21 *C):
FTIR (neat) cmf:
8 10.32 (d, J= 4.4 Hz, 1H, NH), 6.98 (s, 1H, NH), 6.87
(d, 1H, J= 3.9 Hz, 1H, Ci 5H), 6.61 (s, 1H, NH), 6.55 (d,
J= 3.9 Hz, 1H, C14H), 6.49 (d, J= 3.9, 1H, C8H), 4.80
(d, J= 6.9 Hz, 1H, C4H), 4.06 (app-dd, J= 10.5, 5.0 Hz,
1H, C5H), 2.92 (dd, J= 16.2, 2.8 Hz, 1H, C6Ha), 2.81
(dd, J= 16.2, 5.5 Hz, 1H, C6Hb).
8 162.7, 155.5, 127.0, 121.5, 111.9, 111.0, 110.8, 109.0,
48.5, 47.6, 25.5.
3446 (bs), 2361 (w), 1644 (s), 1447 (w), 1194 (m), 1049
(w).
HRMS (ESI) (m/z): calc'd for CIIHIIN4 0 2 , [M+H]*: 231.0887,
found: 231.0886.
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.24 (CAM, UV).
HMBC correlations (500 MHz, DMSO-d, 21 *C): C2-H4, C2-H1, C2-H3, C1O-H8, C13-H5, C13-
H14, C13-H15, C11-H14, C11-H15, C11-H9, C7-H6,
C7-H5, C7-H8, C8-H6, C14-H4, C14-Hi5, C15-H14,
C5-H6, C5-H4, C5-Hi, C5-H3, C4-H6, C4-Hi, C4-H3,
C6-H4. Key correlations are shown in bold.
53
"H MeSO3H, H20 54N- H
H 100 C, 25 h; H HBr - Br -HN-H HCI, MeOH 13 N N-H




agelastatin D (67)-)-ageastatin (4)
Equilibration of (-)-0-methyl-di-epi-agelastatin D (67) to (-)-a2elastatin D (4):
Methanesulfonic acid (34 [tL, 523 [tmol, 57.3 equiv) was added to a solution of (-)-O-methyl-
di-epi-agelastatin D (67, 3.11 mg, 9.12 [imol, 1 equiv) in water (4 mL, degassed thoroughly by
passage of a stream of argon) at 23 'C, and the reaction mixture was heated to 100 'C. After 25 h,
the reaction mixture was allowed to cool to 23 'C, was basified to pH = 8 by addition of ammonium
hydroxide, and was concentrated under reduced pressure. The residue was dissolved in methanol (4
mL) and the resulting mixture was acidified to pH = 3 by the addition of aqueous hydrochloric acid
solution (1 N, 42 [tL, 0.042 mmol, 4.6 equiv). After 10 min, the reaction mixture was basified to pH
= 8 by addition of ammonium hydroxide. The resulting mixture was concentrated under reduced
pressure, and the crude residue adsorbed onto silica gel was purified by flash column chromatography
(silica gel: diam. 1.5 cm, ht. 2.5 cm; eluent: 14.0% methanol, 1.5% ammonium hydroxide in
chloroform) to afford (-)-agelastatin D (4, 2.02 mg, 68%) as a tan solid.
(-)-Agelastatin D (4) was found to be 99% ee by chiral HPLC analysis [Chiralpak AD-H;





65 *C, 2 h
96%





Amberlyst* 15 (50.0 mg) was added to a solution of (-)-agelastatin A (1, 20.0 mg, 58.6 Vmol,
1 equiv) in methanol (11.6 mL) at 23 *C, and the resulting mixture was heated to 65 *C. After 2.5 h,
the reaction mixture was filtered through a plug of cotton, and the filtrate was concentrated to afford
(-)-agelastatin E (5, 21.0 mg, 100%) as a light tan solid. (-)-Agelastatin E (5) was sparingly soluble
in organic solvents, methanol, and water.
'H NMR (500 MHz, CD 30D, 21 'C):




6 6.91 (d, J= 4.0 Hz, 1H, C15H), 6.33 (d, J= 4.1 Hz,
1H, C14 H), 4.62 (app-dt, J= 11.9, 6.1 Hz, 1H, C7H),
4.12 (d, J= 5.6 Hz, 1H, C8H), 4.09 (s, 1H, C4H), 3.18
(s, 1H, C17H3 ), 2.79 (s, 3H, C1 6H3), 2.66 (dd, J= 13.2,
6.5 Hz, 1H, C6Ha), 2.14 (app-t, J= 12.7 Hz, 1H, C6Hb).
8 161.9, 161.1, 124.2, 116.2, 114.0, 107.5, 100.2, 62.1,
61.2, 53.9, 50.8, 39.3, 24.7.
3239 (br-m), 2927 (in), 1703 (s), 1659 (s), 1552 (in),
1425 (s), 1377 (w), 1302 (w), 1198 (w), 1103 (m).
calc'd for C13H1 4BrN40 3, [M-H]~: 353.0255,
found: 353.0254.
-63.4 (c 0.054, methanol).19
186-190 'C (dec.).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.60 (CAM, UV).
18 For a previous report of the semi-synthesis of (-)-agelastatin E (5), see: D'Ambrosio, M.; Guerriero, A.; Chiasera, G.; Pietra, F.
Helv. Chim. Acta 1994, 7, 1§95-1902.
19 Literature value: [a]D = -28 (c 0.09, methanol), Tilvi, S.; Moriou, C.; Martin, M.; Gallard, J.; Sorres, J.; Patel, K.; Petek, S.;
Debitus, C.; Ermolenko, L.; Al-Mourabit, A. J. Nat. Prod. 2010, 73,720-723.
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N-Bromosuccinimide (NBS, 5.9 mg, 33 tmol, 1.5 equiv) was added as a solid in one portion
to a solution of (-)-agelastatin D (4, 7.17 mg, 21.9 [tmol, 1 equiv) and 2,6-di-tert-butyl-4-
methylpyridine (DTBMP, 6.7 mg, 33 [imol, 1.5 equiv) in water (1.5 mL) and tetrahydrofuran (3.0
mL) at 0 'C. After 5 h, the reaction mixture was quenched with a mixture of saturated aqueous
sodium thiosulfate solution and saturated aqueous sodium bicarbonate solution (1:1, 125 [tL). The
resulting mixture was concentrated under reduced pressure, and the crude residue adsorbed onto
silica gel was purified by flash column chromatography (silica gel: diam. 2 cm, ht. 2.5 cm; eluent:
14.0% methanol, 1.5% ammonium hydroxide in chloroform) to afford (-)-agelastatin F (6, 7.69 mg,
86%) as a white solid. (-)-Agelastatin F (6) is sparingly soluble in organic solvents, methanol, and
water.
IH NMR (500 MHz, CD30D, 21 'C):




8 6.96 (s, 1H, C15H), 4.73 (app-dt, J= 11.9, 6.0 Hz, 1H,
C7H), 4.12 (d, J= 5.6 Hz, 1H, C8H), 3.91 (s, 1H, C4H),
2.56 (dd, J= 12.8, 6.4 Hz, 1H, C6Ha), 2.23 (app-t, J=
12.4 Hz, 1H, C6Hb).
8 162.8, 160.2, 124.9, 117.0, 108.8, 101.8, 93.1, 69.5,
62.2, 55.8, 43.7.
3200 (m), 2923 (m), 1677 (s), 1640 (s), 1557 (w), 1420
(m), 1117 (w).
calc'd for CIIHIoBr 2N4NaO 3, [M+H]+: 426.9012,
found: 426.9021.
-47.4 (c 0.10, methanol).20
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.25 (CAM, UV).
20 Literature value: [a]D25  - 34.3 (c 0.11, methanol), Tilvi, S.; Moriou, C.; Martin, M.; Gallard, J.; Sorres, J.; Patel, K.; Petek, S.;
Debitus, C.; Ermolenko, L.; Al-Mourabit, A. J. Nat. Prod. 2010, 73, 720-723.
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Table S1. Comparison of our data for (-)-agelastatin A (1) with literature:
16
Me,1 0
HO N 2 3
6 4N'H




Assignment Pietra's Report1  Du Bois' Report 2  This Work2 1
'H NMR, 300 MHz, CD30D 'H NMR, 400 MHz, CD 30D 'H NMR, 500 MHz, CD 30D
C4 3.89 (br-s, 1H) 3.87 (br-s, 1H) 3.88 (s, 1H)
C6' 2.65 (br-dd, J= 12.9, 6.6 Hz, 1H) 2.64 (dd, J= 12.8, 6.4 Hz, 1H) 2.65 (dd, J= 13.1, 6.3 Hz, 1H)
C6" 2.10 (br-t, J= 12.3, 12.9, Hz, 1H) 2.09 (dd, J= 12.8, 12.4 Hz, 1H) 2.10 (app-t, J= 12.7 Hz, lH)
C7 4.60 (m, J= 12.3, 6.6, 5.4 Hz, 1H) 4.59 (dt, J= 12.0, 6.0 Hz, 1H) 4.60 (app-dt, J= 11.9, 6.0 Hz, 1H)
C8 4.09 (br-d, J= 5.4 Hz, 1H) 4.08 (d, J 5.6 Hz, 1H) 4.09 (d, J = 5.4 Hz, 1H)
C14 6.33 (d, J= 4.2 Hz, 1H) 6.32 (d, J= 4.0 Hz, 1H) 6.33 (d, J= 4.1 Hz, 1H)
C15 6.92 (br-d, J= 4.2 Hz, 1H) 6.90 (d, J= 4.0 Hz, 1H) 6.92 (d, J= 4.0 Hz, 1H)
C16 2.81 (s, 3H) 2.80 (s, 3H) 2.81 (s, 3H)
Assignment Pietra's Report2' Du Bois' Report 2  This Work
'
3 C NMR, 75 MHz, CD 30D 13C NMR, 125 MHz, CD3 OD 3C NMR, 125.8 MHz, CD3 OD
C2 163.00 161.4 161.6
C4 68.98 67.4 67.5
C5 97.24 95.6 95.8
C6 41.58 40.0 40.1
C7 55.96 54.4 54.5
C8 63.76 62.2 62.3
C1O 162.65 161.1 161.2
C1I 125.71 124.1 124.3
C13 108.80 107.3 107.4
C14 115.37 113.8 113.9
C15 117.59 116.0 116.2
C16 25.79 24.2 24.4
" The reference points for the residual protium and carbon resonances of the NMR solvent were not listed. D'Ambrosio, M.;
Guerriero, A.; Debitus, C.; Ribes, 0.; Pusset, J.; Leroy, S.; Pietra, F. J. Chem. Soc., Chem. Commun. 1993, 1305-1306.
2 The reference points for the residual protium and carbon resonances of the NMR solvent were not listed. When, P. M.; Du Bois, J.
Angew. Chem., Int. Ed. Engl. 2009,48, 3802-3805.
23 In this report, the NMR spectra are referenced from the residual protium resonance, CD 30D: 8 3.31 (CHD 20D), and carbon
resonance, CD 30D: 8 49.15.
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Assignment Feldman's Report24  This Work2 1
'H NMR, 300 MHz, CD3 OD 'H NMR, 500 MHz, CD 30D
C4 3.88 (s, 1H) 3.88 (s, 1H)
C6' 2.68 (dd, J= 13.1, 6.5 Hz, 11H) 2.68 (dd, J= 13.1, 6.5 Hz, 1H)
C6" 2.12 (t, J= 12.6 Hz, 1H) 2.12 (app-t, J= 12.6 Hz, 1H)
C7 4.60 (dt, J= 11.8, 6.0 Hz, 1H) 4.60 (app-dt, J= 12.0, 6.0 Hz, 1H)
C8 4.11 (d, J= 5.5 Hz, 1H) 4.11 (d, J= 5.4 Hz, 1H)
C15 6.96 (s, 1H) 6.97 (s, 1H)
C16 2.81 (s, 3H) 2.81 (s, 3H)
Assignment Feldman's Report 2 4  This Work2 1













2 The reference point for the residual protium of the NMR solvent was not listed. The 3 C NMR spectrum is referenced from the
carbon resonance, CD 30D: 6 49.00. Feldman, K. S.; Saunders, J. C. J. Am. Chem. Soc. 2002, 124, 9060-9061.
25 We assign the CI1 13C NMR resonance to the signal at 8 124.9.
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Table S3. Comparison of our data for (-)-agelastatin D (4) with literature:








Assignment This Work2 7












26 The reference points for the residual protium and carbon resonances of the NMR solvent and the magnetic field strength were not
listed. Hong, T. W.; Jimenez, D. R.; Molinski, T. F. J. Nat. Prod., 1998,61, 158-161.
" The 13 C NMR for (-)-agelastatin D (4) has not been previously reported. In this report, the 13 C NMR spectrum is referenced from
the carbon resonances, Pyridine-d: 6 150.35.
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Assignment Molinski's Report26  This Work2 3
'H NMR, CD 30D 'H NMR, 500 MHz, CD 30D
C4 3.91 (s, 1H) 3.91 (s, 1H)
C6' 2.54 (dd, J= 12.9, 6.5 Hz, 1H) 2.54 (dd, J= 12.6, 6.6 Hz, 1H)
C6" 2.21(br-t, J= 12.9, 12.4, Hz, 1H) 2.21 (app-t, J= 12.4 Hz, 1H)
C7 4.73 (m, J= 12.4, 6.5, 5.4 Hz, 1H) 4.74 (app -dt, J= 11.9, 6.0 Hz, 1H)
C8 4.09 (d, J= 5.4 Hz, 1H) 4.10 (d, J= 5.7 Hz, 1H)
C14 6.33 (d, J= 4.1 Hz, 1H) 6.33 (d, J= 4.1 Hz, 1H)
C15 6.91 (br-d, J= 4.1 Hz, 1H) 6.91 (d, J= 4.1 Hz, 1H)











Assignment Al-Mourabit's Report28  This Work2 1
'H NMR, 600 MHz, CD30D 'H NMR, 500 MHz, CD 30D
C4 4.08 (br-s, 1H) 4.09 (s, 1H)
C6' 2.66 (dd, J= 12.9, 6.6 Hz, 1H) 2.66 (dd, J= 13.2, 6.5 Hz, 1H)
C6" 2.14 (br-t, J= 12.9, Hz, 1H) 2.14 (app-t, J= 12.7 Hz, 1H)
C7 4.62 (m, J= 12.6, 6.6 Hz, 1H) 4.62 (app-dt, J= 11.9, 6.1 Hz, 1H)
C8 4.11 (d, J= 5.4 Hz, 1H) 4.12 (d, J= 5.6 Hz, 1H)
C14 6.32 (d, J= 4.1 Hz, 1H) 6.33 (d, J= 4.1 Hz, 1H)
C15 6.91 (d, J= 4.1 Hz, 1H) 6.91 (d, J= 4.0 Hz, 1H)
C16 2.78 (s, 3H) 2.79 (s, 3H)
C17 3.18 (s, 3H) 3.18 (s, 3H)
Assignment Al-Mourabit's Report28  This Work2 1














28 The NMR spectra are referenced from the residual protium resonance, CHD 2OD: 5 3.32, and carbon resonance, CD30D: 5 49.0. S.
Tilvi, S.; Moriou, C.; Martin, M.; Gallard, J.; Sorres, J.; Patel, K.; Petek, S.; Debitus, C.; Ermolenko, L.; Al-Mourabit, A. J. Nat. Prod.
2010, 73,720-723.
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Assignment Al-Mourabit's Report28  This Work"
'H NMR, 600 MHz, CD 3OD 'H NMR, 500 MHz, CD3OD
C4 3.92 (br-s, 1H) 3.91 (s, 1H)
C6' 2.58 (dd, J= 12.9, 6.6 Hz, 1H) 2.56 (dd, J= 12.8, 6.4 Hz, 1H)
C6" 2.24 (br-t, J= 12.9 Hz, 1H) 2.23 (app-t, J= 12.4 Hz, 1H)
C7 4.74 (m, J= 12.6, 6.6 Hz, 1H) 4.73 (app-dt, J= 11.9, 6.0 Hz, 1H)
C8 4.14 (d, J= 5.5 Hz, 1H) 4.12 (d, J= 5.6 Hz, 1H)
C15 6.98 (s, 1H) 6.96 (s, 1H)
Assignment Al-Mourabit's Report28  This Work3













Crystal Structure of Bicycle (+)-49
View 1:
View 2: View 3:
62
Table S6. Crystal data and structure refinement for bicycle (+)-49.
Identification code 10011






Unit cell dimensions a = 8.4061(9) A
b = 9.2037(10) A











Completeness to theta = 29.560
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter








0.35 x 0.20 x 0.15 mm3
2.35 to 29.56'.
-1 1<=h<=l 1, -12<=k<= 12, -24<=1<=24
35594




Full-matrix least-squares on F2
3764 / 155 / 168
1.030
RI = 0.0224, wR2 = 0.0556
RI = 0.0241, wR2 = 0.0561
0.009(6)
0.646 and -0.476 e.A-3
Table S7. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A2x 103)
for bicycle (+)-49. U(eq) is defined as one third of the trace of the orthogonalized Uli tensor.




























































































































































Symmetry transformations used to generate equivalent atoms:
Table S9. Anisotropic displacement parameters (A2x 103) for bicycle (+)-49. The anisotropic












































































































































































displacement parameters (A2x 10 3)
x y z U(eq)
H(8) -75 9846 6065 16
H(6A) 1454 8430 7148 18
H(6B) 2569 9420 7681 18
H(9) 1070(20) 8200(20) 5292(12) 18
H(7) 1718 11442 6786 14
H(14) 7367 10959 6613 20
H(16A) -1233 10550 9060 44
H(16B) -1588 8890 9275 44
H(16C) -2402 9605 8532 44
H(15) 6697 9077 5590 18
H(17A) 261 10338 4475 52
H(17B) 79 12068 4503 52
H(17C) -1060 11065 5016 52
65






Table S11. Crystal data and structure refinement for thioester (+)-57.
Identification code 10013






Unit cell dimensions a = 9.2556(9) A
b= 8.0917(8) A











Completeness to theta = 29.13'
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
















Full-matrix least-squares on F2
4583 / 203 / 222
1.008
RI = 0.0251, wR2 = 0.0560
RI = 0.0282, wR2 = 0.0570
0.014(5)
0.519 and -0.232 e.A-3
Table S12. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 103)
for thioester (+)-57. U(eq) is defined as one third of the trace of the orthogonalized U'i tensor.


























































































































































































































































Symmetry transformations used to generate equivalent atoms:
Table S14. Anisotropic displacement parameters (A2x 103) for thioester (+)-57. The anisotropic
displacement factor exponent takes the form: -2p 2[ h2 a*2 U"l + ... + 2 h k a* b* U 12 ]
U"i U22 U 33  U23 U 13  U 12
Br(1) 18(1) 24(1) 19(1) -3(1) 8(1) -4(1)
S(1) 20(1) 35(1) 24(1) 13(1) -7(1) -8(1)
0(3) 19(1) 16(1) 15(1) 2(1) 2(1) 0(1)
C(5) 17(1) 18(1) 12(1) 1(1) 1(1) 2(1)
C(7) 16(1) 12(1) 13(1) 1(1) 1(1) -3(1)
C(19) 21(1) 30(1) 13(1) 3(1) 2(1) 2(1)
C(17) 12(1) 23(1) 17(1) 8(1) -1(1) 1(1)
C(22) 22(1) 27(1) 14(1) 2(1) -2(1) 6(1)
C(28) 20(1) 23(1) 18(1) 0(1) -4(1) 2(1)
C(6) 19(1) 18(1) 17(1) 2(1) -1(1) -6(1)
C(20) 19(1) 28(2) 19(1) 6(1) -2(1) 3(1)
C(23) 38(1) 32(1) 27(l) 10(1) -2(l) -8(1)
C(2 1) 31(l) 21(1) 21(l) 1 (1) -4(l) 2(1)
O(1) 20(1) 15(1) 19(1) 1(1) 7(1) -0(1)
O(2) 21(1) 19(1) 16(1) -4(1) -3(1) 0(1)
C(1 1) 16(1) 14(1) 12(l) 2(1) 3(l) -1(1)
N(1 2) 15(1) 12(1) 15(l) 1 (1) 2(l) -2(1)
C(1 3) 14(l) 20(1) 13(l) -3(l) 3(1) -2(1)
C(16) 33(l) 26(2) 18(1) -7(1) -2(1) -3(l)
N(9) 19(1) 12(1) 18(1) -1(1) 5(l) 0(1)
C(10) 17(1) 14(1) 13(l) 0(1) -1(1) 2(l)
C(8) 19(1) 12(1) 15(l) 2(1) 1 (1) -2(l)
C(1 5) 22(1) 11(1) 18(1) 0(1) 4(1) 0(1)
C(14) 20(l) 14(1) 20(l) -3(1) 5(l) 1 (1)
Table S15. Hydrogen
for thioester (+)-57.
coordinates ( x 104) and isotropic displacement parameters (A2x 10 3)

























































































Crystal Structure of (+)-0-Methyl-pre-agelastatin A (47)
View 1:
View 2: View 3:
71
Table S16. Crystal data and structure refinement for (+)-O-methyl-pre-agelastatin A (47).
Identification code 10012






Unit cell dimensions a = 10.3843(11) A a= 900.
b= 10.7461(11) A b= 90 .











Completeness to theta = 29.560
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter













Full-matrix least-squares on F2
4413 / 199 / 220
1.016
RI = 0.0276, wR2 = 0.0618
RI = 0.0327, wR2 = 0.0635
-0.007(6)
0.598 and -0.372 e.A-3

















































































































































































































































Symmetry transformations used to generate equivalent atoms:
Table S19. Anisotropic displacement parameters (A2x 103) for (+)-O-methyl-pre-agelastatin A (47).
The anisotropic displacement factor exponent takes the form: -2p2 [ h2 a* 2UII + ... + 2 h k a* b* U 12 ]
U 1  U 22  U33 U 23  U1 3  U12
Br(1) 22(1) 15(1) 20(1) -4(1) 1(1) -4(1)
C(7) 10(1) 12(1) 14(1) -2(1) 1(1) 4(1)
O(1) 11(1) 18(1) 23(1) 2(1) 2(1) 0(1)
N(9) 14(1) 10(1) 17(1) -2(1) 2(1) -2(1)
C(13) 18(1) 12(1) 14(1) -2(1) -2(1) 0(1)
C(4) 16(1) 14(1) 17(1) -2(1) 0(1) 1(1)
N(1) 11(1) 11(1) 17(1) -2(1) -1(1) 0(1)
O(2) 17(1) 14(1) 24(1) -4(1) -1(1) 4(1)
O(3) 20(1) 15(1) 12(l) 0(1) -2(1)-1)
C(1 7) 27(1) 21(1) 14(1) -2(1) -3(1) 11
N(3) 11(1) 16(1) 21(1) 1 (1) 2(1) 0(1)
C(1 5) 13(1) 16(1) 15(1) 0(1) 2(1) 3(1)
C(8) 12(1) 11(1) 13(1) -(111)()
N(12) 11(l) 12(1) 14(1) -1)1()()
C(6) 14(1) 16(1) 14(1) -() () 2(1)
C(1 0) 11(1) 12(1) 15(l) 4(l) -3(1) 0(1)
C(2) 12(1) 19(1) 13(1) -2(1) -1(1) 1 (1)
C(1 6) 14(1) 16(l) 25(l) -3(1) -1(1) -3(1)
C(1 1) 11(1) 15(1) 13(1) 2(l) 0(1) 1 (1)
C(5) 14(1) 14(1) 13(1) -2(1) -1(1) 1 (1)
C(14) 17(1) 16(1) 16(1) -1(1) 0(1) 4(1)
O(lS) 19(1) 29(1) 32(1) 6(l) 5(1) -2(1)
C(l S) 27(1) 19(1) 25(1) 4(l) -2(1) -2(1)
Table S20. Hydrogen coordinates
O-methyl-pre-agelastatin A (47).
(x 104) and isotropic displacement parameters (A2x 10 3) for (+)-










































































































Table S21. Crystal data and structure refinement for (-)-agelastatin A (1).
Identification code 10026






Unit cell dimensions a = 13.5873(14) A a= 900.
b = 6.9161(7) A b= 98.786(2)0.











Completeness to theta = 30.030
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter





0.48 x 0.25 x 0.04 mm 3
1.31 to 30.030.
-19<=h<= 19, -9<=k<=9, -22<=l<=21
39133




Full-matrix least-squares on F2
8508 / 402 / 426
1.017
RI = 0.0346, wR2 = 0.0795
RI = 0.0437, wR2 = 0.0829
0.015(5)
0.875 and -0.490 e.A-3
Table S22. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (A2x 103)
for (-)-agelastatin A (1). U(eq) is defined as one third of the trace of the orthogonalized U'i tensor.















































































































































































































































































































































































































































































Symmetry transformations used to generate equivalent atoms:
Table S24. Anisotropic displacement parameters (A2x 103) for (-)-agelastatin A (1). The anisotropic
displacement factor exponent takes the form: -2p 2[ h 2 a* 2U" I +... + 2 h k a* b* U12 ]
















































































































































































































































































































Table S25. Hydrogen coordinates ( x 104 ) and isotropic displacement parameters (A2x 10 3) for (-)-
agelastatin A (1).

































































































































































Crystal Structure of (-)-Agelastatin B (2)
View 1:
View 2: View 3:
82
Table S26. Crystal data and structure refinement for (-)-agelastatin B (2).
Identification code agb






Unit cell dimensions a = 6.7838(7) A a= 900.
b= 8.1180(9) A b= 100.117(2)0.











Completeness to theta = 29.13'
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter
Largest diff. peak and hole
Table S27. Atomic coordinates













Full-matrix least-squares on F2
3735 / 200 / 200
1.009
RI = 0.0227, wR2 = 0.0488
RI = 0.0243, wR2 = 0.0491
0.012(6)
0.492 and -0.270 e.A-3
( x 104) and equivalent isotropic displacement parameters (A2x 103)
defined as one third of the trace of the orthogonalized UUi tensor.














































































































































































































































Symmetry transformations used to generate equivalent atoms:
Table S29. Anisotropic displacement parameters (A2x 103) for (-)-agelastatin B (2). The anisotropic
displacement factor exponent takes the form: -2p 2[ h2 a*2 Ull +
U"1 U22 U33 U23 U13 U12
Br(1) 19(1) 23(1) 11(1) 3(1) -2(1) 4(1)
N(1 2) 15(l) 12(1) 8(1) 1 (1) 1 (1) 2(1)
O(1) 18(1) 18(1) 17(1) 0(1) 7(1) 1 (1)
C(1 3) 18(1) 12(1) 9(1) 0(1) 1(1) 2(1)
Br(2) 26(1) 24(1) 12(l) 0(1) 4(1)1()
O(2) 9(1) 26(1) 10(1) 3(1) 1(1)-1)
N(9) 18(1) 16(1) 9(1) -3(1) 1(1) 2(1)
C(14) 18(1) 15(1) 10(1) 2(1) 0(1) 0(1)
O(3) 9(1) 26(1) 20(1) -2(l) 2(1) 0(1)
N(3) 10(l) 16(1) 17(1) 1 (1) 0(1) -4(1)
C(1 5) 15(1) 15(1) 15(l) 2(1) 2(1) 1(1)
N(1) 10(1) 13(1) 14(1) 1 (1) 2(1) 0(1)
C(l 1) 14(l) 10(1) 13(1) 0(1) 2(l) 1(1)
C(1 0) 17(1) 10(1) 13(1) 1 (1) 4(1) -2(1)
C(8) 14(1) 9(1) 13(l) -1(1) 3(1) 0(1)
C(7) 11(1) 10(1) 9(1) 0(1) 0(1) 1 (1)
C(6) 14(1) 11(1) 9(1) 0(1) 0(1) 0(1)
C(5) 9(1) 11(1) 8(1) 0(1) 2(1) 0(1)
C(4) 12(1) 13(1) 8(1) -2(1) 1(1) -1(1)
C(2) 11(1) 22(1) 8(1) 0(1) 1(1) -1(1)
C(1 6) 16(1) 11(1) 17(1) 3(1) 2(1) 2(1)
Table S30. Hydrogen coordinates (x 104)
for (-)-agelastatin B (2).
and isotropic displacement parameters (A2x 10 3)
x y z U(eq)
H(202) 3570(30) 6500(30) 4190(20) 18
H(1N9) 4300(40) 10680(30) 4091(15) 17
H(1N3) 10050(30) 8880(30) 3900(20) 18
H(3A) -430 11122 848 18
H(6) 6830 10660 2927 14
H(7) 6574 8405 1783 12
H(8A) 5086 6017 2156 14
H(8B) 3306 6953 2591 14
H(10) 7008 8984 4639 14
H(12A) 6600 3725 3022 22
H(12B) 6795 3544 4266 22
H(12C) 8753 3461 3736 22
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... + 2 h k a* b* U12]







Table S31. Crystal data and structure refinement for (-)-agelastatin D (4).
Identification code 10087






Unit cell dimensions a = 6.1269(7) A a= 900.
b = 6.8919(9) A b= 90 .











Completeness to theta = 30.48*
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter













Full-matrix least-squares on F2
3716 / 188 / 184
1.161
RI = 0.0464, wR2= 0.1115
RI = 0.0515, wR2 = 0.1133
0.046(11)
1.323 and -1.028 e.A-3
Table S32. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 103)
for (-)-agelastatin D (4). U(eq) is defined as one third of the trace of the orthogonalized Uli tensor.













































































































































































































Symmetry transformations used to generate equivalent atoms:











displacement factor exponent takes the form: -2p 2[ h2 a*2 U" +... + 2 h k a* b* U'2
U"1 U22  U 33  U 23  U13  U12
Br(1) 26(1) 25(1) 21(1) -3(1) -7(1) 1(1)
0(2) 13(1) 10(1) 31(1) -2(1) 1(1) 5(1)
N(2) 10(1) 6(1) 20(1) -2(1) 1(1) -2(1)
C(3) 5(1) 15(1) 21(2) 2(1) 0(1) 1(1)
N(1) 8(1) 9(1) 18(2) 1(1) 0(1) 4(1)
C(2) 9(1) 10() 15(2) -3(1) -2(1) -1(1)
N(3) 12(1) 9(1) 15(1) 3(1) 3(1) 3(1)
C(4) 7(2) 7(1) 17(2) 0(1) 1(1) 0(1)
C(5) 8(1) 4(1) 17(2) 13(1) -2(1) 2(1)
C(6) 12(2) 8(2) 18(2) -2(1) 0(1) -1(1)
C(7) 8(1) 9(1) 14(l) -1(1) 0(1) 1 (1)
C(8) 8(1) 11(1) 14(l) 0(1) 1 (1) 2(1)
N(9) 10(1) 9(1) 20(1) -2(1) -2(1) 2(1)
C(1 0) 11(1) 5(1) 22(2) 1 (1) 4(1) -1(1)
C(1 1) 17(2) 8(1) 22(2) -1(1) 3(1) 4(l)
N(1 2) 16(1) 8(1) 19(2) -3(1) 0(1) 2(1)
C(1 3) 16(2) 14(2) 21(2) -2(1) -2(1) -1(1)
C(14) 34(2) 17(2) 26(2) -7(2) -5(2) -1(2)
C(15) 22(2) 12(2) 25(2) -5(1) 4(1) 2(1)
Table S35. Hydrogen
agelastatin D (4).
coordinates ( x 104) and isotropic displacement parameters (A2x 10 3) for (-)-
x y z U(eq)
H(102) 8600(40) 5990(60) 1906(15) 14
H(1N1) 3410(70) 6390(40) 1609(14) 13
H(1N3) 3770(70) 2630(70) 2528(9) 15
H(4) 7377 3178 2295 12
H(6A) 6362 4645 985 16
H(6B) 8617 4009 1229 16
H(7) 4595 1804 1214 12
H(8) 5710 60 1856 13
H(1N9) 9450(80) 550(70) 2091(8) 15
H(14) 8143 -1764 15 31
H(15) 10873 -2493 646 24
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Chapter II.
Total Synthesis of the (-)-Trigonoliimine Alkaloids
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Introduction and Background
In 2010, Hao and co-workers reported the isolation of structurally fascinating (+)-
trigonoliimines A (1), and B (2) along with (-)-trigonoliimine C (3) from the leaves of
Trigonostemon lii Y. T. Chang collected in Yunnan province of China (Figure 1).1 They also
examined trigonoliimines A (1) and C (3) in an anti-HIV assay where 1 was found to exhibit
modest activity (EC 5o = 0.95 [tg/mL, TI = 7.9).1 Fascinated by their unique molecular
architecture and inspired by our hypothesis for their biogenesis, we have completed the first total
synthesis of (-)-trigonoliimines A (1), B (2) and C (3) using a synthetic strategy based on
asymmetric oxidation and reorganization of a single heterodimeric bistryptamine. This work
allowed us to revise the absolute stereochemistry of all (-)-trigonoliimines.'
Oxidation and rearrangement of 2,3-disubstituted indole has served as an efficient
strategy to access indoxyl moiety and has been applied in total synthesis of various alkaloids.4
Representative examples are shown in Schemes 1 and 2. In 1979, Kishi and coworkers reported
an oxidation of 2,3-disubstituted indole 5, followed by base mediated alkyl shift to give indoxyl
R'; "A NH
(+)-Trigonoliimine A (1), R=H, R'=OMe
(+)-Trigonoliimine B (2), R=OMe, R'=H
original stereochemistry (ref. 1)




original stereochemistry (ref. 1)
25
NN
R~ N NR H
(+)-Trigonoliimine A (1), R=H, R'=OMe





(-)-Trigonoliimine A (1), R=H, R'=OMe
(-)-Trigonoliimine B (2), R=OMe, R'=H
revised stereochemistry (our study) (-)-Trigonoliimine C (3), R=H, R'=OMerevised stereochemistry (our study)










Figure 1. Representative trigonostemon alkaloids including the revised absolute stereochemistry of trigonoliimines
A-C (1-3).
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6 (53% yield), which was further derivatized to complete the total synthesis of (±)-austamide (7,
Scheme 1).4b In 1990, Williams and coworkers reported the total synthesis of (-)-brevianamide B
(11) by applying similar oxidation and rearrangement sequence to 2,3-disubstituted indole 8
(Scheme 2).4'
NN H 1.mCPBA. / H N N
| 1  NO 2. NaOMe, MeOH , N H , N
N 'OCONHTos reflux. N O N O
Me Me 53% Me OMe W Me
5 6 austamide (7)
Scheme 1. Kishi's total synthesis of austamide (7).
H
SN Me N MeMe Me MeMe NH Me
mCPBA H NaOMe -- Me 3uLi - Me
CH 2Cl2  HO MeOH THF, -78 *C 0
PMB -N N (2 se) PMB -N N 02 H. -N
O (2 steps) O 00 N00 40% 0
8 9 10 (-)-brevianamide B (11)
Scheme 2. Williams' total synthesis of (-)-brevianamide (11).
In 2008, our laboratory reported a hypothesis for the formation of calycanthaceous
alkaloids from oxidation and rearrangement of a 2,2'-bistryptamine derivative (Scheme 3).5 We
hypothesized that the oxidation of 2,2'-bistryptamine 12 would give mono-oxidized
hydroxyindolenine 13, which after 1,2-aryl shift followed by cyclization of the amine moiety to
the carbonyl group of the resulting oxindole intermediate would afford imine 14. After another
round of oxidation and rearrangement followed by reduction of 16, we speculated the formation
of chimonanthine (17). Our continued interest in this area yielded an efficient synthetic strategy
involving oxidation and rearrangement of 2,3-disubstituted indoles, especially those with an aryl
substituent at the 2-position, for an efficient access to oxindole products.6 Despite the significant
advancement in the area of asymmetric oxidation,7 enantioselective oxidation of 2,3-
disubstituted indole has remained a challenging problem.8 Recently, Miller group, in
collaboration with our laboratory, reported an asymmetric oxidation of 2,3-disubstituted indole
using aspartyl based peptide catalyst.9 The molecular structure of trigonoliimine alkaloids
(Figure 1) drew our immediate attention upon their isolation due to their possible structural
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relevance to hyroxyindolenine 13, the intermediate in our hypothesis for the formation of
chimonanthine (17) (Scheme 3). This observation, in conjunction with our interest in asymmetric
oxidation of 2,3-disubstituted indole led us to set out the synthetic program aimed for the total
synthesis of trigonoliimine alkaloids. Our first total synthesis of (-)-trigonoliimine A-C (1-3)
and the related derivate (-)-isotrigonoliimine C (4), using asymmetric oxidation and
reorganization of 2,3-disubstituted indole derivative and our revision of their absolute
stereochemistry are described in detail in the following pages of this chapter.
NHMe NHMe
3 H HO H 12'
N 2N -[0] N 2 2\N 2 NHMe
SN 3 2\ HNH NNMe
12 13 N
MeHN MeHN 14H We
HN M~N Z O 12'
eN e N Hee
H N N
N/e 1 2 NMMe
H
chimonanthine (17) 16 15
Scheme 3. Our group's hypothesis for the formation of chimonanthine (17) from bistryptamine derivative 12.
Tambar and coworkers reported the total synthesis of (+)-trigonoliimine C using the same
oxidation and rearrangement strategy (Scheme 4).1011 Their synthetic approach involved the
union of 2-stannyltryptamine 20 derived from a Boc-directed lithiation and stannylation
sequence and 2-bromotryptamine derivative 21 by Stille cross-coupling reaction (78% yield).
The resulting bistryptamine 22 was treated with [bis(trifluoroacetoxy)iodo]benzene to afford
hydroxyindolenine (±)-23 in 67% yield along with its regioisomeric hydroxyindolenine (4%
yield). Heating a solution of hydroxyindolenine (±)-23 with hydrochloric acid in wet DMA at
150 *C yielded indoxyl (±)-24 in 56% yield. Hydrazynolysis of phthalamide protecting group of
indoxyl (-)-24 followed by titanium isopropoxide mediated intramolecular condensation resulted
in the formation of (±)-trigonoliimine C (3) in 81% yield over two steps.
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H2N HNCHO HNCHO PhthN ,CHO
PhthN NH
BuSn N N OMe
N OMe N OMe N OMe N H H
18 Boc 19 Boc 20 21 22
e
NH NPhth
N NH2  Nh OHCN
N OMe g 0 OMe PhthN HONI Ih \ Oe HO:
N N OMegHJH NN NN H N I" HHN H H-NH H NH N N OMe
CHO 'CHO 'CHO H
(t)-3 (±)-25 (±)-24 (±)-23
Scheme 4. Tambar's total synthesis of (±)-trigonoliimine C (3). Conditions: (a) HCO 2Et, reflux. (b) Boc 2 0, DMAP,
DMF, 23 0C, 72% (2 steps). (c) TMP, n-BuLi, Bu 3 SnCl, THF, -78 'C, 86%. (d) Pd(PPh3)4, DMF, 110 -C, 78%. (e)
PhI(TFA)2, CH 3CN, H20, 0 -C, 67%. (f) HCl, DMA, H20, 150 'C, 56%. (g) NH 2NH 2, MeOH, CH 2Cl 2, 23 0C. (h)
Ti(Oi-Pr)4, THF, 70 'C, 81% (2 steps).
Recently, Zhu and coworkers reported the total synthesis of (±)-trigonoliimine B (2)
using a late stage Bischler-Napieralski reaction (Scheme 5).12 Their synthesis commenced with a
nucleophilic aromatic substitution reaction between a-isocyanoacetate (26) and 2-
fluoronitrobenzene (27) to afford c-aryl-a-isocyanoacetate (±)-28 in 77% yield. Alkylation of
(±)-28 with 2-azidoiodoethane in the presence of sodium hydride in DMF (74% yield), followed
by treatment with ethanolic hydrogen chloride gave amino ester (t)-29 in 87% yield. This
reaction sequence could be telescoped in one step procedure to give amino ester (h)-29 in 70%
yield (Scheme 5). Reductive amination between amine (.)-29 and aldehyde 30 gave secondary
amine (t)-31 (quantitative yield), which after Staudinger reduction followed by calcium chloride
treatment afforded lactam (±)-32 in 72% yield. Reduction of the nitro group in lactam (±)-32 in
the presence of Raney nickel catalyst (81% yield), followed by treatment with trimethyl
orthoformate in the presence of PPTS yielded the spirocycle (t)-34 in 75% yield. For the key
Bischler-Napieralski reaction, spirocycle (±)-34 was treated with phosphoryl chloride in
sulfolane at 80 *C to yield (±)-trigonoliimine B (2) in 51% yield.
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CO2Et N02 a NC NO2 b,c EtO 2
C NH2 NO2 CHO MeO
NC + Et2C ord HN HN
N3  N OMe EtO 2C NO2
26 27 ()-28 ()-29 30 (t)-31 N3
f
()2N =h MeO N H MeO N HM 0 N
N N __NK
MeO HN 0 H ell Hel
H O NH2  NO2
(t)-34 (t)-33 ()-32
Scheme 5. Zhu's total synthesis of (±)-trigonoliimine B (2). Conditions: (a) Cs 2CO 3, DMSO, 23 'C, 77%. (b)
ICH 2CH 2N 3, NaH, DMF, 23 'C, 74%. (c) Ethanolic HCl (1.25 M), 23 'C, 87%. (d) ICH2CH 2N3, NaH, DMF, 23 'C
then ethanolic HCl (1.25 M), 23 'C, 70%. (e) NaBH(OAc) 3, CH 2Cl 2 23 'C, quantitative. (f) PPh3, THF, H20, 60 'C
then CaCl2 , MeOH, 80 'C, 72%. (g) H2, Raney Ni, MeOH, 23 'C, 81%. (h) HC(OMe) 3, PPTS, 60 'C, 75%. (i)
POCl3 , sulfolane, 80 'C, 51%.
In addition to these total syntheses reports, after our report of the total synthesis of all
(-)-trigonoliimines,2 Hao and Liu reported the synthesis of the skeleton of (±)-trigonoliimine C,
using oxidation and 1,2-alkyl rearrangement (Scheme 6),13 the same strategy used in our total
synthesis of (-)-trigonoliimine C (3).2 Shortly after, Shi and coworkers reported a synthetic
approach to the hexacyclic skeleton of (+)-trigonoliimines A (1) and B (2) (Scheme 7).14 In their
studies, 2-bromotryptamine derivative 41, derived from a known bromide 21 in 2 steps, was
condensed with isatin in 92% yield, and the resulting imine 42 was allowed to react with allyl
magnesium bromide followed by benzenesulfonylation to give tetracycle (±)-43. Upon treatment
with t-BuLi, oxindole (±)-43 underwent structural reorganization to give seven-membered
intermediate (32% yield), which upon treatment with paraformaldehyde in the presence of
cesium carbonate resulted in the formation of pentacycle (±)-44 in 99% yield. Azide (±)-46,
obtained in four steps from (±)-44, underwent aza-Wittig reaction upon treatment with
triphenylphosphine to give imine (±)-47 in 88% yield. Deprotection of the benezenesulfonyl and
p-methoxybenzyl groups of imine (±)-47 was achieved under dissolving metal reduction
condition. The resulting aminal intermediate underwent facile air oxidation to give the








OHC -NH H2N PhthN
(±)-40 (±)-39 (±)-38
Scheme 6. Hao's synthesis of the skeleton of (±)-trigonoliimine C (3). Conditions: (a) TFA. (b) DDQ, 1,4-dioxane,
80% (2 steps) (c) Oxone, acetone, NaHCO 3, 70%. (d) HCO 2H, PhCH3 , 110 'C, 50%. (e) 80% NH 2NH 2-H 20,
CH 2Cl2, MeOH, 23 -C, 86%. (f) HCOOEt, DMF, 65 OC, 40%.
NPhth NH2  / N NR
Nhhab N2 C N- d,e HN f1g Nz-NI
ON BrI
Br N N0 N ON h PMB
H PMB PMB PMB
21 41 42 (±)-43 (R = SO2Ph) (±)-44 (R = SO 2Ph)
R N NN
7J N J\ ~ 0  P N 0
PMB NPB N3  PMB O
(±)-48 (±)-47 (R = SO2Ph) (±)-46 (R = SO2Ph) (±)-45 (R = SO2Ph)
Scheme 7. Shi's synthesis of the hexacyclic skeleton of (±)-trigonoliimines A (1) and B (2). Conditions: (a) NaH,
PMBCl, 0->23 'C, 65%. (b) N2H4-H20, EtOH, reflux (c) Isatin, MeOH, 23 'C, 92%. (d) Allyl magnesium chloride,
BF 3-Et 2O, CH 2Cl2, -40--23 'C, 81%. (e) NaH, PhSO 2Cl, THF, 0 OC, 96%. (f) t-BuLi, Et 20, -40-+23 C, 32%. (g)
CsCO3 , (CH 2O),, Na 2 SO 4 , THF, 23 'C,99%. (h) t-BuLi, Et 2 0, -40->23 0C; H2 0, (CH 2O)n, 23 'C, 30%. (i) Os0 4 ,
NMO-H 20, THF, BuOH, H20, 23 'C; NaIO 4, 23 'C, 85%. (j) NaBH 3CN, THF, AcOH, 0 'C, 78%. (k) MsCl, Et 3N,
CH 2 Cl 2 , 0--23 'C. (1) NaN3, DMF, 23 'C, 71% (2 steps). (in) PPh3, PhCH3, reflux, 88%. (n) Na, NH 3 (1), -76->45
0C; air, 90%.
Results and Discussion
Our unified strategy for the enantioselective total synthesis of all known trigonoliimines
was based on the hypothesis that bistryptamine heterodimer 53 (Scheme 8) could serve as a
common biosynthetic precursor to these alkaloids. While the chemoselectivity of the oxidation of
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bisindole 53 was envisioned to determine the ratio of regioisomeric hydroxyindolenines 51 and
52, the stereoselectivity of the transformation was thought to provide a platform for the
asymmetric synthesis of the trigonoliimines. We postulated that hydroxyindolenines 51 and 52
would serve as the branching point for divergent synthesis of the two distinct structural motifs
found in trigonoliimine alkaloids (Scheme 8). Trigonoliimines A (1) and B (2) were expected to
be accessed via a stereoretentive cyclization of N12 onto the C20 carbinol function of precursors
49 and 50, respectively, followed by N-formylation and condensation (Scheme 8). The requisite
cis-fused aminals 49 and 50 could result from intramolecular cyclization of hydroxyindolenines
51 and 52, respectively. Alternatively, a stereospecific Wagner-Meerwein type
rearrangement 5'16 of intermediates 51 and 52 was envisioned to provide the indoxyls 54 and 55,
respectively. 4'6 Intramolecular condensation of the N 12 amine and the C15 ketone of indoxyls 54
and 55 in addition to N24 formylation was expected to provide trigonoliimine C (3) and
isotrigonoliimine C (4). Thus, the enantioselective synthesis 7'9 of both regioisomeric
hydroxyindolenines 51 and 52 was sought to address the asymmetric synthesis of alkaloids 1-4.
------ N-formylation 12
1 2N zN13 & condensation N
2015 N
R N 2 4  R' R N N R'H HN H
(-)-Trigonoliimine A (1) N-formylation HN 24
R=H, R'=OMe CHO
(-)-Trigonoliimine B (2) (-)-Trigonoliimine C (3)
R=OMe, R'=H R=H, R'=OMe
2 tereoretentive (-)-Isotrigonoliimine C (4)12 NH 2  stereoretene R=OMe, R'=HIIcyclization(N1 2-C20) condensation
23 (N12-C15)
H2N2 20 OH 12 0O15
R N HN 20 1 R'H 13 14
49, R=H, R'=OMe N
50, R=OMe, R'=H R N 22 H
R, H NH224
cyclization 1,2-alkyl 54, R=H, R'=OMe
(N24-C14 shift 55, R=OMe, R'=H
HO asymmetric
I I oxidation\ / I
R N N R (C 150) N N OMeH H H
51, R=H, R'=OMe Suzuki-Miyaura 53
52, R=OMe, R'=H cross-coupling (C2-C14)
Scheme 8. Retrosynthetic analysis of (-)-trigonoliimines A-C (1-3) and isotrigonoliimine C (4).
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Our synthesis of the (-)-trigonoliimine alkaloids commenced with an iridium catalyzed"7
C2-borylation of the 6-methoxy-tryptamine derivative 56.18 We observed that using
dichloromethane as solvent at 23 *C minimized the undesired borylation of the phthalimide
substructure (Scheme 9). Access to bisindole 60 was possible via a Suzuki-Miyaura cross-
coupling1 9 of boronate 57 and 2-iodo-tryptamine 589,20 using a variety of palladium sources in
the presence of XPhos2 1 and potassium phosphate at elevated temperatures, albeit in low and
variable yields (7-44%). Alternatively, the use of Buchwald's aminobiphenyl precatalyst 5922
enabled a robust cross-coupling of pinacol boronate 57 and iodide 58 at 23 'C to give 60 in 31%
yield. After an extensive screening of bases and additives, we noticed that the presence of both a
halophile2 3 and proper base was critical for the overall efficiency of this transformation. We
discovered that the use of silver phosphate (2.0 equiv) and the precatalyst 59 optimally promoted







R N N R' 9
(+)-61, R=H, R'=OMe(+)-62, R=OMe, R'=H
(61:62 = 2.2:1)
Scheme 9. Synthesis of hydroxyindolenines (+)-61 and (+
4,4'-di-'Bu-2,2'-bipyridine, CH 2Cl 2 , 23 'C. (b) Ag 3PO4,




M BPin + /67% MeO N NH H
57 58




MeO N N h0H H
60
)-62. Conditions: (a) HBPin, [Ir(OMe)(cod)] 2 (10 mol%),
59 (20 mol%), PhCH3, H 20, 23 0C. (c) (+)-((8,8-
The bistryptamine 60 was found to be sensitive to oxidation under a variety of conditions.
In fact, simple exposure of bistryptamine 60 to air over 12 days resulted in autoxidation to (±)-
hydroxyindolenines 61 and 62 (61:62 = 1.5:1) in 27% yield along with recovered 60 (65%).
Interestingly, the presence of regioisomeric pairs is commonly observed in the trigonostemon
alkaloids family 24 (Figure 1) and the major autoxidation product (oxidation of 6-methoxy-indole
substructure) is consistent with the major isolated trigonoliimines A (1) and C (3).1 Given the
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rapid oxidation of bistryptamine 60, and based on observations on stereoselective oxidation of
related derivatives,4'6'8' we focused our attention on the use of oxaziridines. Under optimal
conditions, treatment of bistryptamine 60 with readily available (+)-((8,8-
dichlorocamphoryl)sulfonyl)oxaziridine (Davis' oxaziridine)25 provided hydroxyindolenines (+)-
61 and (+)-62 (61:62 = 2.2:1, Scheme 9) in 95% yield and with an outstanding level of
enantioselection for both isomers (96% ee, vide infra).8 '9 This solution provided efficient access
to precursors for the enantioselective synthesis of alkaloids 1-4. While the isomeric
hydroxyindolenines (+)-61 and (+)-62 were separated for complete characterization and
independent derivatization, separation of more advanced intermediates en route to alkaloids 1-4
proved most practical.
PhthN NPhth





CHCl 3, 0 *C










Scheme 10. Oxidation of bistryptamine 60 with Miller's catalytic system.
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H2 0 2, DIC
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While (+)-((8,8-dichlorocamphoryl)sulfonyl)oxaziridine provided us with an excellent
solution for the asymmetric oxidation of bistryptamine 60, exposure of 60 to Miller's aspartyl
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based catalytic asymmetric oxidation9 condition afforded hydroxyindolenines (+)-61 and (+)-62
(61:62 = 1.3:1, Scheme 10) in 20% ee and <5% ee, respectively. We speculate that the
heterogeneity of the reaction mixture contributed to the low conversion and enantioselectivity of
this reaction. However, Miller's catalytic system proved efficient for the asymmetric oxidation of
2,3-disubstituted indoles with 2-nitro-phenyl group in the 2-position (Scheme 11). Treatment of
tryptophol derivative 64 with 10 mol% of Miller's catalyst 63, 5 mol% of 4-
dimethylaminopyridine (DMAP), 1.2 equivalent of hydrogen peroxide (H20 2) and 1.2 equivalent
of NN'-diisopropylcarbodiimide (DIC) in chloroform at 0 "C yielded the desired
hydroxyindolenine (+)-65 in 97% yield and 79% ee (Scheme 11). In the presence of potassium t-
butoxide in t-butanol, hydroxyindolenine (+)-65 could be converted to indoxyl (-)-66 {79% ee,
[a]D24 : -79.5 (c 0.15, chloroform)} via Wagner-Meerwein type 1,2-alkyl shift reaction.4 '' 1 6
Importantly, indoxyl derivative (t)-66 served as an intermediate in Kawasaki's total synthesis of
(±)-hinckdentine (67).26,27 Furthermore, tryptamine derivative 68 could be converted to
hydroxyindolenine (+)-69 in 72% yield and 74% ee (Scheme 11), consistent with our previous
report.9 Notably, 2,3-disubstituted indole 68 was reluctant to oxidation with Davis' oxaziridines.
Heating a solution of hydroxyindolenine (+)-69 in hexafluoroisopropanol (HFIP) and formic acid
mixture at 90 "C afforded indoxyl (+)-70 in 84% yield. Indoxyl (+)-70 would have potential
significance for a more streamlined synthetic access to (-)-hinckdentine A (67).
NPhth NH2
PtN HO NH
a ~ HN b 20
N~~~~~ N - Np.J 
-N \NH 2R HR R H OH R HH H /
(+)-61, R=H, R'=OMe (+)-49, R=H, R'=OMe - (-)-71, R=H, R'=OMe(+)-62, R=OMe, R'=H (+)-50, R=OMe, R'=H 94% ee, 28%




representation of (-)-72: 1R N
H
(-)-Trigonoliimine A (1), 82%
R=H, R'=OMe
(-)-Trigonoliimine B (2), 94%
R=OMe, R'=H
Scheme 12. Total synthesis of (-)-trigonoliimines A (1) and B (2). Conditions: (a) NH 2NH 2-H20, MeOH, 80 "C. (b)
Martin's sulfurane, CH2Cl 2, -78 0C. (c) CH(OPr) 3, PPTS, CH2 Cl2, 23 "C.
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Unveiling the two amino groups of hydroxyindolenines (+)-61 and (+)-62 spontaneously
provided the desired cis-fused aminals (+)-49 and (+)-50 (49:50 = 2.2:1, Scheme 12), our
proposed precursors for trigonoliimines A (1) and B (2), in 99% yield, respectively. Aminals (+)-
49 and (+)-50 were separable at this stage, allowing their independent chemical examination and
characterization. Interestingly, heating a solution of aminal (+)-49 in trifluoroethanol (TFE) at
105 *C provided the desired azepane (-)-71 in 34% yield with significant drop in enantiomeric
excess (15% ee). On the other hand, aminal (+)-50 led to almost complete decomposition under
identical reaction conditions, highlighting the different chemical reactivity of the regioisomeric
series of intermediates in our studies.
12 NH 2
12 23NH 2  protic (+)-49 a 12N
H2N K solvent (+-9 solvent
HO~ Z \ HN 2
'2 \NIN2
24 NOe 73 H +H 13 74
stereoselective
N 12-C20 W~e
12 23 C20-ionization bond formation O
H2N 24 1 bond formation
-- 2 .,N(+)71
NH HO erosion of
75/ H2 enantiomeric excess
75 13 O~
Scheme 13. Possible competing pathways in conversion of amino alcohol (+)-43 to pentacycle (-)-65.
While 'H NMR analysis of aminals (+)-49 and (+)-50 in deuterated chloroform were
consistent with cis-fused pentacycles depicted in Scheme 12, the analysis of the same
compounds in deuterated methanol revealed the presence of multiple species consistent with
reversible formation of aminal and imine isomers (Scheme 13). We reasoned that the
transmutation of (+)-49 to (-)-71, as described above, likely affords the product with greatly
diminished optical activity due to a low level of stereoselection in N12-C20 bond construction
upon ionization of carbinol 75 at C20 (Scheme 13) or upon formation of a solvent/amine adduct
of imine 74. Gratifyingly, treatment of a solution of aminals (+)-49 and (+)-50 (49:50 = 2.2:1) in
dichloromethane with the Martin sulfurane reagent28 at -78 *C provided the desired azepanes
(-)-71 and (-)-72 in 47% combined yield (28% and 19% yield, respectively, after
chromatographic separation). Importantly, azepanes (-)-71 and (-)-72 were obtained with
minimal erosion of enantiomeric excess (94% ee and 95% ee, respectively). The X-ray crystal
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structure analysis of pentacycle (-)-72 (Scheme 12), the direct precursor for (-)-trigonoliimine B
(2), unambiguously confirmed the molecular structure and coherently (vide infra) assigned the S-
configuration at C20. Using optimal conditions, sequential treatment of pentacycle (-)-71 with
pyridinium p-toluenesulfonate (PPTS) and triisopropyl orthoformate in dichloromethane
afforded (-)-trigonoliimine A (1) in 82% yield {[a]D24= -294 (c 0.24, CHCl 3 )} (Scheme 12).
Under identical reaction conditions, the pentacycle (-)-72 was converted to (-)-trigonoliimine B
(2) in 94% yield {[a]D2 4= -352 (c 0.32, CHCl 3)}. All 'H and 13C NMR data for our synthetic
(-)-trigonoliimines A (1) and B (2) matched those provided in the isolation report,I confirming
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Scheme 14. Total synthesis of (-)-trigonoliimine C (3) and (-)-isotrigonoliimine C (4). Conditions: (a) TFE, 102 0C.
(b) NH 2NH 2-H20, MeOH, 80 "C. (c) Ti(OEt) 4, THF, 42 "C. (d) N-formyl imidazole, THF, 23 *C.
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Scheme 15. Synthesis and thermal ellipsoid representation of C18-bromoindoxyl (-)-80.
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We next aimed to access (-)-trigonoliimine C (3) and (-)-isotrigonoliimine C (4) from
the same versatile hydroxyindolenines described above via a divergent synthetic path employing
a Wagner-Meerwein type 1,2-alkyl rearrangement. 15,16 We observed that exposure of
hydroxyindolenines (+)-61 and (+)-62 to various Lewis acids gave the desired indoxyls (-)-76
and (-)-77 along with undesired oxindole byproducts. For example, in the presence of lanthanum
trifluoromethanesulfonate in toluene at 80 'C, hydroxyindolenines (+)-61 and (+)-62 (61:62 =
2.2:1) afforded the undesired oxindoles in 34% yield along with the desired indoxyls (56%).
Upon treatment with europium trifluoromethanesulfonate in acetonitrile at 72 'C,
hydroxyindolenines (+)-61 and (+)-62 (61:62 = 2.2:1) afforded the undesired oxindoles in 50%
yield along with the desired indoxyls in 48% yield. The choice of solvent with this
rearrangement strongly influenced the ratio of indoxyl to oxindole.6 After significant
experimentation, we discovered that heating a solution of hydroxyindolenines (+)-61 and (+)-62
(61:62 = 2.2:1) in TFE at 102 C for 24.5 h resulted in selective formation of the corresponding
indoxyls (-)-76 and (-)-77 (76:77 = 2.2:1) in 93% combined yield (Scheme 14). The masking of
the two amino groups in the form of phthalimides during this rearrangement was critical in the
overall efficiency and selectivity for the formation of the desired products. Separation and
independent analysis of indoxyls (-)-76 and (-)-77 revealed a high level of enantioselection
(96% ee) in the synthesis of the corresponding hydroxylindolenines (+)-61 and (+)-62. For the
confirmation of the absolute stereochemistry, indoxyl (-)-76 was treated with NBS to give C18-
bromide (-)-80 in 90% yield (Scheme 15). The high enantiomeric excess of bromide (-)-80
(96% ee) in conjunction with its X-ray crystal data allowed for unequivocal assignment of the S-
configuration at C14. While intermediates en route to (-)-trigonoliimine C (3) and (-)-
isotrigonoliimine C (4) were separated for characterization and independent derivatization,
delayed separation of isomers proved most practical similar to the case of (-)-trigonoliimines A
(1) and B (2). Unraveling the two amino groups of indoxyls (-)-76 and (-)-77, followed by
condensative cyclization promoted by titanium ethoxide29 as a one pot two-step procedure
provided the cyclic imine (-)-78 and (-)-79 (78:79 = 2:1) in 61% yield. Notably, we did not
observe any of the undesired five-membered ring imines corresponding to condensation of the
N24 with C15 carbonyl. Treatment of pentacyclic amines (-)-78 and (-)-79 with N-formyl
imidazole followed by silica gel chromatographic separation provided (-)-trigonoliimine C (3)
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24=2{[c]D -147 (c 0.12, CHCl3)} and (-)-isotrigonoliimine C (4) ([a]D24= -220 (c 0.10, CHCl 3)}
in 57% and 16% yield, respectively. All 'H and 13 C NMR data for our synthetic (-)-
trigonoliimines C (3) matched those provided in the isolation report,' and analysis of the X-ray
crystal structure of our synthetic (-)-3 further confirmed the S-configuration at C14.
Interestingly, while isotrigonoliimine C (4) has not been isolated from nature at this time, we
have recognized the pentacyclic amine (-)-79 as the most solvolytically sensitive compound
amongst those discussed in this study.
Table 1. Specific rotation values of natural' and synthetic trigonoliimine A-C (1-3).
Entry Alkaloids Natural ([a1OD) Synthetic ([a]24 D)a
1 Trigonoliimine A +13.3 (c 0.3, CHCl 3) -294 (c 0.24, CHCl 3, 94% ee)
2 Trigonoliimine B +5.0 (c 0.5, CHCl 3) -352 (c 0.32, CHCl3, 95% ee)
3 Trigonoliimine C -4.8 (c 0.45, CHCl 3) -147 (c 0.12, CHCl 3, 96% ee)
a % ee of the key precursor for the corresponding synthetic trigonoliimine.
The magnitude and sign of specific rotation of our synthetic trigonoliimines in
conjunction with our X-ray crystal structure data provide valuable information regarding the
stereochemistry of these alkaloids. Interestingly, all of our synthetic (-)-trigonoliimines A-C
(1-3) showed a significantly larger magnitude of specific rotations compared to those reported
for the naturally isolated samples (Table 1). Importantly, the enantiomeric excess 3 0 of our
samples has been quantified by HPLC analysis of enantiomerically enriched samples of several
intermediates against readily available racemic samples from our exploratory studies in this area.
Additionally, our synthetic trigonoliimines A-C (1-3) derived from hydroxyindolenines (+)-61
and (+)-62 exhibit a negative sign in their specific rotation. However, naturally occurring
trigonoliimines A (1) and B (2) were reported to have a positive sign in their specific rotations
whereas trigonoliimine C (3) was reported to have a negative sign in its specific rotation.
Furthermore, our three X-ray structures of highly enantiomerically enriched compounds
(Schemes 12, 14, and 15) provide support for the need to revise the absolute stereochemical
assignment of all trigonoliimines (Figure 1). While the absolute stereochemistry of our synthetic
(-)-trigonoliimines A-C (1-3) are unequivocally assigned through our studies, given the reported
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optical rotation values for the natural samples of 1-3, we raise the possibility that either natural
trigonoliimines A-C (1-3) were not isolated enantiomerically pure or the optical rotation values
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Scheme 16. Total synthesis of (-)-trigonoliimines A-C (1-3) and isotrigonoliimine C (4). Conditions: (a) HBPin,
[Ir(OMe)(cod)] 2 (10 mol%), 4,4'-di-'Bu-2,2'-bipyridine, CH2 Cl 2 , 23 'C. (b) Ag3PO 4 , 59 (20 mol%), PhCH3, H20, 23
0C, 63%. (c) (+)-((8,8-Dichlorocamphoryl)sulfonyl)oxaziridine, CH 2Cl 2 , -35--23 "C, 95%. (d) NH 2NH 2-H 20,
MeOH, 80 "C, 99%. (e) Martin's sulfurane, CH 2 Cl2, -78 "C. (f) CH(O'Pr) 3, PPTS, CH 2 Cl2 , 23 "C. (g) TFE, 102 "C,
93%. (h) NH 2NH 2-H20, MeOH, 80 "C. (i) Ti(OEt) 4 , THF, 42 "C, 61% (2 steps). (j) N-formyl imidazole, THF, 23 0C.
We have developed the first total syntheses of all trigonoliimine alkaloids inspired by a
unified biosynthetic hypothesis 3' for oxidation and reorganization of a single bistryptamine
precursor (Scheme 16). Our concise enantioselective syntheses of (-)-trigonoliimines A (1) and
B (2) are seven steps from commercially available material and employ a critical stereoretentive
condensative cyclization of hydroxyindolenines (+)-61 and (+)-62, respectively. Our succinct
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enantioselective syntheses of (-)-trigonoliimines C (3) and (-)-isotrigonoliimine C (4) are eight
steps from commercially available material and draw on the application of the venerable
Wagner-Meerwein rearrangement of the hydroxyindolenines (+)-61 and (+)-62, respectively.
Rapid access to the key intermediates is enabled by a Suzuki-Miyaura cross-coupling reaction
using Buchwald's precatalyst (59) in conjunction with silver phosphate followed by a highly
enantioselective oxidation at the enantiodetermining and branching point of our syntheses.
Additionally, our studies allow us to revise the absolute stereochemistry of alkaloids (-)-1-3.
The concise total synthesis of (-)-trigonoliimines A-C (1-3) highlights the power of
retrobiosynthetic analysis32 as a source of inspiration in the rational chemical factoring of natural
product targets.
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Experimental Section
General Procedures. All reactions were performed in oven-dried or flame-dried round-bottomed
flasks. The flasks were fitted with rubber septa and reactions were conducted under a positive
pressure of argon. Stainless steel syringes or cannulae were used to transfer air- and moisture-
sensitive liquids. Where necessary (so noted), solutions were deoxygenated by argon purging for a
minimum of 10 min. Flash column chromatography was performed as described by Still et al. using
silica gel (60-A pore size, 40-63 [m, 4-6% H2 0 content, Zeochem).' Analytical thin-layer
chromatography (TLC) was performed using glass plates pre-coated with 0.25 mm 230-400 mesh
silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were
visualized by exposure to ultraviolet light and/or by exposure to an ethanolic phosphomolybdic acid
(PMA), an acidic solution of p-anisaldehyde (Anis), an aqueous solution of ceric ammonium
molybdate (CAM), an aqueous solution of potassium permanganate (KMnO4) or an ethanolic
solution of ninhydrin followed by heating (<1 min) on a hot plate (~250 C). Organic solutions were
concentrated at 29-33 'C on rotary evaporators capable of achieving a minimum pressure of -2 torr.
Materials. Commercial reagents and solvents were used as received with the following exceptions:
dichloromethane, tetrahydrofuran, acetonitrile, toluene, methanol, and dimethylformamide were
purchased from J.T. Baker (CycletainerTM) and were purified by the method of Grubbs et al. under
positive argon pressure. 2 6-Methoxyindole was purchased from Chem-Impex International, Inc.. All
other solvents and chemicals were purchased from Sigma-Aldrich.
Instrumentation. Proton ('H) and carbon (13 C) nuclear magnetic resonance spectra were recorded
with Varian inverse probe 500 INOVA, Varian 500 INOVA and Bruker 400 AVANCE
spectrometers. Proton nuclear magnetic resonance (1H NMR) spectra are reported in parts per million
on the 6 scale and are referenced from the residual protium in the NMR solvent (CDCl 3: 6 7.24
(CHCl 3), CD 30D: 6 3.31 (CHD 2OD), CD 30D/CDCl 3 = 1/3: 6 3.31 (CHD 2OD), DMSO-d: 8 2.50
(DMSO-d 5)). Data is reported as follows: chemical shift [multiplicity (s = singlet, d = doublet, t =
triplet, q = quartet, m = multiplet, app = apparent, br = broad), coupling constant(s) in Hertz,
integration, assignment]. Carbon-13 nuclear magnetic resonance (13 C NMR) spectra are reported in
parts per million on the 6 scale and are referenced from the carbon resonances of the solvent (CDCl 3:
6 77.23, CD 30D: 6 49.15, CD30D/CDCl 3 = 1/3: 6 49.15, DMSO-d: 6 39.51). Data is reported as
follows: chemical shift or chemical shift (assignment). Infrared data (IR) were obtained with a
Perkin-Elmer 2000 FTIR and are reported as follows: [frequency of absorption (cm'), intensity of
absorption (s = strong, m = medium, w = weak, br = broad)]. Optical Rotations were recorded on a
Jasco P-1010 Polarimeter (chloroform, Aldrich, Chromasolv Plus 99.9%; methanol, Aldrich,
Chromasolv Plus 99.9%) and specific rotations are reported as follows: [wavelength of light,
temperature (*C), specific rotation, concentration in grams/100 mL of solution, solvent]. Chiral
HPLC analysis was performed on an Agilent Technologies 1100 Series system. Preparative HPLC
was performed on a Waters system with the 1525 Binary HPLC Pump, 2489 UV/Vis Detector, 3100
Mass Detector, System Fluidics Organizer, and 2767 Sample Manager components. The structures of
(-)-3, (-)-72, and (-)-80 were obtained at the X-ray crystallography laboratory of the Department of
1 Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923-2925.
2 Pangborn, A. B.; Giardello, M. A.; Grubbs, R. H.; Rosen, R. K.; Timmers, F. J. Organometallics 1996, 15, 1518-1520.
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Chemistry, Massachusetts Institute of Technology, with the assistance of Mr. Justin Kim. We are
grateful to Dr. Li Li for obtaining the mass spectrometric data at the Department of Chemistry's
Instrumentation Facility, Massachusetts Institute of Technology. High-resolution mass spectrometric
data (HRMS) were recorded on a Bruker APEXIV 4.7 t FT-ICR-MS spectrometer using
electronspray ionization (ESI) source or direct analysis in real time (DART) ionization source.
Positional Numbering System. In assigning the 'H
to our total synthesis of (-)-1, (-)-2, (-)-3, and (-)-4,
consistent with that of the final targets.
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Iodine (1.9 g, 7.6 mmol, 1.1 equiv) was added as a solid in one portion to a solution of
tryptamine 35 (2.0 g, 6.9 mmol, 1 equiv) in anhydrous tetrahydrofuran (34 mL) at -78 *C. After 4
min, silver trifluoromethanesulfonate (AgOTf, 1.9 g, 7.6 mmol, 1.1 equiv) was added as a solid in
one portion to the reaction mixture to form a yellow precipitate. After 4 h, sodium bicarbonate (1.3 g,
15 mmol, 2.2 equiv) was added as a solid in one portion, and the reaction mixture was allowed to
warm to 23 'C. After 30 min, the resulting slurry was filtered through a plug of celite, and washed
with ethyl acetate (200 mL). The resulting filtrate was quenched with a mixture of saturated aqueous
sodium thiosulfate solution and saturated aqueous sodium bicarbonate solution (1:1, 200 mL), and the
layers were separated. The aqueous layer was extracted with ethyl acetate (200 mL), and the
combined organic layers were dried over anhydrous sodium sulfate, and were concentrated under
reduced pressure. The sample of the crude residue was purified by flash column chromatography
(silica gel: diam. 7 cm, ht. 10 cm; eluent: 33% ethyl acetate in hexanes) to afford iodide 58 (2.7 g,
95%) as a pale yellow solid.
'H NMR (500.4 MHz, CDCl3 , 21 *C):
13C NMR (125.8 MHz, CDCl3, 21 'C):
FTIR (neat) cm- 1:
HRMS (DART) (m/z):
TLC (33% ethyl acetate in hexanes) Rf
8 7.99 (br-s, lH, N1 H), 7.79 (dd, J= 5.5, 3.0 Hz, 2H,
C15H, Ci 8H), 7.67 (dd, J = 5.3, 3.0 Hz, 2H, C16H,
C17H), 7.62 (d, J= 7.9 Hz, 1H, C4H), 7.26 (d, J= 8.0
Hz, 1H, C7H), 7.09 (ddd, J= 8.1, 7.0, 1.2 Hz, 1H, C6H),
7.04 (app-td, J= 7.5, 0.9 Hz, 1H, C5H), 3.91 (app-t, J=
7.5 Hz, 2H, C11H2 ), 3.06 (app-t, J= 7.5 Hz, 2H, CioH 2).
8 168.5, 139.0, 134.1, 132.4, 127.7, 123.4 122.6, 120.3,
118.8, 118.1, 110.6, 78.5, 37.9, 26.3.
3351 (s), 3058 (w), 2944 (w), 1770 (m), 1705 (s), 1397
(s), 1103 (m), 717 (s).

















A suspension of 6-methoxytryptamine3 (18, 2.00 g, 10.5 mmol, 1 equiv) in anhydrous
dimethylformamide (DMF, 8.0 mL) at 23 'C was stirred vigorously under an argon atmosphere to
result in a homogeneous solution. A portion of anhydrous toluene (105 mL) and additional anhydrous
dimethylformamide (1.0 mL) was added to the homogenous solution of tryptamine derivative 18 in
DMF. Phthalic anhydride (1.70 g, 11.6 mmol, 1.10 equiv) was added as a solid in one portion, the
reaction flask was equipped with a Dean-Stark trap, and the reaction set-up was sealed under an
atmosphere of argon and heated to 130 'C. After 11 h, the reaction mixture was allowed to cool to 23
'C and concentrated under reduced pressure to afford a black solid residue. This solid was purified by
flash column chromatography (silica gel: diam. 5 cm, ht. 12 cm; eluent: 2.5% acetone in
dichloromethane) to afford the indole 56 (1.9 g, 56%) as a yellow solid.
'H NMR (500.4 MHz, CDCl 3, 21 'C):
13 C NMR (125.8 MHz, CDCl 3, 21 *C):
FTIR (neat) cm-1:
HRMS (DART) (m/z):
TLC (5% acetone in dichloromethane) Rf
6 7.86 (br-s, IH, NIH), 7.81 (dd, J= 5.5, 3.0 Hz, 2H,
C15H, Ci8H), 7.68 (dd, J= 5.5, 3.0 Hz, 2H, Ci6H,
C17H), 7.57 (d, J= 8.6 Hz, 1H, C4H), 6.96 (d, J= 2.3
Hz, 1H, C2H), 6.81 (d, J= 1.9 Hz, 1H, C7H), 6.77 (dd, J
= 8.6, 2.2 Hz, 1H, C5H), 3.97 (app-t, J= 7.8 Hz, 2H,
CIIH 2), 3.81 (s, 3H, OMe), 3.09 (app-t, J= 7.7 Hz, 2H,
CoH2).
6 168.6 (C13, C20), 156.8 (C), 137.1 (C8), 134.1 (C16,
C 17), 132.4 (C14, C19), 123.4 (Ci 5 , C18 ), 122.0 (C9),
120.9 (C2), 119.7 (C4), 112.6 (C3), 109.7 (C5 ), 94.8
(C7), 55.9 (C22 ), 38.7 (C 1), 24.7 (Cio).
3391 (br-m), 1766 (w), 1706 (s), 1629 (w), 1397 (s),
1161 (w), 990 (w), 713 (m).
calc'd for C19H17N20 3 , [M+H]*: 321.1234
found: 321.1231.
0.63 (CAM, UV).
' 6-Methoxytryptamine (18) can be purchased from commercial sources. Additionally, it can be prepared from 6-methoxyindole:



























Pinacol borane (873 [L, 5.84 mmol, 2.20 equiv) was added to a solution of indole 56 (850
mg, 2.65 mmol, 1 equiv), (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (87.9 mg, 133 [mol, 5.00
mol%) and 4,4'-di-tert-butyl-2,2'-dipyridyl (71.2 mg, 265 [tmol, 10.0 mol%) in degassed (purged
with an argon stream) and anhydrous tetrahydrofuran (27.0 mL) sealed under an argon atmosphere at
23 'C. After 2.5 h, (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (87.9 mg, 133 [imol, 5.00 mol%)
was added at once to the reaction mixture and the contents resealed under an argon atmosphere. After
3 h, the resulting red homogeneous reaction mixture was purged with an air stream. After 10 min,
silica gel (14 g) was added to the reaction mixture, and it was concentrated under reduced pressure.
The resulting crude residue adsorbed onto silica gel was purified by flash column chromatography
(silica gel: diam. 5 cm, ht. 10 cm; eluent: 20% ethyl acetate in hexane) to afford pinacol ester 57 (799
mg, 67.4%) as a yellow solid.
1H NMR (500.4 MHz, CDCl 3, 21 'C):
1C NMR (125.8 MHz, CDCl3, 21 'C):
FTIR (neat) cm-1:
HRMS (DART) (m/z):
TLC (50% hexanes in ethyl acetate), Rf
8 8.25 (br-s, 1H, NIH), 7.76 (dd, J= 5.5, 3.0 Hz, 2H,
CIsH, C18H), 7.63 (dd, J= 5.5, 3.1 Hz, 2H, C16H,
C17H), 7.58 (d, J= 8.6 Hz, 1H, C4H), 6.73 (d, J= 1.8
Hz, 1H, C7H), 6.71 (dd, J= 8.7, 2.2 Hz, 1H, C5H), 3.96
(app-t, J= 7.2 Hz, 2H, C1 1H2), 3.79 (s, 3H, OMe), 3.33
(app-t, J= 7.2 Hz, 2H, C1oH2), 1.27 (s, 12H, C28 H3
-C31H3).
6 168.4 (C1 3, C20), 158.0 (C6 ), 139.1 (Cs), 133.8 (C16,
C17), 132.5 (C 14, C 19), 125.5 (C 2), 123.2 (Ci5, C18),
123.0 (C9 ), 120.5 (C4 ), 110.4 (C3), 110.4 (C5 ), 94.0
(C7 ), 83.9 (C25, C26), 55.7 (C22), 39.4 (C11), 24.9
(C2 8-C 3 1), 24.7 (C1o).
3391 (br-s), 2978 (s), 2937 (s), 2252(w), 1771 (s), 1712
(s), 1549 (s), 1268 (s), 1142 (s), 911 (s), 732 (s).
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Degassed (purged with an argon stream) water (1.9 mL) was slowly added via syringe to a
solution of pinacol ester 57 (0.300 g, 0.672 mmol, 1 equiv), iodide 58 (336 mg, 0.807 mmol, 1.20
equiv), palladium precatalyst 4 (59, 106 mg, 0.134 mmol, 20.0 mol%), and silver phosphate (574 mg,
1.34 mmol, 2.00 equiv) in degassed (purged with an argon stream) toluene (9.6 mL) at 23 *C, and the
resulting solution was sealed under an argon atmosphere in the dark. After 24 h, brine (80 mL) was
added to the reaction mixture and the heterogeneous mixture was extracted with dichloromethane (5
x 80 mL). The combined organic layers were dried over anhydrous sodium sulfate, were filtered and
were concentrated under reduced pressure. The resulting crude residue was adsorbed onto silica gel
(15 g) for loading, and was purified by flash column chromatography (silica gel: diam. 5 cm, ht. 8
cm; eluent: 1% acetone in dichloromethane) to afford dimeric indole 60 (256 mg, 63.0%) as a bright
yellow solid. Structural assignment of 60 utilized additional information from gCOSY, HSQC and
HMBC. Dimeric indole 60 was prone to air oxidation and therefore was immediately moved to the
next step.
'H NMR (500.4 MHz, DMSO-d, 21 'C):
1C NMR (125.8 MHz, DMSO-d, 21 'C):
6 10.98 (br-s, 1H, N1H), 10.83 (br-s, 1H, N 13H),
7.70-7.64 (in, 8H, C37H-C 40H, C29H-C 32H), 7.60 (d, J
= 7.9 Hz, 1H, C7H), 7.48 (d, J= 8.6 Hz, 1H, C17H), 7.30
(dt, J= 8.1, 0.8 Hz, IH,C 4H), 7.10 (ddd, J= 8.1, 7.0,
1.1 Hz, lH, C6H), 7.01 (ddd, J= 7.9, 7.0, 1.0 Hz, 1H,
CsH), 6.77 (d, J= 2.2 Hz, 1H, C2oH), 6.69 (dd, J= 8.6,
2.3 Hz, 1H, C18H), 3.79 (s, 3H, OMe), 3.77-3.73 (in,
4H, C1 1H 2, C2 3H2), 3.01 (t, J = 7.5 Hz, 2H, C10 H2), 2.97
(t, J= 7.7 Hz, 2H, C22H2).
6 167.6 (C27, C 34), 167.6 (C 35 , C42 ), 155.9 (C19 ), 137.1
(C21), 136.2 (C8), 134.0 (C 30, C31), 134.0 (C 38, C39),
131.4 (C28, C33 ), 131.4 (C 36, C 41), 127.7 (C 3), 127.7
(C9 ), 126.1 (C1 5), 122.7 (C 29, C32), 122.7 (C3 7, C4 0),
122.0 (Ci6), 121.5 (C6), 118.9 (C1 7), 118.7 (Cs), 118.2
(C7 ), 111.3 (C4 ), 110.2 (C 14), 109.9 (C2 ), 109.1 (CI),





94.3 (C20), 55.2 (C26), 37.8 (CII), 37.8 (C23), 23.6 (C22),
23.5 (C10).
3365 (br-w), 1766 (m), 1703 (s), 1398 (s), 1352 (m),
714 (s).
calc'd for C37H28N4NaO5 , [M+Na]*: 631.1952,
found: 631.1949.
















diyl))bis(isoindoline-1.3-dione) (61) and (S)-2,2'-((3'-hydroxy-6-methoxy-1H,3'H-[2,2'-biundolel-
3,3'-diyl)bis(ethane-2.1-divl))bis(isoindoline-1,3-dione) (62):
A solution of (+)-(8,8-dichlorocamphorylsulfonyl)oxaziridine (198 mg, 0.645 mmol, 2.00
equiv) in degassed (purged with an argon stream) and anhydrous dichloromethane (16 mL) at -35 *C
was cannula transferred to a solution of dimeric indole 60 (196 mg, 0.323 mmol, 1 equiv) in degassed
(purged with an argon stream) and anhydrous dichloromethane (32 mL) at -35 *C under an
atmosphere of argon. The reaction mixture was allowed to gently warm to 23 *C. After 24 h, the
reaction mixture was concentrated under reduced pressure and the residue was purified by flash
column chromatography (silica gel: diam. 2.5 cm, ht. 13 cm; eluent: 6% acetone in dichloromethane)
to afford hydroxyindolenines (+)-61 and (+)-62 (2.2:1, 61:62, 191 mg, 94.6%) as a yellow foam.
Structural assignment of (+)-61 utilized additional information from gCOSY, HSQC and HMBC.
(S)-2,2'-((3'-Hydroxy-6'-methoxy-1H,3'H-[2,2'-biindolel-3'-diyl)bis(ethane-2,1-
diyl))bis(isoindoline-1,3-dione) (61)
'H NMR (500.4 MHz, CDCl3, 21 'C):
3 C NMR (125.8 MHz, CDCl 3, 21 'C):
5 9.35 (s, 1H, N1H), 7.75 (dd, J= 5.4, 3.1 Hz, 2H, C2 9H,
C32H), 7.67 (dd, J= 5.4, 3.0 Hz, 2H, C30H, C31H), 7.53
(dd, J= 5.4, 3.1 Hz, 2H, C37H, C40 H), 7.45 (dd, J= 5.5,
3.0 Hz, 2H, C38 H, C39H), 7.35 (d, J= 8.1 Hz, 1H,
C17H), 7.25 (d, J= 6.3 Hz, 1H, C7H), 6.82 (app-t, J=
7.6 Hz, 1H, C6H), 6.68-6.64 (m, 2H, C4H, C5H), 6.50
(d, J= 2.2 Hz, 1H, C20 H), 6.44 (dd, J= 8.1, 2.3 Hz, 1H,
Ci8H), 4.29 (s, 1H, 0 43H), 4.14 (ddd, J= 13.8, 8.7, 5.3
Hz, 1H, CIIH), 4.05 (dt, J= 13.5, 0.9 Hz, 1H, CuH),
3.66 (s, 3H, OMe), 3.59-3.50 (m, 2H, C10H, C23H),
3.44-3.37 (m, 1H, CioH), 3.30 (dt, J= 14.2, 5.9 Hz, 1H,
C2 3H), 2.70 (ddd, J= 14.5, 8.7, 6.0 Hz, 1H, C22H), 2.09
(dt, J= 14.2, 5.6 Hz, 1H, C2 2H).
175.0 (C14), 168.7 (C 27, C34), 167.9 (C 35, C42), 161.5
(C19), 154.9 (C 2 1), 137.4 (C8 ), 133.9 (C 3 0, C31), 133.6
(C 38, C39), 132.5 (C 28, C3 3), 132.1 (C 36, C 4 1), 130.2
(C16), 127.9 (C9 ), 127.5 (C2), 124.8 (C6), 123.2 (C29,
C32), 123.0 (C17), 122.9 (C 37, C40), 119.8 (C4), 119.6
(C3), 119.4 (C7), 112.2 (Cs), 111.3 (Cis), 106.9 (C20),
116
19,
85.5 (Ci 5), 55.4 (C26), 39.1 (CII), 34.6 (C 22), 33.5 (C 23 ),
24.5 (C10 ).
3363 (br-s), 2939 (w), 2361 (w), 1771 (m), 1710 (s),





TLC (5% acetone in dichloromethane), Rf
calc'd for C37H29N40 6 , [M+H]*: 625.2082,
found: 625.2059.




1H NMR (500.4 MHz, CDC13, 21 'C):
13C NMR (125.8 MHz, CDC13, 21 'C):
FTIR (neat) cm-1:
HRMS (DART) (m/z):
8 9.23 (s, 1H, NIH), 7.77 (dd, J= 5.4, 3.0 Hz, 2H,
C29,H, C32,H), 7.66 (dd, J = 5.4, 3.0 Hz, 2H, C30,H,
C31.H), 7.52 (dd, J= 5.5, 3.1 Hz, 2H, C3 7'H, C40.H), 7.47
(d, J= 6.8 Hz, 1H, C17,H), 7.44 (dd, J= 5.5, 3.0 Hz, 2H,
C38H, C39,H), 7.08 (d, J= 8.7 Hz, 1H, C4,H), 6.92-6.83
(m, 3H, C18,H, C19 H, C20.H), 6.32 (dd, J= 8.8, 2.2 Hz,
1H, C5.H), 6.08 (d, J= 1.5 Hz, 1H, C7 H), 4.49 (s, 1H,
043,H), 4.17 (ddd, J= 13.8, 9.1, 5.0 Hz, 1H, Ci1H), 4.02
(dt, J= 13.5, 5.4 Hz, 1H, CirH), 3.58-3.45 (m, 2H,
C1 0 H, C23rH), 3.53 (s, 3H, OMe), 3.34-3.27 (m, 2H,
Cio.H, C2 3,H), 2.68 (ddd, J= 14.4, 8.3, 6.2 Hz, 1H,
C22,H), 2.10 (dt, J= 14.0, 5.8 Hz, 1H, C22.H).
173.6, 168.7, 167.9, 158.3, 153.3, 138.7, 138.1, 134.0,
133.5, 132.5, 132.1, 130.4, 126.6, 125.4, 123.2, 122.9,
122.6, 122.5, 120.5, 120.2, 120.2, 112.0, 93.5, 85.7,
55.1, 39.2, 34.5, 33.4, 24.6.
3365 (br-w), 2932 (w), 2361 (w), 1771 (m), 1710 (s),
1626 (w), 1545 (m), 1396 (s), 1347 (m), 1240 (w), 717
(s).
calc'd for C3 7H29N40, [M+H]: 625.2082,
found: 625.2070.
+121 (c 0.10, CHCl3).



















To a glass vial charged with tryptophol derivative 64 (22.6 mg, 57.0 [mol, 1 equiv) and
catalyst 67 (3.7 mg, 5.7 Rmol, 0.1 equiv) was added DMAP (0.35 mg, 2.9 [mol, 0.05 equiv) in
chloroform (200 pL) and the reaction mixture was cooled to 0 *C. After 3 min, hydrogen peroxide
(30 % w/w in water, 7.0 RL, 68 [imol, 1.2 equiv) was added to the reaction mixture. After 9 min,
additional chloroform (80 pL) was added to the reaction mixture. After 4 min, DIC (10.7 RL, 68.4
Rmol, 1.20 equiv) was added to the reaction mixture and the resulting dark orange solution was
placed in a cryogenic cooler adjusted at 0 *C. After 22 h, the reaction mixture was diluted with
chloroform (0.5 mL) and directly purified by flash column chromatography (silica gel: diam. 2.0 cm,
ht. 11 cm; eluent: 13% ethylacetate in hexanes) to afford hydroxyindolenine (+)-65 (22.9 mg, 97%)
as a colorless oil. Hydroxyindolenine (+)-65 was found to be 79% ee by chiral HPLC analysis
[Chiralpak IC 0.5 mL/min; 80% hexanes, 20% isopropanol; tR(major) = 12.4 min, tR(minor) = 10.1
min].
'H NMR (500.4 MHz, CDC13, 21 'C):




TLC (25% ethyl acetate in hexanes), Rf
6 8.15 (dd, J= 7.7, 1.4 Hz, 1H), 7.93 (dd, J= 8.1, 1.1
Hz, 1H), 7.66 (dt, J = 7.6, 1.3 Hz, 1H), 7.58 (appt-dt, J
= 7.7, 1.5 Hz, 1H), 7.51-7.49 (m, 1H), 7.46-7.45 (m,
1H), 7.35 (dt, J= 7.6, 1.4 Hz, 1H), 7.27 (dt, J= 7.4, 1.1
Hz, lH), 5.11 (s, 1H), 3.98 (ddd, J= 10.6, 7.9, 4.1 Hz,
1H), 3.77 (ddd, J= 10.7, 6.1, 4.6 Hz, 1H), 2.21 (ddd, J
12.6, 8.0, 4.6 Hz, 1H), 2.03 (ddd, J= 10.26, 6.1, 4.2 Hz,
1H), 0.88 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H).
6 177.6, 152.9, 149.4, 140.5, 132.5, 130.9, 130.4, 129.8,
129.6, 127.1, 124.6, 123.0, 122.1, 89.1, 61.1, 37.4, 26.0,
18.2, -5.5, -5.6.
3406 (s), 2955 (s), 2857 (m), 1649 (w), 1538 (s), 1471
(m), 1361 (m), 1258 (m), 1984 (m), 838 (s).
calc'd for C22 H29N20 4 Si, [M+H]*: 413.1891,
found: 413.1890.

























To a solution of hydroxyindolenine (+)-65 (26.2 mg, 63.5 [tmol, 1 equiv) in a freshly distilled
tert-butanol (1.6 mL) under argon was added a solution of potassium tert-butoxide (3.8 mg, 32[tmol,
0.50 equiv) in tert-butanol (1.6 mL) via syringe at 23 *C. After 16.5 h, saturated aqueous ammonium
chloride solution (3 mL) was added to the reaction mixture and the resulting mixture was diluted with
water (4.5 mL) and ethyl acetate (6 mL) and the layers were separated. The aqueous layer was
extracted with ethylacetate (2 x 6 mL), and the combined organic layers were dried over anhydrous
sodium sulfate, were filtered, and were concentrated under reduced pressure. The sample of the crude
residue was purified by flash column chromatography (silica gel: diam. 2.0 cm, ht. 1 cm; eluent: 13%
ethylacetate in hexanes) to afford indoxyl (-)-66 (17.6 mg, 67%) as a yellow oil. Indoxyl (-)-66 was
found to be 79% ee by chiral HPLC analysis [Chiralpak IC 0.5 mL/min; 80% hexanes, 20%
isopropanol; tR(major) = 14.9 min, tR(minor) = 24.8 min].
'H NMR (500.4 MHz, CDCl 3, 21 *C):
13C NMR (125.8 MHz, CDCl3, 21 *C):
FTIR (neat) cm 1:
HRMS (DART) (m/z):
6 7.79 (appt-d, J= 7.4 Hz, 1H), 7.61 (td, J= 7.7, 0.6 Hz,
1H), 7.53-7.50 (m, H), 7.48 (ddd, J= 8.3, 7.1, 1.3 Hz,
1H), 7.36-7.35 (m, 2H), 6.90 (appt-t, J= 7.8 Hz, 1H),
6.86 (td, J= 8.2, 0.7 Hz, 1H), 6.13 (s, 1H), 3.79-3.72
(m, 2H), 2.53 (ddd, J= 14.9, 6.8, 2.9 Hz, 1H), 2.08
(ddd, J= 14.8, 9.7, 4.9 Hz, 1H), 0.84 (s, 9H), -0.09 (s,
3H), -0.10 (s, 3H).
6 201.5, 160.8, 150.9, 137.7, 131.0, 130.9, 129.7, 128.5,
125.3, 123.9, 120.6, 119.8, 113.7, 70.6, 60.1, 40.2, 26.0,
18.2, -5.7.
3350 (m), 2954 (m), 2929 (m), 1705 (s), 1617 (s), 1533
(s), 1484 (m), 1369 (m), 1324 (m), 1258 (m), 1096 (s),
836 (s), 778 (s).
calc'd for C22H 29N2 0 4 Si, [M+H]*: 413.1891,
found: 413.1903.
-79.5 (c 0.15, CHCl 3).












blindol-3a-ol (49) and (3aS,8aS)-8a-(3-(2-aminoethyl)-6-methoxv-1H-indol-2-yl)-1,2.3,3a,8,8a-
hexahydronyrrolo[2,3-blindol-3a-o1 (50):
Hydrazine monohydrate (252 [tL, 5.09 mmol, 20.0 equiv) was added to a solution of
hydroxyindolenines (+)-61 and (+)-62 (2.2:1, 61:62, 163.0 mg, 0.2601 mmol, 1 equiv) in methanol
(25 mL) at 23 'C and the reaction flask was equipped with a reflux condenser, was sealed under an
atmosphere of argon and heated to 80 *C. After 2 h, the resulting yellow homogeneous solution was
allowed to cool to 23 'C and concentrated under reduced pressure. The residue was purified by flash
column chromatography (silica gel: diam. 5 cm, ht. 12 cm; eluent: 9% methanol, 1% ammonium
hydroxide in chloroform) to afford hydroxyaminals (+)-49 and (+)-50 (2.2:1, 49:50, 94.2 mg, 99.4%)
as a yellow solid mixture. Structural assignment of (+)-49 utilized additional information from
gCOSY, HSQC and HMBC.
(3aS.,8aS)-8a-(3-(2-Aminoethyl)-1H-indol-2-v)-6-methoxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-
blindol-3a-ol (49)
'H NMR (500.4 MHz, CDCl3, 21 *C):
13C NMR (125.8 MHz, CDCl 3, 21 'C):
FTIR (neat) cm':
8 9.10 (s, 1H, NiH), 7.43 (d, J= 7.2 Hz, 1H, C4H), 7.33
(dt, J= 8.1, 0.8 Hz, 1H, C7H), 7.16 (d, J= 8.2 Hz, 1H,
C IH), 7.13 (ddd, J= 8.1, 7.0, 1.1 Hz, 1H, C6H), 7.04
(ddd, J= 7.9, 7.0, 1.0 Hz, 1H, C5H), 6.34 (dd, J= 8.2,
2.2 Hz, 1H, C17H), 6.16 (d, J= 2.2 Hz, 1H, C15H), 3.79
(s, 3H, OMe), 3.12 (app-dd, J= 9.1, 5.8 Hz, 1H, C22H),
2.97-2.91 (in, 3H, CioH, CIIH, C22H), 2.72 (app-t, J=
10.5 Hz, 1H, CnH), 2.54 (t, J= 11.5 Hz, 1H, CloH),
2.32-2.21 (m, 2H, C2 1H2).
8 161.4 (C,6), 151.4 (C, 4), 136.1 (C2), 134.4 (C8), 129.5
(C9), 125.6(Ci8 ), 125.0 (C19), 121.7 (C6 ), 119.0 (Cs),
118.3 (C4), 111.5 (C7 ), 110.2 (C3 ), 104.6 (C17), 94.3
(Ci5), 89.5 (C20), 89.2 (C24), 55.5 (C26), 42.5 (C22), 41.5
(C2 1), 41.1 (C,,), 26.4 (C1o).
3394 (br-m), 2961 (m), 2931 (m), 2853 (m), 1618 (s),
















calc'd for C2 1H25N40 2 , [M+H]*: 365.1972,
found: 365.1987.
+61.1 (c 0.17, CHCl 3).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf: 0.19 (CAM, UV).
(3 aS.8aS)-8a-(3-(2-Aminoethvl)-6-methoxy-1H-indol-2-yl)-1,2,3,3a8,8a-hexahydropyrrolo[2,3-
blindol-3a-ol (50)
'H NMR (500.4 MHz, CDC13, 21 *C):




8 9.00 (s, 1H, N1.H), 7.28 (d, J= 8.8 Hz, 1H, C4 H), 7.28
(dd, J= 6.9, 0.9 Hz, 1H, C18H), 7.13 (td, J= 7.7, 1.3
Hz, 1H, CI 6H), 6.84 (d, J= 2.2 Hz, 1H, C7,H), 6.78 (td,
J= 7.4, 0.8 Hz, 1H, C17,H), 6.71 (dd, J= 8.6, 2.2 Hz,
1H, C5,H), 6.61 (d, J= 7.9 Hz, 1H, Cis.H), 3.81 (s, 3H,
OMe), 3.12 (app-t, J= 7.2 Hz, 1H, C22H), 2.98-2.86
(m, 3H, CioH, CirH, C2 2.H), 2.68 (app-t, J = 10.5 Hz,
1H, CirH), 2.53-2.47 (m, 1H, CioH), 2.34-2.25 (m, 2H,
C2rH 2).
8 156.5, 150.1, 135.1, 134.8, 132.7, 129.5, 125.3, 124.0,
119.5, 119.0, 110.1, 109.2, 108.4, 94.9, 89.8, 89.1, 55.9,
42.5, 41.6, 41.2, 26.5.
3359 (br-m), 2927 (s), 1691 (w), 1610 (s), 1464 (s),
1205 (s), 751 (s).
calc'd for C2 1H25N40 2, [M+H]*: 365.1972,
found: 365.1978.
+34.6 (c 0.17, CHC 3).




OH dehydrating a 1 1q 46 OMe 1eO 16
HN reagent 1 I H1I "OH + 2'H egn ' 2H
NH 7 Ne NHN CH 2CI 2  M 2 0 MeO N 24111. HNHN He N6 OH Ni 24\" _ NH 2  7' N131\ H
H10min H 23N 22 13 H 23Nmin
OMe 47% 28% 19%
2.2:1 94% ee 95% ee(+)-49 (+)-50 (-)-71 (-)-72
(S)-2-(3.3a,4,5.6,11-Hexahydro-2H-nyrrolo[3',2':2,31azepinol4,5-blindol-3a-vl)-5-
methoxy aniline (71) and (S)-2-(9-methoxy-3,3a4,5.6,11-hexahvdro-2H-
Pyrrolol3',2':2,31azenino[4,5-blindol-3a-vbaniline (72):
A solution of aminals (+)-49 and (+)-50 (2.2:1, 49:50, 91.2 mg, 0.250 mmol, 1 equiv) in
anhydrous dichloromethane (8 mL) at -78 *C under an atmosphere of argon was cannula transferred
to a solution of bis[a,a-bis(trifluoromethyl)benzenemethanolato]diphenylsulfur (Martin's sulfurane
dehydrating reagent, 202 mg, 0.300 mmol, 1.20 equiv) in anhydrous dichloromethane (5 mL) at -78
*C under an atmosphere of argon. After 10 min, saturated aqueous sodium bicarbonate solution (20
mL) was added to the reaction mixture and the resulting mixture was diluted with dichloromethane (5
mL), and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 20
mL), and the combined organic layers were dried over anhydrous sodium sulfate, and were
concentrated under reduced pressure. The sample of the crude residue was purified by flash column
chromatography (silica gel: diam. 2.5 cm, ht. 18 cm; eluent: 0.9% methanol, 0.1 % ammonium
hydroxide in chloroform to 2.3% methanol, 0.3 % ammonium hydroxide in chloroform) to afford
pentacycle (-)-71 (24.2 mg, 27.9%) and pentacycle (-)-72 (16.4 mg, 18.9%) as pale yellow solids.
Structural assignment of (-)-71 and (-)-72 utilized additional information from gCOSY, HSQC and
HMBC.
Pentacycle (-)-71 was found to be 94% ee by chiral HPLC analysis [Chiralcel OD-H 0.5
mL/min; 100% hexanes to 20% hexanes in isopropanol over 80 min; tR(major) = 65.1 min, tR(minor)
= 41.8 min]. Pentacycle (-)-72 was found to be 95% ee by chiral HPLC analysis [Chiralcel OD-H
0.5 mL/min; 100% hexanes to 20% hexanes in isopropanol over 80 min; tR(major) = 54.5 min min,




H NMR (500.4 MHz, CDCl3 , 21 C): 8 9.54 (s, IH, N1H), 7.48 (d, J= 8.0 Hz, 1H, C4H), 7.35
(dt, J= 8.2, 0.8 Hz, 1H, C7H), 7.24 (app-td, J= 7.6, 1.1
Hz, 1H, C6H), 7.06 (ddd, J= 8.0, 7.0, 1.0 Hz, 1H, C5H),
6.57 (d, J= 8.6 Hz, 1H, CI8H), 6.21 (d, J= 2.6 Hz, 1H,
C15H), 5.99 (dd, J= 8.5, 2.6 Hz, 1H, C17H), 5.25 (s, 2H,
N13H 2), 4.01 (dd, J= 15.4, 7.7 Hz, 1H, C22H), 3.67 (s,
3H, OMe), 3.45 (ddd, J= 15.5, 10.2, 5.5 Hz, 1H, C22H),
3.22-3.10 (m, 2H, C11H2), 3.03-2.91 (m, 2H, CioH 2),
2.75 (dd, J= 12.1, 5.7 Hz, 1H, C21H), 1.93 (ddd, J=
12.1, 10.5, 7.8 Hz, 1H, C21H).
"C NMR (125.8 MHz, CDCl 3, 21 *C): 8 174.4 (C24), 160.2 (C16), 147.7 (C 14), 137.3 (Cs),
129.6 (C2), 129.1 (C18), 128.4 (C9), 124.9 (C6), 120.0
122
(C5), 119.8 (C4), 118.7 (C3), 114.9 (C19),
102.5 (C17), 102.4 (Cis), 75.6 (C20), 56.0





3286 (br-s), 2924 (s), 1599 (s), 1509 (m), 1450 (m),
1331 (m), 1211 (s), 748 (s).
calc'd for C21H23N40, [M+H]*: 347.1866,
found: 347.1852.
[a]D 24: -96.2 (c 0.15, CHC13).
TLC (9% methanol, 1% ammonium hydroxide in chloroform), Rf 0.41 (CAM, UV).
(S)-2-(9-Methoxy-3,3a,4,5,6,1-hexahvdro-2H-vrrolo[3',2':2,31 azevino[4.5-blindol-3a-
v)aniline (72)
'H NMR (500.4 MHz, CDC13, 21 'C):




8 9.46 (s, 1H, NiH), 7.33 (d, J = 8.7 Hz, 1H, C4,H), 7.02
(app-td, J= 7.6, 1.5 Hz, 1H, Ci,6 H), 6.78 (d, J= 2.1 Hz,
1H, C7,H), 6.72 (dd, J= 8.7, 2.2 Hz, 1H, CsH), 6.69 (dd,
J= 7.7, 1.3 Hz, 1H, Ci,8 H), 6.64 (dd, J= 7.9, 1.1 Hz,
1H, CIsH), 6.44 (td, J= 7.5, 1.2 Hz, 1H, C17 H), 3.99
(dd, J= 15.2, 7.7 Hz, 1H, C22,H), 3.82 (s, 3H, OMe),
3.44 (ddd, J= 15.5, 10.3, 5.5 Hz, 1H, C22.H), 3.18 (dt,
1H, J= 14.4, 5.0 Hz, 1H, C,,H), 3.09 (ddd, J= 14.3,
9.6, 4.7 Hz, 1H, CivH), 2.99-2.92 (m, 1H, CioH), 2.86
(dt, J= 16.8, 4.7 Hz, 1H, C10 H), 2.77 (dd, J= 12.2, 5.6,
Hz, 1H, C21H), 1.94 (ddd, J= 12.1, 10.5, 7.8 Hz, 1H,
C21,H),
6 173.9 (C24'), 158.6 (C6 .), 146.4 (C14), 138.2 (C8'),
128.9 (C2'), 128.7 (C, 6'), 128.2 (Ci,8'), 122.8 (C9 ,), 122.3
(C,9 ,), 120.8 (C4'), 118.7 (C 3'), 117.5 (C,7'), 116.7 (Ci,5'),
110.5 (C5'), 94.0 (C7'), 76.0 (C20'), 56.1 (C22'), 55.8
(C26'), 42.2 (C 1,.), 40.7 (C21), 28.4 (Co').
3284 (br-m), 2924 (br-m), 1596 (s), 1495 (w), 1454 (w),
1273 (m), 752 (s).
calc'd for C2jH23N40, [M+H]*: 347.1866,
found: 347.1876.
-176 (c 0. 15, CHC13).
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(-)-trigonolii mine A (1)
82%
(-)-Trigonoliimine A (1):
Anhydrous dichloromethane (4 mL) was added via syringe to a flask charged with pentacycle
(-)-71 (14.0 mg, 40.4 [tmol, 1 equiv) and pyridinium p-toluenesulfonate (PPTS, 31.0 mg, 0.121
mmol, 3.00 equiv) at 23 *C under an atmosphere of argon to form a bright yellow solution. After 2
min, triisopropyl orthoformate (93.0 tL, 0.404 mmol, 10.0 equiv) was added to the reaction mixture.
After lh, saturated aqueous sodium bicarbonate solution (6 mL) was added to the reaction mixture
and the resulting mixture was diluted with dichloromethane (2 mL), and the layers were separated.
The aqueous layer was extracted with dichloromethane (2 x 6 mL), and the combined organic layers
were dried over anhydrous sodium sulfate, and were concentrated under reduced pressure. The
sample of the crude residue was purified by flash column chromatography (silica gel: diam. 2 cm, ht.
12 cm; eluent: 1.8% methanol, 0.2 % ammonium hydroxide in chloroform to 4.5% methanol, 0.5 %
ammonium hydroxide in chloroform) to afford (-)-trigonoliimine A (1, 11.8 mg, 81.9%) as a pale
yellow solid.
'H NMR (500.4 MHz, DMSO-d, 21 'C):
'H NMR (500.4 MHz, CDCl 3/CD 30D (3:1),
"C NMR (125.8 MHz, DMSO-d, 21 'C):
8 11.50 (s, 1H, NiH), 7.47 (s, 1H, C2 5H), 7.45 (d, J=
7.9 Hz, IH, C4H), 7.34 (d, J= 8.2 Hz, 1H, C7H), 7.16
(ddd, J= 8.1, 7.0, 1.1 Hz, 1H, C6H), 7.00 (app-t, J= 7.9
Hz, 1H, C5H), 6.56-6.55 (in, 3H, C15H, C17H, C18H),
4.11 (dd, J= 16.1, 8.1 Hz, 1H, C22H), 4.01 (dt, J= 14.3,
3.3 Hz, 1H, CI1 H), 3.74 (app-t, J= 12.1 Hz, 1H, CIH),
3.66 (s, 3H, OMe), 3.55 (ddd, J= 16.1, 9.9, 6.1 Hz, 1H,
C2 2H), 3.07 (app-d, J= 17.1 Hz, 1H, CioH), 2.96 (ddd, J
= 16.9, 12.1, 4.3 Hz, IH, CioH), 2.19-2.13 (m, 1H,
C2 1H), 2.06 (dd, J= 12.0, 5.8 Hz, 1H, C21H).
21 C): 8 7.43 (d, J= 8.0 Hz, 1H, C4H), 7.34 (d, J= 8.3
Hz, 1H, C7H), 7.32 (s, 1H, C25H), 7.20 (ddd, J= 8.2,
7.1, 1.1 Hz, 1H, C6H), 7.03 (ddd, J= 8.0, 7.1, 0.9 Hz,
lH, C5H), 6.65 (d, J= 2.0 Hz, 1H, C15H), 6.57-6.53 (m,
2H, C17H, C18H), 4.13 (dd, J= 16.1, 8.1 Hz, 1H, C22H),
3.92 (dt, J= 14.5, 3.5 Hz, 1H, CIH), 3.84 (ddd, J=
14.3, 11.0, 3.1 Hz, 1H, C1IH), 3.70 (s, 3H, OMe), 3.65
(ddd, J= 16.1, 10.2, 5.9 Hz, 1H, C22H), 3.19-3.08 (m,
2H, CioH 2), 2.27 (dd, J= 12.3, 5.8 Hz, 1H, C21H), 2.16
(ddd, J= 12.1, 10.3, 8.3 Hz, 1H, C21H).
8 166.5 (C 24 ), 159.6 (Ci6 ), 150.2 (C 25), 143.1 (C14 ),
136.5 (C8), 128.0 (C2), 127.1 (C9 ), 123.4 (C6), 123.2
(Ci 8), 119.2 (C5), 119.1 (C4), 115.6 (C3), 115.0 (C19),
124
111.6 (C 7), 110.2 (C1 7), 109.3 (C15), 76.5 (C20), 56.2
(C22), 55.0 (C27), 46.6 (C 11), 40.6 (C21), 29.2 (C1o).
13 C NMR (125.8 MHz, CDC13/CD 30D (3:1), 21 C): 8 168.2 (C24 ), 160.7 (C16), 150.5 (C25), 142.0
(C 14), 137.4 (C8), 127.9 (C9 ), 127.2 (C2), 125.0 (C6),
123.9 (C18 ), 120.2 (C5), 119.6 (C4), 118.1 (C3 ), 114.5
(C19 ), 112.1 (C7), 112.0 (C17), 109.4 (Ci5), 77.5 (C 20),
56.6 (C22), 55.6 (C27), 48.5 (C11), 41.1 (C 2 1), 30.1 (C10 ).
FTIR (neat) cm-: 3406 (br-s), 1594 (s), 1488 (m), 1394 (w), 1251 (w),
1126 (w), 730 (s).
HRMS (ESI) (m/z): calc'd for C22H21N40, [M+H]*: 357.1710,
found: 357.1702.
[aID 24: 
-294 (c 0.24, CHC13).
TLC (9% methanol, 1% ammonium hydroxide in chloroform), Rf: 0.38 (CAM, UV).
125
H2N 4 10 25
NH CH(OPr) 9 3 12
Me -e 1 2 41M PPTS MN - 2 1 2 19N27 7 N1 H 8 1H N CH2CI2  H23 22 17
23 0C
(-)-72 1 h (-)-trigonoliimine B (2)
94%
(-)-Trigonoliimine B (2):
Anhydrous dichloromethane (4.3 mL) was added via syringe to a flask charged with
pentacycle (-)-72 (16.4 mg, 47.3 Vmol, 1 equiv) and pyridinium p-toluenesulfonate (PPTS, 33.3 mg,
0.130 mmol, 3.00 equiv) at 23 *C under an atmosphere of argon to form a bright yellow solution.
After 2 min, triisopropyl orthoformate (99.5 [tL, 0.433 mmol, 10.0 equiv) was added to the reaction
mixture. After lh, saturated aqueous sodium bicarbonate solution (6 mL) was added to the reaction
mixture and the resulting mixture was diluted with dichloromethane (2 mL), and the layers were
separated. The aqueous layer was extracted with dichloromethane (2 x 6 mL), and the combined
organic layers were dried over anhydrous sodium sulfate, and were concentrated under reduced
pressure. The sample of the crude residue was purified by flash column chromatography (silica gel:
diam. 2 cm, ht. 11.5 cm; eluent: 2.6% methanol, 0.3 % ammonium hydroxide in chloroform) to afford
(-)-trigonoliimine B (2, 15.9 mg, 94.3%) as a pale yellow solid. Structural assignment of (-)-2
utilized additional information from gCOSY, HSQC and HMBC.
H NMR (500.4 MHz, CDCl3/CD 30D (3:1), 21 C): 5 7.33 (s, 1H, C25H), 7.28 (dd, J= 8.7, 0.4 Hz,
1H, C4H), 7.18 (td, J= 7.6, 1.4 Hz, 1H, Ci6H), 7.10 (dd,
J= 7.9, 1.2 Hz, 1H, CisH), 6.99 (td, J= 7.6, 1.3 Hz, 1H,
C17H), 6.80 (d, J= 2.1 Hz, 1H, C7H), 6.68 (dd, J= 8.7,
2.2 Hz, 1H, C5H), 6.66 (dd, J= 7.8, 1.4 Hz, 1H, CI8H),
4.11 (dd, J= 16.0, 8.1 Hz, 1H, C22H), 3.92-3.81 (m,
2H, Cn H2), 3.78 (s, 3H, OMe), 3.63 (ddd, J= 16.0,
10.2, 5.9 Hz, 1H, C2 2H), 3.12 (td, J= 17.3, 2.7 Hz, IH,
CioH), 3.09-3.02 (m, lH, CioH), 2.28 (dd, J= 12.2, 5.7
Hz, 1H, C2 1H), 2.15 (ddd, J = 12.2, 10.3, 8.3 Hz, 1H,
C21H).
13C NMR (125.8 MHz, CDCl 3/CD 30D (3:1), 21 C): 8 167.7 (C2 4), 158.8 (C6), 150.2 (C2 5), 140.7
(C14), 138.6 (C), 129.5 (Ci6), 126.3 (C 2), 126.0 (C17),
124.7 (Cis), 122.9 (Ci 8 ), 122.5 (C9), 122.1 (C19), 120.5
(C4), 118.9 (C3 ), 111.2 (C5 ), 94.5 (C7), 77.6 (C20), 56.4
(C2 2), 55.8 (C 2 7), 48.7 (C,,), 41.0 (C21), 30.2 (C1o).
FTIR (neat) cm-1: 3406 (br-s), 1609 (s), 1590 (s), 1560 (m), 1478 (w),
1275 (w), 1164 (w), 754 (s).
HRMS (DART) (m/z): calc'd for C22H21N40, [M+H]*: 357.1710,
found: 357.1715.
[a]D 24: -352 (c 0.32, CHC13).








N N 93% 9 e 22 1 96% ee- W4 96% ee 96%e
2.2:1 ;42 0 2.2:1 1 2N
38 .(+)-61 (+)-62 (-)-76 (-)-77
(S)-2-(2-(2-(3-(2-(1,3-Dioxoisoindolin-2-yl)ethyl)-1H-indol-2-yl)-6-methoxy-3-oxoindolin-2-
yl)ethyl)isoindoline-1.3-dione (76) and (S)-2-(2-(2-(2-(2-(1,3-dioxoisoindolin-2-vl)ethyl)-3-
oxoindolin-2-vl)-6-methoxy-1H-indol-3-yl)ethyl)isoindoline-1,3-dione (77):
Trifluoroethanol (TFE, 15 mL) was added via syringe to a pressure vessel charged with
hydroxyindolenines (+)-61 and (+)-62 (2.2:1, 61:62, 150 mg, 0.239 mmol, 1 equiv). Tightly sealed
reaction vessel was heated to 102 'C. After 24.5 h, the homogeneous orange reaction mixture was
allowed to cool to 23 'C and was concentrated under reduced pressure. The residue was purified by
flash column chromatography (silica gel: diam. 2.5 cm, ht. 12 cm; eluent: 3.3% acetone in
dichloromethane) to afford indoxyls (-)-76 and (-)-77 as a yellow solid mixture (2.2:1, 76:77, 140
mg, 93.3%). Structural assignment of (-)-76 and (-)-77 utilized additional information from gCOSY,
HSQC and HMBC.
The indoxyls (-)-76 and (-)-77 could be separated at this stage by preparative HPLC [Waters
X-Bridge preparative HPLC column, C18, 5 [m, 19 x 250 mm; 20.0 mL/min; 40% water in
acetonitrile; tR( 7 7 ) = 8.5 min, tR(7 6 ) = 9.5 min], but a more practical separation was possible after the
next step. Indoxyl (-)-76 was found to be 96% ee by chiral HPLC analysis [Chiralpak IC 0.7
mL/min; 45% hexanes in isopropanol; tR(major) = 24 min min, tR(minor) = 55 min]. Indoxyl (-)-77
was found to be 96% ee by chiral HPLC analysis [Chiralpak IC 0.7 mL/min; 45% hexanes in
isopropanol; tR(major) = 29.5 min min, tR(minor) = 35.5 min].
(S)-2 -(2 -(2-(3-(2-(1,3-Dioxoisoindolin-2-yl)ethyl)-1H-indol-2-vl)-6-methoxy-3-oxoindolin-2-
yl)ethyl)isoindoline-1,3-dione (76)
'H NMR (500.4 MHz, CDCl3, 21 'C):
"C NMR (125.8 MHz, CDCl3, 21 'C):
8 9.10 (s, 1H, NH), 7.87 (dd, J= 5.4, 3.0 Hz, 2H, C37H,
C4oH), 7.73 (dd, J= 5.4, 3.0 Hz, 2H, C3 8H, C39H), 7.61
(dd, J= 5.5, 3.0 Hz, 2H, C29H, C32H), 7.52 (dd, J= 5.5,
3.0 Hz, 2H, C3 0H, C3 1H), 7.49 (d, J= 7.9 Hz, 1H, C4H),
7.42 (d, J= 8.7 Hz, 1H, C17H), 7.22 (d, J= 8.1 Hz, 1H,
C7H), 7.05 (app-t, J= 8.1 Hz, 1H, C6H), 6.97 (app-t, J=
7.9 Hz, 1H, CH), 6.78 (s, 1H, N 13H), 6.64 (d, J= 2.1
Hz, 1H, C20H), 6.34 (dd, J= 8.7, 2.1 Hz, 1H, CI8H),
3.91-3.73 (m, 4H, C11 H2, C23H2), 3.87 (s, 3H, OMe),
3.11 (t, J= 8.7 Hz, 2H, CioH 2), 2.70-2.64 (m, 1H,
C2 2H), 2.41-2.36 (M, 1H, C22H).
8 198.2 (C15), 168.8 (C3 5, C4 2), 168.7 (C19), 168.3 (C 27,
C34), 163.4 (C 2 1), 135.5 (C8 ), 134.3 (C 38 , C39), 134.0
(C 30, C31), 132.4 (C 36, C41), 131.7 (C 28, C33), 131.1
(C2 ), 128.6 (C9 ), 126.8 (C1 7), 123.5 (C 37 , C40), 123.2
(C29 , C32), 122.5 (C6), 119.8 (Cs), 118.1 (C4), 111.9
127
(C1 ), 111.2 (C7), 109.9 (C18), 108.7 (C3 ), 94.8 (C20 ),
68.2 (C1 4), 55.9 (C26), 39.0 (C11), 37.0 (C 22), 33.7 (C2 3),
24.4 (C10).






TLC (5% acetone in dichloromethane), Rf
calc'd for C37H27N4 0 6 , [M-H]-: 623.1936,
found: 623.1936.




'H NMR (500.4 MHz, CDC13, 21 'C):




TLC (5% acetone in dichloromethane), Rf
6 8.89 (s, 1H, NrH), 7.87 (dd, J= 5.4, 3.0 Hz, 2H,
C37 H, C40,H), 7.72 (dd, J= 5.4, 3.0 Hz, 2H, C3 ,H,
C39.H), 7.60 (dd, J= 5.5, 2.9 Hz, 2H, C29,H, C32,H), 7.52
(dd, J 5.5, 3.2 Hz, 2H, C30 H, C3 1 H), 7.52 (d, J= 9.1
Hz, IH, C17 H), 7.48 (ddd, J= 8.3, 7.1, 1.3 Hz, 1H,
C19,H), 7.32 (d, J= 8.6 Hz, 1H, C4,H), 7.20 (d, J= 8.3
Hz, IH, C20,H), 6.76 (app-t, J= 7.8 Hz, 1H, Cis.H), 6.70
(d, J= 2.0 Hz, 1H, C7,H), 6.70 (s, 1H, N13,H), 6.61 (dd,
J= 8.6, 2.3 Hz, 1H, C5H), 3.89-3.71 (m, 4H, Ci IH 2,
C2 3.H2), 3.78 (s, 3H, OMe), 3.11-3.03 (m, 2H, CioH 2),
2.71-2.66 (m, 1H, C22.H), 2.37-2.32 (m, 1H, C22.H).
8 200.9 (Ci 5), 168.7 (C 35', C42'), 168.3 (C 27', C34'), 161.0
(C2 5), 156.9 (C6'), 138.4 (C1 9'), 136.3 (C8'), 134.2 (C38',
C39'), 133.9 (C30', C31 ), 132.4 (C 36', C 41'), 131.7 (C28',
C33'), 128.8 (C2'), 125.4 (C 17'), 123.5 (C 37', C40'), 123.1
(C2 9', C3 2 '), 123.0 (C9'), 119.2 (Ci 8'), 118.9 (C4'), 118.5
(C16 .), 113.1 (C20'), 110.0 (CO'), 109.2 (C3'), 94.5 (C7'),
67.8 (C 14.), 55.8 (C26'), 39.0 (Ci1r), 36.7 (C22'), 33.8
(C23'), 24.3 (CIo.).
1769 (m), 1705 (s) 1615 (m), 1467 (w), 1396 (m), 716
(m).
calc'd for C37H27N40 6 , [M-H]-: 623.1936,
found: 623.1938.












N-Bromosuccinimide (NBS, 2.4 mg, 0.013 mmol, 1.2 equiv) was added as a solid in one
portion to a solution of indoxyl (-)-76 (7.2 mg, 0.011 mmol, 1 equiv) in anhydrous acetonitrile (1.1
mL) at 0 'C and the reaction mixture was allowed to warm to 23*C. After 12 h, saturated aqueous
sodium thiosulfate solution and saturated aqueous sodium bicarbonate solution (1:1, 3 mL) was
added to the reaction mixture, the solution was diluted with dichloromethane (3 mL), and the layers
were separated. The aqueous layer was extracted with dichloromethane (2 x 3 mL), and the
combined organic layers were dried over anhydrous sodium sulfate and were concentrated under
reduced pressure. The sample of the crude residue was purified by flash column chromatography
(silica gel: diam. 1.5 cm, ht. 8 cm; eluent: 2.5% acetone in dichloromethane) to afford brominated
indoxyl (-)-80 (7.3 mg, 90%) as a yellow solid.
Brominated indoxyl (-)-80 was found to be 96% ee by chiral HPLC analysis [Chiralpak IC
0.7 mL/min; 45% hexanes in isopropanol; tR(major) = 20.7 min, tR(minor) = 30 min]. Crystal of
brominated indoxyl (-)-80 was obtained by slow evaporation of a hexanes-dichloromethane (1:1, 0.5
mL) solution of (-)-80 (7.2 mg).
IH NMR (500.4 MHz, CDCl3, 21 'C):
13C NMR (125.8 MHz, CDCl3, 21 'C):
8 8.95 (s, 1H, NiH), 7.87 (dd, J= 5.5, 3.0 Hz, 2H, C37H,
C4oH), 7.75 (dd, J= 5.4, 3.0 Hz, 2H, C3 8 H, C39H), 7.61
(s, 1H, C17H), 7.60 (dd, J= 5.6, 2.9 Hz, 2H, C29H,
C3 2H), 7.52 (dd, J= 5.4, 3.1 Hz, 2H, C30 H, C31H), 7.47
(d, J= 8.0 Hz, 1H, C4H), 7.21 (app-dt, J= 8.1, 0.8 Hz,
1H, C7H), 7.05 (ddd, J= 8.1, 7.0, 1.1 Hz, 1H, C6H),
6.97 (ddd, J= 7.9, 7.0, 1.0 Hz, 1H, C5H), 6.83 (s, 1H,
N13H), 6.75 (s, 1H, C2oH), 4.00 (s, 3H, OMe), 3.90-3.83
(m, 3H, C11H, C2 3H2), 3.77-3.70 (ddd, J= 13.8, 10.4,
7.2 Hz, 1H, CIIH), 3.07 (ddd, J= 10.8, 6.4, 4.1 Hz, 2H,
CioH 2), 2.67 (dt, J= 14.6, 7.3 Hz, C22H), 2.38 (dt, J=
14.5, 6.4 Hz, C22H).
5 197.1 (C15 ), 168.8 (C 35, C 42), 168.3 (C 27, C 34), 163.9
(C 19), 162.1 (C 2 1), 135.6 (C8), 134.4 (C 3 8, C 3 9), 134.0
(C30, C31), 132.4 (C 36, C 41), 131.6 (C 28, C33), 130.4
(C2 ), 129.5 (C 17 ), 128.5 (C9), 123.5 (C3 7, C4 0), 123.2
(C2 9, C3 2), 122.7 (C6 ), 119.9 (Cs), 118.2 (C4 ), 112.4




68.5 (CI 4), 56.9 (C26), 38.9 (C 1), 36.9 (C 22), 33.6 (C2 3),
24.4 (C10).
3378 (br-m), 1770 (m), 1708 (s), 1609 (s), 1457 (m),
1397 (s), 1211 (m), 1034 (w), 717 (s).
calc'd for C37H28BrN406 , [M+H]*: 703.1187,
found: 703.1187.
[a]D 24: -56.2 (c 0.15, CHC13).
TLC (5% acetone in dichloromethane), Rf 0.5 (CAM, UV).
130
U N 1. NH2NH2-H20 i 1 10'MeOH N
0 Oe- 80 0 C, 2h. 16 \ 16
N O 2. Ti(OEt)4  h. 5 N MeO N22" N 21N N THF H4 3 1 OMe 2U H 2 3 13MeO N H 42 C, 10 h. 2 23
H H2N H2N
NN 61% (--82 1(-)-79
N O 2.2:1 N (2 steps) (-)-78 2:1
(-)-76 (-)-77
(S)-2-(2-Methoxy-7,12,12b,13-tetrahydro-6H-azepino[3,2-b:4,5-b ' diindol-12b-ylbethanamine
(78) and (S)-2-(10-methoxv-7,12,12b,13-tetrahydro-6H-azepino[3,2-b:4,5-b 'diindol-12b-
yl)ethanamine (79):
Hydrazine monohydrate (81.0 [tL, 1.64 mmol, 10.0 equiv) was added via syringe to a solution
of indoxyls (-)-76 and (-)-77 (2.2:1, 76:77, 103 mg, 0.164 mmol, 1 equiv) in methanol (16 mL)
under an atmosphere of argon at 23 'C, and the reaction flask was equipped with a reflux condenser,
and the reaction set-up was sealed under an atmosphere of argon and heated to 80 'C. After 2 h, the
pale yellow homogeneous reaction mixture was allowed to cool to 23 'C and the volatiles were
removed under reduced pressure to result in a pale yellow solid. A solution of titanium ethoxide (153
[tL, 0.656 mmol, 4.00 equiv) in anhydrous tetrahydrofuran (16 mL) was added via syringe to the
yellow solid under an atmosphere of argon, and the resulting mixture was warmed to 42 'C. After 10
h, the reaction mixture was concentrated under reduced pressure, the crude residue adsorbed onto
silica gel (6 g) was dry loaded and purified by flash column chromatography (silica gel: diam. 3 cm,
ht. 9 cm; eluent: 6% methanol, 0.6% ammonium hydroxide in chloroform) to afford imines (-)-78
and (-)-79 (2:1, 78:79, 34.6 mg, 60.9%, 2 steps) as a yellow solid mixture. Structural assignment of
(-)-78 utilized additional information from gCOSY, HSQC and HMBC.
(S)-2-(2-Methoxy-7,12,12b,13-tetrahydro-6H-azepino[3,2-b:4,5-b 'diindol-12b-vl)ethanamine
(78)
'H NMR (500.4 MHz, CD 30D, 21 'C):
'H NMR (500.4 MHz, CD30D, 21 oC)5 :
6 7.46 (d, J= 8.6 Hz, 1H, C17H), 7.43 (dt, J= 7.8, 1.0
Hz, 1H, C4H), 7.32 (dt, J= 8.1, 0.9 Hz, 1H, C7H), 7.09
(ddd, J= 8.2, 7.0, 1. Hz, 1H, C6H), 6.99 (ddd, J= 7.9,
7.0, 1.0 Hz, lH, C5H), 6.34 (dd, J= 8.5, 2.3 Hz, 1H,
Ci8H), 6.32 (d, J= 2.1 Hz, 1H, C2oH), 4.31 (br-s, 1H,
CIIH), 3.93 (br-s, 1H, C,1 H), 3.80 (s, 3H, OMe), 3.12
(app-d, J= 16.4 Hz, 1H, C1oH), 2.95 (app-dt, J= 14.9,
3.4 Hz, 1H, C1 oH), 2.81-2.69 (m, 2H, C2 3H2 ), 2.65-2.59
(m, 1H, C2 2H), 2.40-2.34 (m, 1H, C22H).
8 7.59 (app-d, J= 9.4 Hz, 1H, C17H), 7.47 (dt, J= 7.9,
0.9 Hz, 1H, C4H), 7.41 (dt, J= 8.2, 0.8 Hz, 1H, C7H),
7.16 (ddd, J= 8.2, 7.1, 1.1 Hz, 1H, C6H), 7.04 (ddd, J
8.0, 7.1, 0.9 Hz, 1H, C5H), 6.46 (app-s, 1H, C20H), 6.45
(dd, J= 8.7, 2.2 Hz, 1H, CI 8H), 4.46 (td, J= 13.5, 2.9
Hz 1H, C IH), 4.02 (dt, J= 13.7, 3.6 Hz 1H, C IH), 3.88
(s, 3H, OMe), 3.24 (dt, J= 16.8, 3.0 Hz, 1H, CioH),
5 2 equivalent of acetic acid-d 4 was added, which resulted in sharpening of peaks: See attached copies of spectra.
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1H, CioH), 3.09-3.03 (m, 1H, C2 3H),
IH, C23H), 2.79-2.75 (m, 2H, C22 H).
8 176.9 (Ci 5), 170.8 (C1 9 ), 162.7 (C21), 137.4 (C8),
129.5 (C9), 128.1 (C2 ), 126.8 (C1 7 ), 123.9 (C), 120.6
(Cs), 119.1 (C4 ), 112.5 (C16), 112.3 (C18), 112.3 (C7),
111.3 (C3 ), 94.7 (C20), 69.8 (C 14), 56.7 (C26), 46.0 (C1 1),
39.1 (C22), 36.9 (C23), 25.1 (C1o).
3180 (br-m), 2927 (m), 1612 (s), 1460 (m), 1303 (m),
1206 (m), 1165 (m), 741 (m).
calc'd for C21 H23N40, [M+H: 347.1866,
found: 347.1856.
-179 (c 0.21, CD 30D).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.36 (CAM, UV).
(S)-2-(10-Methoxy-7,12,12b,13-tetrahvdro-6H-azepino[32-b:4,5-b 'diindol-12b-yl)ethanamine
(79')
'H NMR (500.4 MHz, CD 30D, 21 'C):




8 7.61 (dd, J= 7.3, 0.6 Hz, 1H, C17TH), 7.36 (ddd, J=
8.3, 7.1, 1.2 Hz, 1H, C19 .H), 7.32 (d, J= 8.6 Hz, 1H,
C4.H), 6.90 (d, J= 2.1 Hz, 1H, C7H), 6.87 (d, J= 8.2
Hz, 1H, C20.H), 6.79 (app-td, J= 8.0, 0.8 Hz, 1H,
CI8 H), 6.69 (dd, J= 8.7, 2.2 Hz, 1H, C5H), 4.38 (app-
td, J= 13.1, 2.6 Hz, 1H, C 1 H), 4.07 (app-dt, J= 12.4,
3.5 Hz, 1H, CoiH), 3.81 (s, 3H, OMe), 3.14 (app-dt, J=
16.8, 3.3 Hz, 1H, Cio.H), 3.07-2.93 (m, 3H, Cio.H,
C2 3.H2), 2.76 (ddd, J= 13.7, 12.1, 5.2 Hz, 1H, C22.H),
2.63 (ddd, J= 13.5, 12.3, 4.5 Hz, 1H, C22.H).
8 177.4, 158.4, 157.6, 138.1, 136.4, 129.1, 124.5, 124.1,
123.5, 120.4, 119.7, 112.7, 111.2, 110.4, 95.4, 67.9,
56.1, 48.0, 39.1, 37.3, 24.4.
3271 (br-m), 2924 (m), 1647 (w), 1612 (s), 1465 (s),
1318 (m), 1252 (w), 1159 (m), 1030 (w), 750 (m).
calc'd for C21H23N40, [M+H]*: 347.1866,
found: 347.1876.
-194 (c 0.07, CHC 3).















(-)-Trigonoliimine C (3) and (-)-Isotrigonoliimine C (4):
Freshly prepared N-formyl imidazole 6 solution (0.0574 M solution in tetrahydrofuran, 1.80
mL, 0.105 mmol, 1.05 equiv) was added dropwise via syringe to a flask containing a mixture of
amines (-)-78 and (-)-79 (2:1, 78:79, 34.6 mg, 99.9 [tmol, 1 equiv) at 23 'C and placed under an
argon atmosphere. After 40 min, additional N-formyl imidazole 6 solution (0.0574 M solution in
tetrahydrofuran, 200 [tL, 11.7 [imol, 0.117 equiv) was slowly added to the reaction mixture. After 20
min, saturated aqueous sodium bicarbonate solution (14 mL) was added to the reaction mixture and
the resulting mixture was diluted with dichloromethane (14 mL), and the layers were separated. The
aqueous layer was extracted with dichloromethane (2 x 14 mL), and the combined organic layers
were dried over anhydrous sodium sulfate, and were concentrated under reduced pressure. The
sample of the crude residue was purified by flash column chromatography (silica gel: diam. 2.5 cm,
ht. 9.5 cm; eluent: 2.2% methanol, 0.2 % ammonium hydroxide in chloroform) to afford (-)-
trigonoliimine C (3, 21.3 mg, 57.0%) and (-)-isotrigonoliimine C (4, 5.8 mg, 15.5%) as yellow
solids. Crystal of (-)-trigonoliimine C (3) was obtained by slow evaporation of a methanol (0.5 mL)
solution of (-)-3 (5.0 mg). Structural assignment of (-)-4 utilized additional information from
gCOSY, HSQC and HMBC.
(-)-Trigonoliimine C (3)
'H NMR (500.4 MHz, DMSO-d, 21 'C):
'H NMR (500.4 MHz, CD 30D, 21 'C):
8 10.79 (s, 1H, N1H), 8.00 (app-s, 1H, N24H), 7.93 (d, J
= 1.7 Hz, 1H, C2 5H), 7.40 (d, J = 7.8 Hz, 1H, C4H),
7.34 (d, J = 7.8 Hz, 1H, C7H), 7.31 (d, J = 8.2 Hz, 1H,
C17H), 7.07 (ddd, J= 8.1, 7.1, 1.1 Hz, 1H, C6H), 6.97
(br-s, 1H, N 13H), 6.96 (app-t, J = 7.9 Hz, 1H, C5H),
6.24 (d, J = 2.2 Hz, 1H, C2oH), 6.23 (dd, J= 10.4, 2.2
Hz, 1H, Ci 8H), 4.22 (app-dt, J = 13.8, 2.3 Hz, 1H,
C11H), 3.99 (app-dt, J= 11.8, 3.4 Hz, 1H, C1,H), 3.75
(s, 3H, OMe), 3.17-3.08 (m, 2H, C23H2), 3.05 (app-dt, J
= 17.1, 3.2 Hz, 1H, CioH), 2.80 (ddd, J= 16.7, 13.7, 3.2
Hz, 1H, CioH), 2.54-2.48 (m, 1H, C2 2H), 2.33-2.27 (m,
1H, C22H).
8 7.96 (s, 1H, C25H), 7.50 (app-d, J= 9.3 Hz, 1H,
C17H), 7.43 (dt, J= 7.9, 0.9 Hz, 1H, C4H), 7.33 (dt, J=
8.1, 0.8 Hz, 1H, C7H), 7.10 (ddd, J= 8.1, 7.0, 1.1 Hz,
1H, C6H), 7.00 (ddd, J= 7.9, 7.0, 0.9 Hz, 1H, C5H),
6.36 (d, J= 2.4 Hz, 1H, C17H), 6.36 (dd, J= 6.8, 2.2 Hz,
1H, Ci8H), 4.42 (app-td, J= 14.3, 2.7 Hz, 1H, CInH),





1C NMR (125.8 MHz, DMSO-d, 21 'C):
13C NMR (125.8 MHz, CDCl 3/CD 30D (3:1), 21 *C): 8174.1 (Cis), 166.1 (C19 ), 162.9 (C2 5), 158.3
(C2 1), 135.7 (C8), 130.8 (C 2), 128.7 (C9 ), 124.9 (C17),
122.5 (C), 119.5 (Cs), 118.3 (C4), 116.2 (C16), 111.2
(C7), 110.2 (C3), 108.1 (C18), 95.1 (C20), 67.6 (C14),
55.8 (C28), 47.2 (CII), 39.8 (C22), 34.6 (C23), 24.0 (CIo).
13C NMR (125.8 MHz, CD 30D, 21 'C):
FTIR (neat) cm-1 :
HRMS (ESI) (m/z):
[C]D 24:
4.01 (dt, J= 12.4, 3.5 Hz, 1H, C11H), 3.82 (s, 3H,
OMe), 3.30-3.28 (m, 2H, C2 3H2), 3.15 (dt, J= 16.7, 3.1
Hz, 1H, C1oH), 2.99 (ddd, J= 16.8, 13.5, 3.4 Hz, 1H,
C1oH), 2.75 (ddd, J= 14.1, 10.2, 6.5 Hz, IH, C2 2H),
2.40 (ddd, J= 14.0, 8.9, 6.9 Hz, 1H, C2 2H).
8 170.0 (Cis), 164.2 (C19), 161.0 (C 25), 156.6 (C2 1),
134.8 (C8), 131.9 (C2 ), 127.9 (C9 ), 123.4 (C 17), 121.3
(C), 118.4 (Cs), 117.7 (C4 ), 116.5 (C 16), 110.8 (C7),
108.7 (C3 ), 105.3 (C1 8), 93.8 (C20), 66.3 (C 14 ), 55.2
(C28), 46.6 (C 1), 39.5 (C22), 33.6 (C23), 23.3 (C1o).
6 175.6 (Ci5), 167.3 (C19 ), 164.0 (C25 ), 159.6 (C2 1),
137.1 (C8 ), 132.3 (C2), 130.0 (C9), 125.6 (C17), 123.1
(C), 120.1 (Cs), 119.0 (C4), 117.4 (C 16), 111.9 (C7),
110.6 (C 3), 108.7 (Ci8), 95.9 (C20), 68.7 (C14), 56.1
(C2 8), 48.1 (C11), 40.8 (C22), 35.3 (C23), 24.7 (C10).
3305 (br-w), 1732 (w), 1640 (s), 1610 (s), 1458 (m),
1376 (m), 1329 (m), 1300 (m), 1223 (w), 1029 (w), 735
(s).
calc'd for C22H23N4 0 2 , [M+H]*: 375.1816,
found: 375.1818.
-147 (c 0.12, CHCl 3).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.52 (CAM, UV).
(-)-Isotrigonoliimine C (4):
'H NMR (500.4 MHz, CD 30D, 21 'C):
13C NMR (125.8 MHz, CD 30D, 21 'C):
8 7.95 (s, 1H, C2s.H), 7.59 (d, J= 7.8 Hz, 1H, C17 H),
7.31 (app-dt, J= 9.5, 1.2 Hz, 1H, C19,H), 7.30 (d, J= 8.7
Hz, 1H, C4,H), 6.87 (d, J= 2.1 Hz, 1H, C7,H), 6.84 (d, J
= 8.1 Hz, 1H, C2 0 H), 6.77 (app-t, J= 7.1 Hz, 1H,
CI 8,H), 6.67 (dd, J= 8.6, 2. 2 Hz, 1H, CsH), 4.43 (app-
td, J= 14.7, 2.8 Hz, 1H, CI.H), 4.06 (app-dt, J 12.1,
3.5 Hz, 1H, CiH), 3.81 (s, 3H, OMe), 3.29-3.22 (m,
2H, C2 3,H2), 3.11 (app-dt, J= 16.5, 3.1 Hz, 1H, Cio.H),
2.96 (ddd, J= 16.8, 13.7, 3.4 Hz, 1H, CioH), 2.71 (ddd,
J= 14.0, 10.5, 5.7 Hz, 1H, C22,H), 2.39 (ddd, J= 14.0,
10.1, 5.8 Hz, 1H, C22,H).
6 176.6 (Cis'), 164.0 (C25.), 158.1 (C6 ), 157.6 (C21'),
137.8 (C8'), 135.5 (C19 ,), 130.8 (C2'), 124.8 (C16.), 124.3(C9'), 124.2 (C17.), 120.2 (Ci,8'), 119.5 (C4'), 112.6 (C20),
134
110.6 (C3 .), 110.1 (C5 ), 95.4 (C7'), 68.0 (C 14'), 56.1
(C 2 8 .), 48.6 (C1 r), 40.7 (C22'), 35.4 (C23.), 24.4 (C10 .).
3278 (br-m), 2923 (br-m), 2361 (w), 1647 (s), 1613 (s),
1467 (m), 1316 (m), 1156 (m), 1027 (w), 745 (m).
FTIR (neat) cm-1:
HRMS (DART) (m/z): calc'd for C22H2 1N40 2 , [M-H]~: 373.1670,
found: 373.1684.
[a]D 24: 
-220 (c 0.10, CH 30H).
TLC (18% methanol, 2% ammonium hydroxide in chloroform), Rf 0.50 (CAM, UV).
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Table S1. Comparison of our 111 NMR data for (-)-trigonoliimine A (1) with literature data:
(-)-trigonoliimine A (1)
7 The reference points for the residual protium and carbon resonances of the NMR solvent were not listed. Tan, C. J.; Di, Y. T.;
Wang, Y. H.; Zhang, Y.; Si, Y. K.; Zhang, Q.; Gao, S.; Hu, X. J.; Fang, X.; Li, S. F.; Hao, X. J. Org. Lett. 2010,12,2370-2373.
8 In this report, the NMR spectra are referenced from the residual protium resonance, DMSO-d: 8 2.50 (DMSO-d5 ), and carbon
resonance, DMSO-d6 : 8 39.51.
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Assignment Hao's Report7  This Work8
H NMR, 500 MHz, DMSO-d, 'H NMR, 500.4 MHz, DMSO-d, 21 *C
NI 11.50 (s, 1H) 11.5 (s, 111)
C4 7.44 (d, J= 7.5 Hz, 1H) 7.45 (d, J= 7.9 Hz, 1H)
C5 6.99 (t, J = 7.5 Hz, 1H) 7.00 (app-t, J= 7.9 Hz, 1H)
C6 7.15 (t, J= 7.5 Hz, 1H) 7.16 (ddd, J= 8.1, 7.0, 1.1 Hz, 1H)
C7 7.32 (d, J= 7.5 Hz, 1H) 7.34 d J= 8.2 Hz, 1H)
Cloa 3.06 (m, 1H) 3.07 (d, J= 17.1 Hz, 1H)
C10p 2.95 (m, 1H) 2.96 (ddd, J= 16.9, 12.1, 4.3 Hz, IH)
C1 la 4.00 (br-d, J= 14.5 Hz, IH) 4.01 (dt, J= 14.3, 3.3 Hz, 1H)
C11p 3.74 (t, J= 12.5 Hz, 1H) 3.74 (app-t, J= 12.1 Hz, IH)
C15 6.55 (overlapped, 1H) 6.56 (overlapped, 1H)
C17 6.54 (overlapped, 1H) 6.56 (overlapped, 1H)
C18 6.53 (overlapped, 1H) 6.55 (overlapped, 1H)
C21a 2.05 (m, 1H) 2.06 (dd, J= 12.0, 5.8 Hz, IH)
C21 P 2.14 (m, 1H) 2.19-2.13 (m, IH)
C22a 3.55 (m, 1H) 3.55 (ddd, J= 16.1, 9.9, 6.1 Hz, 1H)
C22p 4.10 (m, 1H) 4.11 (dd, J= 16.1, 8.1 Hz, 1H)
C25 7.48 (s, 1H) 7.47 (s, 1H)
C27 3.65 (s, 3H) 3.66 (s, 3H)
Table S2. Comparison of our 13 C NMR data for (-)-trigonoliimine A (1) with literature data:
11 25
5 4 12NN 1/20 14
8N 2412J 9
H 23 22 1 OMe
7 27
(-)-trigonoliimine A (1)
Assignment Hao's Report7  This Work8

























Table S3. Comparison of our 13C NMR data for (-)-trigonoliimine A (1) with literature data:
11 Or,
(-)-trigonoliimine A (1)
I In this report, the NMR spectra are referenced from the residual protium resonance, CD 30D: 6 3.31 (CHD 2OD), and carbon
resonance, CD 30D: 6 49.15.
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Assignment Hao's Report This Work9  Chemical Shift DifferenceC NMR, 100 MHz, "C NMR, 125.8 MHz, A8
CDCl3/CD 30D (3:1) CDC13/CD 30D (3:1), 21 0C 8 (Hao's Report) - 8 (This
Report)
C2 126.5 127.2 -0.7
C3 117.4 118.1 -0.7
C4 119.0 119.6 -0.6
C5 119.6 120.2 -0.6
C6 124.3 125.0 -0.7
C7 111.4 112.1 -0.7
C8 136.8 137.4 -0.6
C9 127.2 127.9 -0.7
C1O 29.4 30.1 -0.7
Cli 47.9 48.5 -0.6
C14 141.0 142.0 -1.0
C15 108.6 109.4 -0.8
C16 160.1 160.7 -0.6
C17 111.4 112.0 -0.6
C18 123.2 123.9 -0.7
C19 113.7 114.5 -0.8
C20 77.2 77.5 -0.3
C21 40.4 41.1 -0.7
C22 56.0 56.6 -0.6
C24 167.4 168.2 -0.8
C25 149.9 150.5 -0.6
C27 55.0 55.6 -0.6
Table S4. Comparison of our 13 C NMR data for (-)-trigonoliimine B (2) with literature data:
10 11 25
5 3 1 2 N N
1 3
6 \20 14
MeO 2 N 241 2
27 H N 2' 1
23 2 17
(-)-trigonoliimine B (2)
Assignment Hao's Report 0  This Work9  Chemical Shift DifferenceAC NMR, 100 MHz, "C NMR, 125.8 MHz, A8
CDC13/CD30D (3:1) CDC13/CD 30D (3:1), 21 *C 8 (Hao's Report) - 6 (This
Report)
C2 125.1 126.3 
-1.2
C3 117.7 118.9 
-1.2
C4 119.3 120.5 
-1.2
C5 110.0 111.2 
-1.2
C6 157.6 158.8 -1.2
C7 93.4 94.5 -1.1
C8 137.4 138.6 
-1.2
C9" 121.0 122.5 -1.5
C1O 29.0 30.2 
-1.2
Cli 47.5 48.7 
-1.2
C14 139.6 140.7 -1.1
C15 123.4 124.7 -1.3
C16 128.2 129.5 -1.3
C17 124.8 126.0 -1.2
C18 121.8 122.9 -1.1
C19 1  121.3 122.1 -0.8
C20 76.5 77.6 -1.1
C21 39.8 41.0 
-1.2
C22 55.2 56.4 
-1.2
C24 166.6 167.7 -1.1
C25 149.0 150.2 
-1.2
C27 54.6 55.8 
-1.2
'0 The provided copy of the NMR spectra in the Supporting Information of the report indicates referencing of the residual carbon
resonance of CDC13 at 6 76.51. Tan, C. J.; Di, Y. T.; Wang, Y. H.; Zhang, Y.; Si, Y. K.; Zhang, Q.; Gao, S.; Hu, X. J.; Fang, X.; Li, S.
F.; Hao, X. J. Org. Lett. 2010, 12, 2370-2373.
" Our assignment of these resonances is supported by key HMBC signals ('H, '3C) in ppm: (2.28 (C21H), 122.1 (C19)), (6.68 (C5H),
122.5 (C9)), (6.80 (C7H),122.5 (C9)).
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Assignment Hao's Report7  This Work8
'H NMR, 500 MHz, DMSO-d 'H NMR, 500.4 MHz, DMSO-d, 21 *C
NI 10.64 (s, 1H) 10.79 (s, 1H)
C4 7.41 (d, J= 7.5 Hz, IH) 7.40 (d, J= 7.8 Hz, 1H)
C5 6.98 (t, J= 7.5 Hz, 1H) 6.96 (app-t, J= 7.9 Hz, 1H)
C6 7.08 (t, J= 7.5 Hz, 1H) 7.07 (ddd, J= 8.1, 7.1, 1.1 Hz, 1H)
C7 7.36 (d, J 7.5 Hz, 1H) 7.34 (d, J= 7.8 Hz, 1H)
C1oa 3.05 (br-d, J= 11.0 Hz, 1H) 3.05 (app-dt, J= 17.1, 3.2 Hz, IH)
C10p 2.80 (t, J= 11.0 Hz, 1H) 2.80 (ddd, J= 16.7, 13.7, 3.2 Hz, 1H)
Cl la 4.24 (t, J= 12.0 Hz, 1H) 4.22 (app-dt, J= 13.8, 2.3 Hz, 1H)
C11p 3.99 (br-d, J= 12.0 Hz, IH) 3.99 (app-dt, J= 11.8, 3.4 Hz, 1H)
N13 6.83 (br-s, 1H) 6.97 (br-s, 1H)
C17 7.34 (d, J= 8.0 Hz, 1H) 7.31 (d, J= 8.2 Hz, 1H)
C18 6.26 (dd, J= 8.0, 2.5 Hz, 1H) 6.23 (dd, J= 10.4, 2.2 Hz, 1H)
C20 6.27 (d, J= 2.5 Hz, 1H) 6.24 (d, J= 2.2 Hz, 1H)
C22a 2.29 (m, 1H) 2.54-2.48 (m, 1H)
C22p 2.51 (m, 1H) 2.33-2.27 (m, 1H)
C23 3.14 (m, 2H) 3.17-3.08 (m, 2H)
N24 7.99 (br-s, 1H) 8.00 (app-s, 1H)
C25 7.93 (s, 1H) 7.93 (d, J= 1.7 Hz, 1H)
C28 3.77 (s, 3H) 3.75 (s, 3H)







Assignment Hao's Report7  This Work8



























Asin etHao's ReotThis Work' Chemical Shift Difference
13C NMR, 100 MHz, C NMR, 125.8 MHz,
CDCl3/CD 30D (3:1) CDCl3 /CD3 0D (3:1), 21 *C b (H~ao's Report) - 5 (This
Report)
C2 131.4 130.8 0.6
C3 110.3 110.2 0.1
C4 118.5 118.3 0.2
C5 119.7 119.5 0.2
C6 122.7 122.5 0.2
C7 111.5 111.2 0.3
C8 136.3 135.7 0.6
C9 129.2 128.7 0.5
C10 24.3 24.0 0.3
C11 47.5 47.2 0.3
C14 68.1 67.6 0.5
C15 174.9 174.1 0.2
C16 116.5 116.2 0.3
C17 125.2 124.9 0.3
C18 108.4 108.1 0.3
C19 166.8 166.1 0.7
C20 95.3 95.1 0.2
C21 159.0 158.3 0.7
C22 40.2 39.8 0.2
C23 34.9 34.6 0.3
C25 163.4 162.9 0.5
C28 55.8 15.8 0.0
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Table S8. Crystal data and structure refinement for (-)-72.
Identification code x8_11097






Unit cell dimensions a = 15.1283(4) A
b = 15.9902(4) A











Completeness to theta = 66.580
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [1>2sigma(I)]
R indices (all data)
Absolute structure parameter













Full-matrix least-squares on F2
6942/8/531
1.058
R1 = 0.0305, wR2 = 0.0823
R1 = 0.0306, wR2 = 0.0824
0.008(8)





Table S9. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 103) for
(-)-72. U(eq) is defined as one third of the trace of the orthogonalized U'i tensor.





















































































































































































































































































































































































































































































































































































































Symmetry transformations used to generate equivalent atoms:
148
Table S11. Anisotropic displacement parameters (A2x 103) for (-)-72. The anisotropic
displacement factor exponent takes the form: -2p 2[ h2 a* 2 Ul1 + ... + 2 h k a* b* U 12 ]










































































































































































































































































































































































































Table S12. Hydrogen coordinates
for (-)-72.
(x 104) and isotropic displacement parameters (A2x 10 3)








































































































































































































































Table S13. Crystal data and structure refinement for (-)-80.
Identification code x8_11013






Unit cell dimensions a = 41.6761(19) A
b= 7.7113(3) A











Completeness to theta = 30.32
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2sigma(I)]
R indices (all data)
Absolute structure parameter













Full-matrix least-squares on F2
9654/0 / 448
1.181
RI = 0.0476, wR2 = 0.0877
RI = 0.0564, wR2 = 0.0899
0.021(7)





Table S14. Atomic coordinates (x 104) and equivalent isotropic displacement parameters (A2x 103) for
(-)-80. U(eq) is defined as one third of the trace of the orthogonalized UUi tensor.























































































































































































































































































































































































































































































































Symmetry transformations used to generate
equivalent atoms: #1 -x+2,-y+1,z
156
Table S16. Anisotropic displacement parameters (A2x 103) for (-)-80. The anisotropic displacement
factor exponent takes the form: -2p 2[ h2 a* 2U"l + ... +2hka*b* U12 ]
































































































































































































































































































































































Table S17. Hydrogen coordinates (x 104) and isotropic displacement parameters (A2x 10 3) for (-)-80.
x y z U(eq)
H(1) 9580 -1642 9868 18
H(2) 8747 274 7555 21
H(3) 7155 27 12335 40
H(4) 6705 -264 10906 53
H(5) 6760 -129 8654 51
H(6) 7263 298 7652 38
H(9A) 8412 1202 11322 26
H(9B) 8441 1500 9750 26
H(IOA) 8402 -1878 10947 22
H(1OB) 8450 -1538 9392 22
H(13) 8667 -369 13169 26
H(14) 9033 76 14891 27
H(15) 9585 -175 14511 27
H(16) 9785 -1009 12445 22
H(22) 8821 -6098 6052 23
H(25) 8226 -873 6223 22
H(27A) 7687 -1812 6106 40
H(27B) 7520 -2203 4707 40
H(27C) 7824 -938 4781 40
H(28A) 9594 -1087 7929 21
H(28B) 9420 -1004 6520 21
H(29A) 9622 1731 7114 25
H(29B) 9242 1809 6933 25
H(32) 8760 4622 11290 30
H(33) 8978 5459 13328 35
H(34) 9516 4941 13803 38
H(35) 9849 3589 12245 36
H(IS) 10190 5144 6998 26
H(2S) 9810 4856 6998 26
158






Table S18. Crystal data and structure refinement for (-)-Trigonoliimine C (3).
Identification code d8_10127






Unit cell dimensions a = 7.3013(2) A a = 90*.
b = 7.5801(2) A b = 90*.











Completeness to theta = 66.57*
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [1>2sigma(I)]
R indices (all data)
Absolute structure parameter













Full-matrix least-squares on F 2
3212 /3 /263
1.056
RI = 0.0306, wR2 = 0.0798
RI = 0.0309, wR2 = 0.0802
-0.1(2)
0.220 and -0.160 e.A-3
160
Table S19. Atomic coordinates (x
for (-)-trigonoliimine C (3). U(eq)
104) and equivalent isotropic displacement parameters (A2x 103)
is defined as one third of the trace of the orthogonalized Ui tensor.















































































































































































































































































































['] for (-)-trigonoliimine C (3).
Table S21. Anisotropic displacement parameters (A2x 103) for (-)-trigonoliimine C (3). The anisotropic
displacement factor exponent takes the form: -2;62[ h2 a*2 U"l + ... + 2 h k a* b* U12]






































































































































































































Table S22. Hydrogen coordinates (x 104) and isotropic displacement
trigonoliimine C (3).
parameters (A2x 10 3) for (-)-
x y z U(eq)
H(24N) 550(30) -2340(20) 952(6) 28
H(1N) 5110(20) 1760(20) 1977(5) 25
H(13N) 5170(20) 1380(20) 1173(6) 23
H(18) 4947 6947 45 27
H(4) 595 5521 2809 27
H(5) 2171 4925 3410 28
H(6) 4659 2985 3419 29
H(22A) 2515 -114 1433 25
H(22B) 628 926 1480 25
H(7) 5781 1751 2815 28
H(25) -2290 -2457 863 29
H(26A) 9973 4086 319 39
H(26B) 10217 4334 -161 39
H(26C) 8869 2846 11 39
H(23A) 512 1259 756 31
H(23B) 2330 86 722 31
H(11A) -964 3235 1474 27
H(11B) -1954 5110 1428 27
H(1OA) 234 6344 1889 30
H(1OB) -1030 4880 2097 30
H(17) 2391 6662 464 26
H(20) 7544 3003 665 24
164
Appendix A.







































































































































Injection Date Seq. Line : 1
Sample Name Location : Vial 91
Acq. Operator Inj : 1


















Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 C, Sig=240,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# (min] (min] [mAU*s] [mAU] %
---- I ------- I ---- I ------- I---------- I---------- --------
1 4.591 MM 0.2209 549.21417 41.44402 100.0000
Totals : 549.21417 41.44402
Results obtained with enhanced integrator!










Injection Date Seq. Line :
Sample Name Location : Vial 73
Acq. Operator Inj : 1


















3.5 4 4.5 5 5.5 6 mId
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 C, Sig=240,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min] (min] (mAU*s] [mAU] %
---- I------- I-----------I----------I------ ----
1 4.515 BV 0.1810 342.47797 27.56392 50.0382
2 5.223 VB 0.2221 341.95474 22.15433 49.9618
Totals : 684.43271 49.71825
Results obtained with enhanced integrator!
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80 20 0 
-20 ppm60 40
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240 220 200 180 160 140 120 100
I I -
Injection Date Seq. Line : 1
Sample Name Location : Vial 74
Acq. Operator Inj : 1











Use Multiplier & Dilution Factor with ISTDs














Peak RetTime Type Width Area
# [min] [min] [mAU*s}
1 3.470 BV 0.1392 209.35068






Results obtained with enhanced integrator!
**End of Report**
173
Injection Date Seq. Line : 1
Sample Name Location : Vial 91
Acq. Operator Inj : 1















3.4 3.6 3.8 4 4.2 4.4 mir
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 D, Sig=254,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# (min] [min] (mAU*s] [mAUJ %
-- I ----- I -------- I------------
1 3.604 VP 0.1247 207.81982 24.56680 100.0000
Totals : 207.81982 24.56680
Results obtained with enhanced integrator!
*** End of Report *
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Injection Date Seq. Line : 1
Sample Name Location : Vial 91
Acq. Operator Inj : 1

























Signal 1: MWD1 E, Sig=270,16 Ref=360,100
Peak RetTime Type Width Area
# [min] (min] [mAU*s]
---- I-------I----I-------I----------
1 11.552 MF 1.5397 151.20343








Results obtained with enhanced integrator!







Injection Date Seq. Line 1
Sample Name 
.Location : Vial 91Acq. Operator Inj 1












4i - I - - - -- I I..........7 - ---- 1, .












Signal 1: MWD1 E, Sig=270,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min] (min] (mAU*s] [mAU) %
---- I------- ------------ I----------I----------I--------
1 16.523 MM 1.8067 483.25354 4.45788 100.0000
Totals : 483.25354 4.45788
Results obtained with enhanced integrator!
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1 PPM
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8a71 1 10 9
DEC. a vr
difrq 500.229





to C19 dreg 1.0
at 1.730 howe n
up 131010 PROCESSING
sw 37735.8 lb 0.30
ftb not used tf I le
be 4 proc ft
es 1 tn 131072
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SAMPLE DEC. & VT
date Mar 19 2010 dfrq 500.229
solvent CDC13 dn H1
file /data/export/~ dpwr 38
home/movassag/Nds/- dof -500.0
Nds501/DS8-178-FR1~ dm y1-17-13C.fid dmm w
ACQUISITION dmf 10000
sfrq 125.795 dseq
tn C13 dres 1.0
at 1.736 homo n
np 131010 PROCESSING
sw 37735.8 lb 0.30
fb not used wtfile
bs 4 proc ft
ss 1 fn 131072
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160 140 120 100 80 60 40 20
.--I 's .1 . t. - I . - 1 .1.
240 220 200 180 0 
-20 PPM
LL1. .1.. J-11181 .- k I I,,.- 111A .1.
Injection Date :Seq. Line : 1
Sample Name :Location : Vial 61
Acq. Operator :Inj : 1
























Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 A, Sig=220,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min] [min] [mAU*s] [mAU) %
1 12.137 BV 1.1608 1499.41431 15.28030 49.0828
2 14.864 VB 1.1626 1555.45105 15.82612 50.9172
Totals : 3054.86536 31.10642
Results obtained with enhanced integrator!
**End of Report**
198
Injection Date Seq. Line : 1
Sample Name 
. Location : Vial 91
Acq. Operator Inj : 1













0 ---- - ~-
10 11 12 13 14 15 16 17 18 mir
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 A, Sig=220,16 Ref=360, 100
Peak RetTime Type Width Area Height Area
# (min] [mini [mAUJ*s] (mAU]%
0 ------FI-- 
I---------I----
1 15.245 PB 1.4033 875.68500 7.33223 100.0000
Totals :875.68500 7.33223
Results obtained with enhanced integrator!
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240 220 200 180 160 140 120 100 80 0 








Seq. Line : 1
Location : Vial 91
Inj : 1
Inj Volume : 5 pl




















25 30 40 45 50 55
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 E, Sig=270,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# (min) [min) [mAU*s) [mAU] %
-------- ------- I----------I----------|--------
1 24.638 MF 6.6959 338.59686 8.42801e-1 46.8535
2 40.054 FM 8.6223 384.07428 7.42408e-1 53.1465
Totals : 722.67114 1.58521
Results obtained with enhanced integrator!










Seq. Line : 1
Location : Vial 91
Inj : 1



















Signal 1: DAD1 E, Sig=270,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# (min] (min] [mAU*s] (mAU] %
---- I------- I-----------I----------I----------I--------I
1 37.458 MM 8.1336 2750.29980 5.63566 100.0000
Totals : 2750.29980 5.63566
Results obtained with enhanced integrator!
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78.28 . .... . I-- -- ------














































































r . .- -.r rrr- -r-
0 987 6 s 3 21ppm
DEC. a VT










sw 37735.8 lbfb not used utile
ba 4 proc
6s 1 fn 1
tpwr 5 math
pw 6.9
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4000.0 3000 2000 1500 1000 500 400.0
cm-1
0










C13 N30 HO0 Nnnn H
dmm c
ACOUISITION dmf 200 H
sfrq 500.437 dseq BH
tn H1 dres 1.0 N-H
at 4.999 homo n
np 120102 PROCESSING
sw 12012.0 wtfile
fb not used proc ft Br
bs 1 fn 262144
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120 100 80 60 40 20 0 -20 ppm
WTWr




Seq. Line : 1
Location : Vial 79
Inj : 1






















Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: MWD1 E, Sig=270,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# (min] (min] (mAU*s] (mAU] %
---- I-------I----I-------I----------I----------|--------I
1 21.048 MF 4.2737 1230.71851 4.79959 43.6941
2 27.637 FM 5.2827 1585.95435 5.00365 56.3059
Totals : 2816.67285 9.80324
Results obtained with enhanced integrator!






Injection Date Seq. Line : 1
Sample Name Location : Vial 80
Acq. Operator Inj : 1






















Signal 1: MWD1 E, Sig=270,16 Ref=360, 100
Peak RetTime Type Width Area Height Area
# [min] (min] [mAU*s] [mAU) %
---- I------- I-----------I----------I----------I--------|
1 27.024 MM 5.3130 4076.89722 12.78911 100.0000
Totals : 4076.89722 12.78911
Results obtained with enhanced integrator!
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Injection Date Seq. Line : 1
Sample Name Location : Vial 61
Acq. Operator Inj : 1
Inj Volume : 1 pl























Signal 1: DAD1 E, Sig-270,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min] [min] [mAU*s] (mAU] %
---- I-------lI---- I------- I---------- I---------- I--------I
1 29.289 MF 11.8707 2562.06494 3.59718 47.5924
2 48.179 FM 14.0578 2821.28418 3.34485 52.4076
Totals : 5383.34912 6.94203
Results obtained with enhanced integrator!
*** End of Report ***
228
Injection Date Seq. Line : 1
Sample Name Location : Vial 62
Acq. Operator Inj : I
Inj Volume : 1 pl












Sorted By : Signal
Multiplier : 1.0000
Dilution 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 E, Sig-.270,16 Ref=360, 100
Peak RetTime Type Width Area Height Area
# [min] [min) [mAU*s] [mAU) %
----I ------- ------- I --------- I -------- 0--------
1 47.661 M 14.4059 2772.36328 3.20744 100.0000
Totals : 2772.36328 3.20744
Results obtained with enhanced integrator!
End of Report ***
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60 40 20 0





















































0.171 temp not used
2048 gain 54












































I , - 17 .I . . . I - r ,.-
220 200 180 160 140 120 100 80
F1 (ppm)









48-- , 1 1 I I.. 1 1 .. . . . M
I-0T

































































































HI MeO.,38 4 N500.0 ',H
y
w












L ..I I -I.L .



































1500 1000 500 400.0
DEC. & VT





sfrq 500.437 dseqtn 1 dres 1.0
at 4.99 how- n
np 120102 PROCESSING
sw 12012.0 wtfile
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be 2 fn 262144
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sOlvent CDOD dfrq 500.231
dn HIdpwr 38
dof -500.0
dm ydmn wdof 10000
A:QUISITION dseq
afrq 125.795 dres 1.0
tn C13 homo 
at 1.736 PROCESSING
np 131010 lb 0.30
sw 37735.8 Wttile
fb not used proc ft
bs 2 tn 19872
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SAMPLE DEC. & VT
dfrq 500
dn









fb not used tfile
bS 4 proc















































240 220 200 180 160 140 120 160 80 60 40
-20 ppm240 220 200 180 160 140 120 100 80 6o 40 201 0 i

























fb not used proc
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DEC. & VT
dfrq 500.229






afrq 125.755 dres 1.0
tn CiS homo n
at 1.736 temp 20.0
np 131510 PROCESSING
aV 37735.8 lb 0.30
fb not used Wtfile
be 2 proc ft
96 1 fn 131072
tpur 53 math f
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sfrq 125.795 dres 1.0
in C13 hamo n
at 1.736 PROCESSING
np 131010 lb 0.30
sw 37735.8 Wtfle
fb not used proc ft
bs 2 In 131072
s I math I
tpwr 53
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tn 1 dres 1.0
at 4.999 hmo n
np 120102 PROCESSING
sw 12012.0 wile mgfb not used proc ft
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sfrq 125.795 dres 1.0
tn CIS iMo n
at 1.736 PROCESSING
np 131010 lb 0.30
sw 37735.8 wtfIle
fb not Used proc ft
bs 2 fn 131072
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sfrq 125.795 dres 1.0
tn C13 homo n
at 1.796 PROCESSING
np 131010 lb 0.30
sw 37735.8 wtfile
fb not used proc ft
bs 2 fn 131072
































160 140 120 100 80 60 40 20 0 
-20 ppm
I. 9a -J L. I - .- .. I . .
240 220 200 180
chiralpak IC-H 0.5 mL/min 80:20=Hx:IPA
Injection Date Seq. Line : 3
Sample Name Location : Vial 91
Acq. Operator SH Inj : 1
Inj Volume : 0 pl



















8 9 10 11 12 13 min
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# (min] (min] (mAU*s] (mAU} %
---- I-------I----I-------I----------I----------I--------
1 10.287 MM 0.2718 3738.68066 229.28889 49.9031
2 12.779 MM 0.3450 3753.20703 181.29138 50.0969
Totals : 7491.88770 410.58028
Results obtained with enhanced integrator!
Summed Peaks Report
Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Final Summed Peaks Report
Signal 1: DAD1 A, Sig=254,16 Ref=360,100 273
chiralpak IC 80:20=Hx:IPA 0.5 mL/min
Injection Date Seq. Line : 1
Sample Name Location : Vial 91
Acq. Operator SH Inj : 1
Inj Volume : 0 pl














Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 D, Sig=240,16 Ref=360, 100
Peak RetTime Type Width Area Height Area
# [min] [min] (mAU*s] [mAU] %
---- I--------I-----------I --------- I ----------- I---------
1 10.174 MM 0.2661 1473.06104 92.25103 10.4020
2 12.623 MM 0.3503 1.26882e4 603.61407 89.5980
1. 41613e4 695.86510
Results obtained with enhanced integrator!
Summed Peaks Report
Signal 1: DAD1 D, Sig=240,16 Ref=360,100
Final Summed Peaks Report















































fb not used proc
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sfrq 125.795 dres 1.0
tn CIS homo n
at 1.736 PROCESSING
np 131010 lb 0.30
sw 37735.8 wtfile
fb not used proc ft





































40 120 100 80 60 40 20 0 -20 ppm
-1
a . . I
160 1
chiralpak IC 80:20=Hx:IPA 0.5 mL/min
Injection Date Seq. Line :
Sample Name : Location : Vial 91
Acq. Operator SH Inj : 1
Inj Volume : 0 pl


















10 12.5 15 17.5 20 22.5 25 27.5 mi
Area Percent Report
Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DADI D, Sig=240,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min) [min] [mAU*s] [mAU] %
--- I---I--- I 
--- I------- I------------
1 14.911 BB 0.3701 4303.46680 177.35651 50.1508
2 24.710 BB 0.6603 4277.58594 96.65764 49.8492
Totals : 8581.05273 274.01414
Results obtained with enhanced integrator!
Summed Peaks Report
Signal 1: DAD1 D, Sig=240,16 Ref=360, 100
278
chiralpak IC 83:17=Hx:IPA 0.5 mL/min
Injection Date Seq. Line 2
Sample Name : Location Vial 92
Acq. Operator SH Inj 1
Inj Volume 0 pl














Signal 1: DAD1 B, Sig=220,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min] [min) [mAU*s] (mAU %
---- I------- I-----------I----------I----------I--------
1 14.921 BB 0.3776 3.41137e4 1364.64807 89.3473
2 24.798 BB 0.6212 4067.29736 91.39735 10.6527
Totals : 3.81810e4 1456.04542
Results obtained with enhanced integrator!
Summed Peaks Report










































fb not used proc
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1 CIS dres 1.0
at 1.736 homo n
np 131010 PROCESSING
sw 37735.8 lb 0.30fb not used wtfile
bs 2 proc ft
s 1 in 131072
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tn Hl dres 1.0
at 4.911 homo n
nP 120102 PROCESSING
sw 12012.0 wifile
fb not used proc ft
be 2 in 262144
tpwr 60 math f
pw 8.0dl 0.100 worr
tot 3003.2 wexp
Ut 32 wbs
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sire 121.731 dres 1.0
in 012 bone
et 1.76 C
op 181010 lb s.n
ow 87SS.8 wtll slb at used 3roc ftbs 2 tn 18107
au smath I
twur 5sPu 6.8dl 0.763
t 681.4
at 1900












































fb not used proc
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Chiralcell OD- 0.SmL/min, 100% Hexane -> 80:20wi9r0RsH
x in 80 min
Injection Date : Seq. Line : 6
Sample Name : Location : Vial 27
Acq. Operator : Inj t I
Inj Volume : 0 Pl

















Signal 1: DADI C, Sig-230,16 Refa360,100
Peak RetTime Type Width Area Height Area
# (min] (.ini [MAU*s] (mAU) %
---- I ------------ ----------- --------------I
1 40.141 MN 1.0038 4.24912e4 705.52020 50.3479
2 62.798 MM 1.6881 .4.19041e4 413.71451 49.6521
Totals a 8.43953e4 1119.23471
Results obtained with enhanced integrator!
*** End of Report *
289
chiralpak OD-H 100%aexanes to 80% IPrOH over 80 min
Injection Date : Seq. Line : 1
Sample Name Location : Vial 24
Acq. Operator : Inj: 1
Inj Volume : 0 p.






Sorted By t Signal
Multiplier : 1.0000
Dilution a 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DADI D, Sig=240, 16 Ref'off
Peak RetTime Type Width Area Heig
# [min) [min) [mAU*s] (AU
---- |-------- ---------------.----..-.---.
1 41.867 BB 0.8883 854.34039 11.4
2 65.106 BB 1.5928 2.76173o4 247.5
Totals : 2.94717e4 258.9









End of Report ***
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200 180 160 140 120 100 80 60 40 20240 220 0-20 ppm
OD-H 100%8exanes->80%IPA:20%Hxns over 80 min
Injection Date : Seq. Line : 1
Sample Name I Location : Vial 23
Acq. Operator : Inj 2 1
Inj Volume 2 0 p1








Sorted By : Signal
Multiplier : 1.0000
Dilution : 1.0000
Use Multiplier & Dilution Factor with ISTDs
Signal 1: DAD1 A, 8g'254,16 Refooff
Peak RetTime Type Width Area
4 [min] (min] [mU*s]
----I-------I ---- W------I----------
1 43.255 MM 1.3339 3656.88037







Results obtained with enhanced integratorl
* End of Report ***
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chiralpak OD-H 100%Bexanes to 80% PrOR over 60 min
Injection Date : Seq. Line : 1
Sample Name z Location : Vial 26
Acq. Operator : In : 1
Inj Volume : 0 p1














Signal 1: DADI D, Sig=240,16 Refwoff
Peak RetTime Type Width Area Heig
( [min) (min) (maU*s [
1 43.830 M 1.2124 311.47989 4.2
2 54.522 IN 1.6907 1.35736e4 119.6
Totals : 1.38851e4 123.9
Results obtained with enhanced integrator I
ht Area
I %






















































































fb not used proc



















































wft (-)-trigonoliimine A (1)(CDCI3'CD3OD = 3:1)
1iLi~
i I I . I .' ~ I I I I I
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(CDC13:CD 3OD = 3:1)
I
11 10 9 8 7 6 5 4 3 2 1 ppm
-- A" 111 




























































(CDCI3:CD 3OD = 3:1)































tn H1 dros 1.0
at 4.995 Mom n
up 120102 PROCESSING
sw 12012.0 Wtile
fb nut used proc ft
bs 2 in 202144
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sfrq 125.795 dres 1.0
n C13 homo ni
at 1.736 PROCESSING
np 131010 lb 0.30
sv 37735.8 wtfle
fb not used proc ft
hs I fn 131072
































60040020 0 - 0 , ppm
I .11 . L . . LA
11
I
140 120 ido 802 00 180 160 1
ChiralPak IC 0.7mL/min, 55:45=PH:HOliKexane
Injection Date t Seq. Line : 1Sample Name Location : Vial 23
Acq. Operator : Inj : 1
















Signal 1: DAD1 A, Sig=254,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [min) (min) [mAU*a] (EAI)
---- - I- I-------.---------------------I
1 24.570 MH 1.7985 1.33343.4 123.56780 49.6839
2 50.486 NN 3.4308 1.35040e4 65.60233 50.3161
Totals : 2.68383e4 189.17013
Results obtained with enhanced integrator I




chiralpak IC 45ORexanes:55%IPA; 0.7 mL/min
Injection Date : Seq. Line : 2
Sample Name Location : Vial 25
Acq. Operator : Inj : 1
Inj Volume : 0 pl






Sorted By s Signal
Multiplier 1.0000
Dilution a 1.0000
Use Multiplier G Dilution Factor with ISTDs
Signal 1: DADI C, Sig=230,16 Ref=360,100
Peak RetTime Type Width Area Height Area
# [minL [mini [MAD*83 [MAUI a
--- I------ ------- ---- ------- I---------- --------1
1 25.486 104 2.0268 2.11269e4 173.72997 98.0876
2 54.763 10 4.0101 411.85291 1.71173 1.9122
Totals : 2.15387e4 175.44169
Results obtained with enhanced integratori




























sw 12012.0 wtf I
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sfrq 125.795 dres 1.0
tn C13 homo n
at 1.736 PROCESSING
np 181010 lb 0.30
sw 37735.8 wtfile
fb not used proc ft
bs 2 fi 131072

































chiralPak IC O.?m/min, 55:45=iPrOiN:Rexane
Injection Date : Seq. Line : 1
Sample Name Location : Vial 27
Acq. Operator : Inj: 1
Inj Volume : 0 pl











Ose Kultiplier 6 Dilution Factor with ISTDs
Signal 1: DRD1 B, Sigw220, 16 Ref=360, 100
Peak RetTime Type Width Area 'Height Area
# tMin] [min] [mAW*al [mA] I
-- QwI ------- -- ---- I---------|------------
1 29.506 MM 2.0782 2.393004 191.91936 49.9974
2 35.527 MN 2.5518 2.39333e4 156.31505 50.0026
Totals I 4.78641e4 348.23441
Results obtained with enhanced integrator I
* End of Report ***
312
catLralpak IC 45%Rexanes:55%IPAr 0.7 Wa/min
Injection Date : Seq. Line : 1
Sample Name Location : Vial 24
Acq. Operator : Inj: 1
Inj Volume : 0 pl













Use Multiplier & Dilution Factor with ESTDs
Signal 1: DADI C, Sig=230,16 Reg.360, 100
Peak RetTime Type Width Area
# [min] [min) [mAO*S)
---- |I-----f---I--- 
-- I--------
1 30.702 MN 2.3934 1.63575e4







Results obtained with enhanced integrator t





























tn H1 dres 1.0
at 4.999 hom. n
np 120102 PROCESSING
su 12012.0 Wtfile
fb not used proc ftb$ 2 fn 262144
tpvr 97 math f
pw 8.0dl 0.100 verr
tof 3003.2 wexp
at 32 wbs







































sfrq 125.795 dres 1.0
tn C13 hemo n
at 1.736 PROCESSING
ap 181010 lb 0.30
su 87735.8 Wtile
fb not used proc ftbs 2 fn 181072
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ChiralPak IC 0.7ML/min, 55:45.iPrO2:Hexane
Injection Date : Seq. Line s 1
Sample Name Location : Vial 23
Acq. Operator : Inj : 1
Inj Volume : 0 p1






Sorted By t Signal
Nultiplier 1.0000
Dilution 2 1.0000
Use Multiplier & Dilution factor with ISTDa
Signal 1: DADI C, Sigu230,16 Ref=360,100
Peak RetTime Type Width Area
0 (mini (mini [mU*gs]
---- I------.I-I' --......-I
1 20.640 MM - 1.5072 8728.03906







Results obtained with enhanced integratorl
*** End of Report ***
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ChirajPak IC 0.7mL/mnin, 55:4s5iPrO:tHetane
.. .... U=C w= = = = = . . -" - -- - --- --- =a----
Injection Date : Seq. Line : 1
Sample Name Location : Vial 27
Acq. Operator : Inj : 1
Inj Volume : 0 pl















Signal 1: DAD1 C, Siqm230,16 Ref=360,100
Peak Retfime Type Width Area Height Area
# (min] [mini [mAU*sl [mU)
---- I----- 
-- - -|-------- 
- ----- - - ------ ..-
1 20.727 NM 1.6073 3.36937e4 349.37302 98.0317
2 29.769 NM 2.7526 676.51196 4.09626 1.9683
Totals : 3.43702e4 353.46927
Results obtained with enhanced integratorI
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(-)-78(2 equtv aceuc acld-df)
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(2 equiv acetic acid-d4)
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fb not used proc
























































IILJA AK1 9 11 1 --- 9- I I I 5 4 i i I I I I I I I a I I a I I I I I I T T
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fb not used proc
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fb not used proc




















































f (-)-trigonoliimne C (3)
I - . I
200 i80 iO 140 120 100
k)
11





































fb not used proc
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Born in July 17th, 1982, Pisa, Italy (residence in Italy from 1982 to 1990).
EDUCATION
Massachusetts Institute of Technology
Ph.D. candidate, Organic Chemistry (September 2006 - present)
Advisor: Professor Mohammad Movassaghi
Korea Advanced Institute of Science and Technology
B.S. Chemistry, summa cum laude, 2 nd out of 412 (February 2006).
Thesis title: "An asymmetric alkylation of the amidine and intramolecular multi-component reaction for the
synthesis of cyclic amidine."
Advisor: Professor Sukbok Chang
RESEARCH
Massachusetts Institute of Technology
Graduate Research Assistant, Professor Mohammad Movassaghi
November 2006-present
Completed the enantioselective total synthesis of all trigonoliimine alkaloids.
Completed the enantioselective total synthesis of all agelastatin alkaloids.
Cambridge, MA
Korea Institute of Science and Technology Seoul, Korea
Research Scientist, Dr. Hee-Sup Shin and Dr. Changjoon Justin Lee
March 2006-July 2006 2
Designed and synthesized selective blockers for Ca -activated CF channel.
Tested biological activity of Ca 2-activated Cl- channel blockers using Xenopus laevis oocytes. .
Korea Advanced Institute of Science and Technology
Undergraduate Research Assistant, Professor Sukbok Chang
January 2005-February 2006
- Conducted research on asymmetric induction of amidine.
- Designed and synthesized aminoalkynes for copper catalyzed cyclic amidine formation.
Daejon, Korea
Undergraduate Research Assistant, Professor Jie-oh Lee
September 2001-December 2002
- Conducted cloning, protein expression, purification and crystallization for BAFF-BAFF-R complex.
Kyonggi Science High School Suwon, Korea
Student Researcher, Mr. Jungheang Park
March 1998-February 2000
e Conducted research on "The optimal condition of clay court based on the moisture content the clay."
FELLOWSHIPS & AWARDS
- Kenneth M. Gordon Summer Graduate Fellowship in Organic Chemistry (MIT, 2011)
- EMD Serono Summer Graduate Fellowship (MIT, 2010)
- The Korea Foundation for Advanced Studies Scholarship. (presented to 30 Korean university students
in all fields of studies including humanities, social sciences, engineering, and natural sciences, KAIST,
2005)
- ARCOM (Army Commendation Medal), awarded by Brigadier General Richard W. Mills (Special
Operations Command Korea (SOCKOR), 2004).
337
GE Foundation Scholar-Leaders Award (presented to 7 Korean Undergraduate students in the fields of
engineering and natural sciences, KAIST, 2002)
e Departmental Scholarship for academic excellence (KAIST, 2001, 2002, 2005).
* Gold Prize (1st place) in the 6 Samsung Humantech Thesis Prize, thesis: "The Optimal Condition of
Clay Court Based on the Moisture Content the Clay." (Kyonggi Science High School, 2000)
PUBLICATIONS
e Han, S.; Siegel, D. S.; Movassaghi, M. "Lithiation and Electrophilic Substitution of Dimethyl Triazones"
Tetrahedron Lett. 2012, in press.
e Han, S.; Movassaghi, M. "Concise Total Synthesis and Stereochemical Revision of all (-)-
Trigonoliimines." J. Am. Chem. Soc. 2011, 133, 10768 (Most Read Paper on July, 2011 in the J. Am.
Chem. Soc).
e Movassaghi, M.; Han, S. "Total Synthesis of all (-)-Agelastatin Alkaloids." Asymmetric Synthesis-The
Essentials 2 Wiley-VCH, 2011, submitted.
e Movassaghi, M.; Siegel, D. S.; Han, S. "Total Synthesis of all (-)-Agelastatin Alkaloids." Chem. Sci.
2010, 1, 561.
" Oh, S.; Park, J.; Han, S.; Lee, J.; Roh, E.; Lee, C. J. "Development of Selective Blockers for Ca 2 -
Activated Cl Channel Using Xenopus laevis oocytes with an Improved Drug Screening Strategy."
Molecular Brain, 2008, 1, 14.
e Chang, S.; Lee, M.; Jung, D.; Yoo, E.; Cho, S.; Han, S. "Catalytic One-pot Synthesis of Cyclic Amidine
by Virtue of Tandem Reactions Involving Intramolecular Hydroamination Under Mild Condition." J. Am.
Chem. Soc. 2006, 128, 12366.
PRESENTATIONS
- Gordon Research Conference (Natural Products) Poster Presentation (Jul, 2011).
e AstraZeneca Excellence In Chemistry Symposium Poster Presentation (Oct, 2010).
e EMD Serono Science Day Symposium Oral Presentation (Sep, 2010).
e MIT Graduate Research Symposium Oral Presentation (May, 2010).
EXPERIENCES & SKILLS
e Head Teaching assistant for an undergraduate level second semester organic chemistry course (MIT,
5.13, Professor Mohammad Movassaghi, Fall 2011).
e Teaching assistant for an undergraduate level first semester organic chemistry course (MIT, 5.12,
Professor Rick Danheiser and Professor Timothy Jamison, Spring 2009).
e Teaching assistant for an undergraduate level first semester organic chemistry course (MIT, 5.12,
Professor Sarah E. O'Connor and Dr. Kimberly Berkowski, Spring 2007).
e Teaching assistant for an undergraduate level organic chemistry laboratory (MIT, 5.310, Dr. Mircea
Gheorghiu and Dr. Janet Schrenk, Fall 2006).
- Constitutional Military Services as a KATUSA (Korean Augmentee to the United States Army,
SOCKOR, December 2002-December 2004)
e Korean (native), English (fluent), Italian (conversational).
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